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The evolution of ALL from presentation to relapse is often accompanied by the emergence of 
resistance to commonly used chemotherapeutics, including dexamethasone (Dex), a 
synthetic glucocorticoid that has been the backbone of ALL treatment since the 1950s. In 
order to investigate the evolution of drug resistance we focused on the L707 cells, a 
matched Dex-sensitive presentation and Dex-resistant relapse pair from a patient with 
t(17;19) B ALL. A major genetic difference between presentation and relapse is a 5q deletion 
spanning 6 genes, including NR3C1, the glucocorticoid receptor and the site of action for 
Dex. It was found previously that the L707 presentation engrafts and proliferates faster than 
the relapse cells in the NSG mouse model. The loss of NR3C1 was hypothesised as the cause 
for reduced fitness of the relapse. This thesis investigated this, and the mechanisms behind 
the Dex resistance in the L707 relapse. Using shRNA approaches to look at the function of 
the genes in the relapse 5q deletion identified NR3C1 as the major driver of resistance but 
did not provide evidence that loss resulted in reduced fitness. Further in depth analysis of 
the L707 cells using microarrays has shown that the differences between presentation and 
relapse extend past the genetic differences, including alterations in transcriptional 
programmes. To identify further novel drivers of resistance, a whole genome in vivo CRISPR 
screen was carried out, implicating several genes in leukaemic fitness and Dex resistance as 
well as being a proof of concept for the use of these screens in primary material. Finally, an 
incidental finding that 697 pre B leukaemic cell line was Dex resistant in vivo, but not in vitro, 
and examination of these cells using RNA sequencing resulted in the finding that alterations 
in transcription induced by the murine microenvironment may be responsible for this 
change.  
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 Chapter 1: Introduction 
 
1.1 The Haematopoietic System 
 
The haematopoietic system is essential for the production of the immune system, as well as 
the cells responsible for the transport of oxygen around the body. The system is a hierarchy, 
with a stepwise progression from the multipotent haematopoietic stem cell (HSC) through 
several intermediates to fully differentiated mature immune cells. HSCs have the capacity to 
produce every cell of the immune system, and in mice, the injection of a single HSC 
(CD34low/neg, c-kit+, Sca-I+, Lin-) into a sub lethally irradiated recipient results in the 
production of the entire range of immune cells (Osawa et al. 1996; LeBien 2000; Welner, 
Pelayo, and Kincade 2008). Differentiation and commitment to each of these immune cell 
lineages is determined by several complex transcriptional programmes that alter the pattern 
of gene expression within the cells.  
1.2 Development of the Haematopoietic system  
 
The production of the complex multi-lineage haematopoietic system starts pre-natally, in the 
yolk sac. The commencement of haematopoiesis occurs with the development of 
haemangioblasts, precursor cells with both endothelial and haematopoietic potential 
(Kennedy et al. 2007). Haemangioblasts initiate the first stage of haematopoiesis, primitive 
haematopoiesis. This occurs at embryonic day 7 (E7) in the mouse and between days 16-19 
in human gestation in blood islands in the mesodermal layer of the yolk sac. These blood 
islands consist of immature erythroid cells surrounded by endothelial cells (Palis et al. 1999). 
The first wave of haematopoiesis results in the production of primitive erythroid cells to 
enable oxygenation of the embryo.  
After primitive haematopoiesis there is a transient wave of definitive haematopoiesis that 
also occurs in the yolk sac, and results in the production of erythroid and myeloid 
progenitors. This second wave occurs at E8.25 in the mouse, and with the start of circulation 
at E8.5 the foetal liver is colonised. Mature erythrocytes produced from this transient wave 
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are detectable in circulation shortly after, at E11.5 (Cumano and Godin 2007; Godin and 
Cumano 2005; Palis et al. 1999; Jagannathan-Bogdan and Zon 2013; Kennedy et al. 2007).  
The second phase of definitive haematopoiesis, which initiates the production of HSC occurs 
in the aorta-gonad-mesonephros (AGM) region, specifically the ventral wall of the dorsal 
aorta (Moore 2009; Ivanovs et al. 2011), where haematopoietic clusters form. This is thought 
to occur through the haematopoietic transition of endothelial cells. This mechanism has 
been shown experimentally in both zebrafish and mice, and is the most likely route of 
formation for human HSC as well  (Bertrand et al. 2010; Kanz et al. 2016). The exact 
mechanism is still unclear though as pre-HSC have been found in the sub-endothelial layer of 
the AGM, whereas the mature HSC are found in the endothelial layer of the aortic wall. It is 
not known if these pre-HSC incorporate into the haemogenic endothelium or migrate 
directly to the lumen of the aorta (Figure 2). The haemogenic endothelial cells of the AGM, 
from mid-gestation are the first cells to show HSC engraftment potential in mouse models 
(Müller et al. 1994; Medvinsky et al. 1993). 
Figure 1: Primitive haematopoiesis and definitive haematopoiesis. The schematic shows the two 
routes of haematopoiesis in the foetus, with a progression from the pluripotent mesoderm down 
one of the two pathways. The primitive HSC has no self-renewal capacity and can only produce 
the myeloid and erythroid cells of primitive haematopoiesis. Definitive haematopoiesis and the 
production of the classical HSC comes later by way of the haemogenic endothelium. This is the 
route by which the entire complement of blood and immune cells is produced in both the foetus 
and adult (Jagannathan-Bogdan and Zon 2013; Ivanovs et al. 2011; Kennedy et al. 2007; Cumano 
and Godin 2007; Godin and Cumano 2005).  
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Figure 2: The development of HSC from the haemogenic endothelium in the dorsal wall of the 
aortic endothelium. The haemogenic endothelium differentiate into haematopoietic clusters 
which contain HSC and are located on the wall of the dorsal aorta. Pre-HSC have also been 
found in the sub-endothelial layers and it is not known whether these pre-HSC are 
incorporated into the haemogenic endothelia or head straight to the haematopoietic clusters 
(dotted lines) (Ivanovs et al. 2011; Kennedy et al. 2007; Costa, Kouskoff, and Lacaud 2012).  
HSC produced by the haematopoietic clusters of the AGM colonise the foetal liver at E14.5 in 
mice, and by 2-4 days post-natally foetal liver haematopoiesis has finished and the HSC have 
homed to, and colonised the BM (Bone Marrow) (Sasaki and Sonoda 2000). In humans foetal 
liver haematopoiesis occurs slightly differently with 2 waves of hepatic colonisation, the first 
at day 23, when primitive erythromyeloid cells are found in the liver, and the second a week 
later at day 30 when the first CD34+ precursor cells can be detected in foetal liver (Tavian 
and Péault 2005).  
It is not just the liver where foetal haematopoiesis occurs, After HSC have colonised the 
foetal liver they also spread to other sites of extramedullary haematopoiesis, the thymus 
and the spleen. The thymus in the embryonic mouse is seeded with haematopoietic cells at 
E11. The thymus, unlike the other extramedullary haematopoietic organs, is derived from 
the endoderm rather than the mesoderm. It has a complex spongiform structure and it is the 
interplay between developing haematopoietic cells and the thymic endothelial cells that 
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promotes the development of this structure (Dzierzak and Speck 2008; van Ewijk et al. 2000).  
The foetal spleen starts forming at E11.5 in mice and is seeded with HSC from circulation, 
presumably from the foetal liver, between E12.5-E13. The foetal spleen does not have the 
same levels of HSC seen in the foetal liver and equivalent to 4 foetal spleens are needed to 
reconstitute the entire haematopoietic system in recipient mice compared to just one foetal 
liver (Bertrand et al. 2006).  
Haematopoiesis in the BM initiated by HSC born in the AGM region and expanded in the 
foetal liver is a late occurring event; E18.5 in mice and 10.5 weeks post-natally in humans 
(Baron, Isern, and Fraser 2012; Babovic and Eaves 2014; Jagannathan-Bogdan and Zon 2013). 
Limited haematopoiesis in the marrow can be detected earlier, in mesodermal structures 
(E17 in mice and week 11 in humans). This is thought to be the maturation of pre committed 
progenitors seeded from other sites with HSC in the developing embryo (Tavian and Péault 
2005; Blazsek, Chagraoui, and Péault 2000). Once the HSC have colonised the BM they retain 
the characteristics of foetal HSC for a short period before switching to a quiescent adult 
phenotype. In both humans and mice foetal HSC are proliferative, human foetal HSC 
proliferate around 10x faster than adult HSC, once every 3.5-4 weeks vs 40 weeks 
respectively (Ivanovs et al. 2011; Catlin et al. 2011). This switch occurs 1-2 years after birth 
as inferred from a dramatic reduction in the rate of telomere shortening in leukocytes, 
which is used as a surrogate for measuring proliferation (Rufer et al. 1999). 
The switch in proliferative capacity of HSC is accompanied by a change in the transcriptional 
landscape.  Using murine foetal HSC to investigate the transcriptional differences between 
foetal and adult HSC reveals increased expression of CEBPa (CCAAT/enhancer-binding 
protein alpha) as a key factor in the switch. Indeed knockout of CEBPa in adult murine HSC 
reverts them to a proliferative state with characteristics of HSC found in the foetal liver (Ye 
et al. 2013). 
Even before the switch to an adult HSC phenotype there is already heterogeneity in the HSC 
compartment, as both foetal and adult HSC contain different subtypes which have different 
clonal differentiation potential. Three subtypes of HSC have been described, α β and γ. αHSC 
have reduced lymphoid potential compared to β and γ HSC but the number of these in foetal 
liver is very low (2/43 measured). In the adult mouse (10 months) this is increased to 45% 
(Benz et al. 2012). This increase in lymphoid deficient αHSC is mirrored by the 
5 
 
downregulation of lymphoid specific and upregulation of myeloid specific transcriptional 
programmes in HSC from old mice (Rossi et al. 2005; Cho, Sieburg, and Muller-Sieburg 2008). 
This reduction in lymphoid progenitor cells is mirrored in humans with increasing age, and 
assuming a similar picture for the subtypes of HSC could account for the increase in myeloid 
malignancies in adults, as there are less lymphoid competent HSC (Benz et al. 
2012).Conversely the increased number of HSC that can form lymphoid cells in the young 
could account for the tendency towards lymphoid leukaemia in children (Babovic and Eaves 
2014). The development of the haematopoietic system from these HSC follows a hierarchy, 
Figure 3 outlines the process of haematopoiesis in the adult, starting from the mature HSC 
with a focus on B lymphoid development.   
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Figure 3: Lymphoid differentiation from the multipotent HSC to the terminally differentiated mature B cells that defines definitive haematopoiesis. The 
schematic incudes immunophenotype for B cells which shows the progressive loss of stem cell markers such as CD34 and acquisition of lineage specific 
markers such as CD19 and CD10. This process takes place entirely in the bone marrow (after birth). Greyed out cells are haematopoietic cells not in 
the B lymphoid lineage (Carroll et al. 2009; LeBien 2000; Sanz et al. 2010; Welner, Pelayo, and Kincade 2008; Rieger and Schroeder 2012). 
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1.3 Transcriptional control of HSC 
 
The differentiation stages in haematopoiesis are tightly controlled by specific transcriptional 
programmes, driven by key transcription factors. At the earliest stages of haematopoiesis 
transcription factors are required for HSC maintenance. Two important examples are GATA2 
(GATA binding protein 2) and RUNX1 (Runt-related transcription factor 1). GATA2 is 
expressed in the precursor cells that give rise to HSC and marks them as haematopoietic cells 
(Minegishi et al. 1999). Without GATA2 expression mice die at embryonic day 10/11 with 
severe anaemia. In vitro, GATA2 null progenitor cells do not proliferate well, and the colonies 
that are formed are small with a high percentage of dead cells (Tsai and Orkin 1997). RUNX1 
is another gene that is an essential HSC factor required for haematopoiesis. Mice lacking 
RUNX1 die at E12.5 with no definitive haematopoietic cells, just primitive erythropoiesis 
(Okuda et al. 1996). These are just two of the genes with vital functions in the regulation of 
HSC and haematopoiesis. For example the loss of GFI1 (Growth factor 1 independent 
transcriptional repressor) expression results in a cascade of changes that causes HSC to enter 
cell cycle more often, resulting in reduced long term repopulating efficiency (Muench et al. 
2015). E2A, encoded by the TCF3 gene (transcription factor 3) is another protein that 
controls cell cycle within the HSC, and loss results in increased cell cycle.; E2A null mice have 
a reduced HSC pool, as well as a reduction in myeloid and lymphoid progenitors in the BM, a 
direct result of increased cell cycling and reduced long term self-renewal (Semerad et al. 
2009). 
Even small changes in the expression of transcriptional modulators can have drastic effects 
on HSC. In a study looking at the transcriptional differences between long term-HSC (LT-HSC) 
and short-term HSC (ST-HSC) just 210 genes were found to be differentially expressed. 
However, it appears this is sufficient for the loss of long term repopulating potential (Zhong 
et al. 2005). This switch from LT-HSC to ST-HSC, and the associated change in gene 
expression is also is accompanied by a change in phenotype. 75% of HSC have cell surface 
markers that denote long term repopulation potential has been lost, either the expression of 
CD38 or CD34 (Zhong et al. 2005; Morrison and Weissman 1994). These ST-HSC have more 
colony forming units in vitro as a result of being in cell cycle more often, but have a reduced 
capacity for self-renewal (Morrison and Weissman 1994). The ST-HSC give rise to multi-
potent progenitor cells (MPP), the last cells able to generate all cells of the haematopoietic 
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system.  The MPP pool is heterogeneous and among other cell types gives rise to the 
common lymphoid progenitor (CLP) (Adolfsson et al. 2005).  
1.4 B lymphoid haematopoiesis 
 
Once the HSC have passed through the ST-HSC and MPP stages, those cells that will become 
B lymphocytes become committed to the lymphoid lineage by differentiating into CLP.  This 
is marked by the expression of several genes defined as lymphoid lineage commitment 
factors such as E2A, EBF (Early B cell factor) and PAX5 (Paired box 5), which are each heavily 
implicated in the development of B lymphocytes. Each of these drives specific transcriptional 
programmes that bring about the changes needed within the cell for further differentiation 
This change in transcription and commitment marks the start of B lymphoid haematopoiesis, 
the result of which is the 2x1012 lymphocytes in a healthy human. Each of these mature cells 
is the end product of clonal selection with several steps and checkpoints and are important 
in the ability to mount an immune response upon exposure to foreign antigens.  
Passage through these checkpoints is determined by the expression of appropriate factors, 
and levels of immunoglobulin (IgG) recombination, a process that increases as the cells move 
further down the B lymphoid pathway. This rearrangement, which involves 3 variable 
regions of the Ig gene is mediated through the recombinase activating genes (RAG) RAG1 
and RAG2, which in turn are modulated by transcription factors. Three regions of the IgG 
gene are involved in this rearrangement; variable (V), diverse (D) and joining (J), and it is the 
juxtaposition of different segments of each region to produce a novel transcript that 
constitutes recombination. It is a tightly controlled and ordered process with D-J 
recombination first, followed by V-DJ recombination, rearrangement of heavy chains 
precedes light chains (Sigaux 1994; González et al. 2003).  
Progression of CLP into the B lymphoid pathway is controlled by the transcription factor E2A, 
encoded by the TCF3 gene. The gene codes for 2 basic helix loop helix (bHLH) proteins, E47 
and E12 made by alternate splicing of the exon encoding the DNA binding region in E2A. The 
interaction of E12 and E47 with immunoglobulin genes is how this gene exerts control over 
differentiation. In E2A null mice there is a no RAG1 expression, resulting in the absence of DJ 
recombination, and thus lack of progression past the earliest lymphoid development 
checkpoints. As a result, E2A null mice have no mature B cells, and the progenitors do not 
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progress past the CLP stage (Bain et al. 1994; Zhuang, Soriano, and Weintraub 1994) EBF is 
expressed in B lymphocytes from the pro B stage to mature B cells, but not in mature plasma 
cells, it is important for B cell development at a similar time point as E2A. EBF knockout mice 
have a block in differentiation early in B cell development, prior to any VD recombination. 
Mice with heterozygous loss of one EBF allele on the other hand do have pro B cells but at a 
reduced frequency, indicating a dose response for EBF (O’Riordan and Grosschedl 1999). 
Interestingly, the block in differentiation and resultant lack of cells past the pre/pro B cell 
stage caused by E2A knockout can be reduced in vitro by the addition of EBF and E2A related 
proteins to E2A null cells (Seet, Brumbaugh, and Kee 2004) indicating that there is a 
cooperating role for these two proteins. Mice with double knockout of  both alleles of E2A 
and EBF have a differentiation block of B cells earlier in lymphobpoiesis than mice with 
heterozygous E2A and EBF knockout (O’Riordan and Grosschedl 1999).  
PAX5 is a transcription factor exclusively expressed in B cells, and is an early irreversible B 
cell commitment factor. PAX5 expression is repressed in HSC through histone modifications, 
but upon entry to the B cell pathway these are lost and PAX5 expression increased 
(Weishaupt, Sigvardsson, and Attema 2010). Pro B cells without expression of PAX5 are not 
committed B cells and they are still able to produce cells of the myeloid lineage. This is the 
result of deregulation of lineage commitment genes, and the expression of non B lineage 
markers in these cells belies the underlying expression of myeloid associated genes; genes 
that under normal circumstances are repressed by the expression of PAX5 (Nutt et al. 1999). 
PAX5 null progenitor cells show DJ rearrangement, but not VDJ rearrangement indicating a 
later role than E2A and EBF in B lymphoid haematopoiesis (Nutt et al. 1997). 
 
1.5 Paediatric B cell ALL 
 
Understanding the normal biology of haematopoiesis is important for the study of acute 
lymphoblastic leukaemia (ALL) because they are inextricably linked. There are two main 
subtypes of ALL, B cell and T cell, dependent on the immunophenotype and morphology of 
the leukaemic blasts, which can be correlated with stages in normal haematopoiesis. Of the 
acute leukaemias, B cell ALL is the most common, accounting for approximately 85% of all 
cases (Carroll et al. 2009). 
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B cell ALL is a disseminated haematological malignancy characterised by the uncontrolled 
proliferation of differentiation arrested immature B lymphocytes. As is the name suggests, 
the disease has an acute presentation with a swift disease progression in the absence 
medical intervention. The overproduction of leukaemic blasts results in changes in the BM 
that lead to the failure of normal haematopoiesis. As well as BM failure, leukaemic blasts 
infiltrate other organs and patients often present with splenomegaly or hepatomegaly  
(Reiter et al. 1994; Marwaha et al. 2010).  
Although B cell ALL has an excellent prognosis with current treatment regimens in developed 
countries, around 85%, those patients that suffer a relapse have a significantly worse 
outcome with survival rates falling to less than 50% (le Viseur, Hotfilder, Bomken, Wilson, 
Rottgers, et al. 2008; Rivera et al. 2005; Nguyen et al. 2008). The incidence of ALL has a 
marked distribution, with a peak in children less than 4 years with an average of 122 male 
and 101 female patients presenting in the UK each year, an average of 6 and 5.2 cases per 
100,000 per year respectively. This rate decreases as age increases, and by age 20 is around 
0.8 cases per 100,000 (Tobergte and Curtis 2013). The upper age limit for patients to be 
described as paediatric ALL is not clear cut, but it is generally accepted that paediatric ALL 
includes adolescents up to age 20. It has been shown for this group of older children and 
adolescents (age 15-20) that treatment on a paediatric regime results in better outcomes  
compared to those treated with adult protocols (Boissel et al. 2003). Interestingly, there 
have also been studies in which a paediatric regimen was used for the treatment of adults 
and it was found that intensive treatment was beneficial up to the age of 55 (Huguet et al. 
2016).  
 
1.6 Biology of ALL 
 
ALL is characterised by leukaemic fusion genes, which are the result of chromosomal 
translocations. These fusion genes are in most cases the driving force behind the aetiology of 
ALL, but the factors that cause the chromosomal translocation responsible for the 
production of fusion proteins is less well known. Only 5% of ALL cases are associated with 
predisposing factors such as ionizing radiation and Downs syndrome (Pui and Robison 2008). 
Several other factors have been hypothesised including household chemicals (Freedman et 
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al. 2001) , paternal exposure to ionizing radiation (McKinney et al. 1991) and 
electromagnetic fields (Linet et al. 1997), but these have mostly been found to be unfounded 
or only weakly associated.  
One of the prevailing theories about the development of paediatric ALL is the hygiene 
hypothesis. First described by Strachan in 1989, the hypothesis was described after a study 
linked hay fever to family size. It was theorised that “unhygienic contact” with older siblings 
and family members was protective against the development of hay fever (Strachan 1989). 
Greaves was the first to link this hypothesis to the development of paediatric ALL in 1997. He 
postulated that the reduced exposure to infection of children, as a result of lower numbers 
of women breast feeding and cleaner environments, results in the abnormal programming of 
the immune system. This mis-priming of the immune system means that later infections 
result in an aberrant immune response and increased risk for ALL (Greaves 1997). This has 
been expanded on since then and is now thought of as the delayed infection hypothesis. In 
support of this theory, it has been found that there is a reduced risk of paediatric ALL in 
children who received their childhood immunisations on time. The childhood immunisations 
could be described as the early insult to the immune system, which is possibly enough to 
modulate the immune system so that later infections do not result in abberant immune 
response and increased risk of ALL (MacArthur et al. 2008).  
However, in refute of this, another study done in the 1990s in Canada found that being born 
2nd or later and having older siblings increased the risk of paediatric ALL which would suggest 
that older siblings do not result in a protective effect as initially postulated with the hygiene 
hypothesis. The same study did find that attendance at nursery and breast feeding reduced 
the risk of paediatric ALL. This does indicate a role for childhood infections in the 
development of ALL, but also serves as a reminder that it is a complex association and it is 
still not fully understood (Infante-Rivard, Fortier, and Olson 2000).  
A meta-analysis published in 2013 found that 16 out of 21 studies investigating the effect of 
maternal infection on the risk of leukaemia development found them to be positively 
correlated. The remaining 5 studies found no significant correlation. Again the picture is not 
clear regarding the effect of childhood infections on the development of ALL. 5 of the studies 
investigated found that childhood infections lowered the risk of ALL development, whereas 2 
found the opposite, a remaining 5 studies that looked at the risk from childhood infections 
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found that some increased risk and others decreased the risk (Maia and Wünsch 2013). This 
unclear picture reinforces the need for meta-analysis of large scale epidemiology studies as 
they can present with very different results.  
The cells characteristic of B ALL are malignant B lymphoid progenitor cells with an arrest in 
differentiation. These malignant cells can often be correlated with a step in normal B 
lymphoid haematopoiesis, dependent on the stage of differentiation the blasts are arrested 
(Figure 4). However, there is overlap between the different subtypes and in up to 30% of pre 
B ALL cases there is also the expression of myeloid markers, so this relationship between ALL 
subtype and differentiation stage may not be as simple as it first seems (Cobaleda and 
Sánchez-García 2009). 
 
Figure 4: The correlation of B ALL subtype with stages in B lymphoid differentiation. The 
subtypes are not fully correlated and there is crossover as leukaemic transformation can 
result in aberrant expression of surface markers used for discrimination of differentiation 
stages (Cobaleda and Sánchez-García 2009).  
 
1.6.1 Genetic translocations 
 
Genetic translocations involve the juxtaposition of separate genes at the DNA level, they can 
involve a small part or the whole gene and often result in the production of chimeric fusion 
proteins. These proteins are the hallmark of many haematological malignancies including 
ALL. The link between cytogenetics and prognosis in ALL was first demonstrated in the 
1970s, when it was found that hyper-diploid patients had an increase in the length of 
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remission compared to other subtypes (Secker-Walker, Lawler, and Hardisty 1978). Since 
then there has been an expansion of research and the differential prognosis conferred by 
the recurrent subtypes is known (Table 1). Thanks to the advent of gene expression profiling 
subtypes can be grouped according to the expression profile of leukaemic blasts. Different 
cytogenetic subgroups cluster together indicating similar transcriptional programmes are 
active in the cells  (Yeoh et al. 2002). One subtype for which this has been important is the 
BCR/ABL like cases. This subtype of ALL is characterised by similar gene expression profile as 
the t(9;22), BCR/ABL positive cases but without the BCR/ABL translocation. As these cases 
have a similarly poor prognosis as cases with t(9;22) they benefit from intensified 
chemotherapy, which without transcriptional stratification of the subtype might not have 
happened (Den Boer et al. 2009). 
Some of the genetic translocations are associated with particular subtypes of B ALL. For 
example, 25% of Pre-B ALL cases are t(1;19), compared to around 5% in all B precursor ALL 
(Raimondi et al. 1990). Hyperdiploid ALL, (>50 chromosomes) is also seen more frequently in 
pre pro B ALL, and t(12;21) translocations, which are more common in paediatric ALL than 
adult, have a skew towards pre-pro B ALL and pre B ALL (Yeoh et al. 2002). Another 
interesting finding is that CRLF2 translocations are found in 50% of Downs syndrome ALL 
(Mullighan 2012). MLL (Mixed lineage leukaemia) rearranged ALL cases have low levels of 
CD24 and CD79b, a phenotype associated with pro B cells in normal haematopoiesis (De 
Braekeleer et al. 2010).  
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Chromosomal 
abnormality 
Frequency Genes 
involved 
Prognosis Relapse 
(%) 
5-year survival 
(%) 
t(9;22) 2 BCR/ABL Poor unless 
imatinib used 
42 80 
t(12;21) 20-25 ETV/RUNX1 Very good 13 80-95 
t(1;19) 3-5 E2A/PBX intermediate 21 80-85 
t(14;various) 2-5 IGH@/several 
partner genes 
intermediate   
t(8;14) 2 IGH@/MYC intermediate   
t(17;19) <1 E2A/HLF Very poor 100 0 
t(4;11) 1-2 MLL/AF4 Very poor 43 30-40 
t(11;various) 4 MLL/Several 
partner genes 
Variable/poor  30-50 
iAMP21 3-5 RUNX1 
amplification 
Very poor, 
increased risk 
of relapse 
76 30-40 
Various 10-15 BCR/ABL like Very poor 50 57 
high 
hyperdiploidy 
(>50 
chromosomes) 
25-35 - good 15 85-93 
near haploidy 
(<30 
chromosomes) 
1 - Very poor 60 35-40 
Table 1: Some of the genetic translocations that are seen in several subsets if paediatric B 
ALL including the frequency at which they are seen, the genes involved in the fusion protein, 
the associated prognosis, rates of relapse and the overall survival. As can be seen, those 
subtypes with a higher risk of relapse are also associated with a poorer prognosis, for 
example iAMP21, t(17;19). (Den Boer et al. 2009; Harrison 2009; Moorman et al. 2010; C H 
Pui et al. 2011; Ching Hon Pui et al. 2012).  
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1.6.2 Leukaemic transformation 
 
The first step in leukaemogenesis is frequently the genetic translocation and resulting 
oncogenic fusion protein which characterises ALL. This first step is thought to primarily be a 
pre-natal event. The MLL/AF4 translocation can be found in neonatal blood spots (Gale et al. 
1997). Despite this being a pre-natal event not all babies with a translocation develop ALL. 
For example, the AML1/ETO fusion gene is found at 100x higher frequency in cord blood 
than the incidence of ALL, and concordance of ALL is only around 5% in monozygotic twins. 
This demonstrates the need for post-natal secondary events to drive leukaemogenesis (Mori 
et al. 2002). The presence of a genetic translocation may pre-dispose cells to further 
secondary hits, for example by the down regulation of DNA repair genes or stem cell 
maintenance (Alcalay et al. 2003; Forster et al. 2015).  
As outlined in previous sections, haematopoiesis is a tightly controlled process with an 
ordered progression from progenitor to differentiated cells. Cells that fail any of the several 
differentiation check points are induced to apoptosis. In ALL however, cells are able to evade 
apoptosis as well as blocking differentiation, forming the pathophysiological basis of the 
disease. There are several mechanisms by which leukaemogenesis occurs, and the 
mechanisms can differ between the subgroups, but there are a few genes and pathways that 
are frequently affected across several ALL subtypes.  
Several B cell differentiation factors have been implicated in leukaemogenesis (Mullighan et 
al. 2007) and considering the differentiation block seen in ALL this is unsurprising. For 
example, PAX5, the B cell commitment factor essential for B cell development. Loss of PAX5 
results in cells arrested at the pro B stage (Nutt et al. 1999). PAX5 loss of function mutations 
are found in one third of ALL cases and can be considered the mechanism of differentiation 
block in these cases (Mullighan et al. 2008). Furthermore, PAX5 also functions as a tumour 
suppressor, as re-expression of PAX5 in established disease results in ALL regression (Liu et 
al. 2014).  
Another important player in B cell differentiation, the pre-B cell receptor (pre-BCR) is also 
implicated in leukaemogenesis. The pre-BCR is a membrane bound immunoglobulin 
composed of both heavy chains and light chains that acts as a marker for differentiation 
checkpoints during B lymphoid haematopoiesis as well as a tumour suppressor (Klein et al. 
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2004). Without the correct arrangement of the pre-BCR as a result of VDJ recombination pro 
B cells are not able to transition to the pre B stage (LeBien 2000). In the majority of ALL 
leukaemic blasts do not express the pre-BCR, but in the 13% that do re-expression of the 
receptor results in loss of leukaemic growth (Klein et al. 2004; Geng et al. 2015). 
Downstream of the pre-BCR is Ikaros (IKZF1), and this gene is mutated or deleted in 15% of 
ALL cases, it is especially prevalent in ALL with the translocation t(9;22) (BCR/ABL), where is 
it present in 80% of cases. IKZF1 modulates gene expression by chromatin remodelling, and 
is also a tumour suppressor. Forced expression of IKZF1 can reverse the differentiation block 
in blasts, providing a mechanism for this gene in leukaemogenesis (Trageser et al. 2009; 
Payne 2011). 
As well as genes associated with B cell differentiation such as PAX5 and IKZF1, genes 
associated with a wide range of other pathways can be mutated in ALL. One important 
spectrum of mutations in genes not considered B cell factors are seen in the RAS pathway. 
RAS pathway activating mutations are common in ALL, and 35% of B ALL cases have 
mutations in RAS pathway genes such as NRAS (Neuroblastoma RAS viral oncogene 
homolog) and KRAS (Kirsten Rat Sarcoma viral oncogene homolog) and PTPN11 (protein 
tyrosine phosphatase, non-receptor type 11). The majority of mutations in this pathway 
result in constitutive activation, which in turn activates expression of RAS pathway target 
genes. Importantly in ALL the RAS pathway is involved in the regulation of apoptosis by the 
BCL-2 proteins as well as interactions with the PI3K pathway, a pathway integral for cell 
growth and survival signalling (Yamamoto et al. 2006; Case et al. 2008; Paulsson et al. 2008; 
Balmanno and Cook 2009; Mendoza, Er, and Blenis 2011; Julie Irving et al. 2014).  
Despite recurrent mutations being seen frequently in ALL, the overall picture is one of 
genetic stability as somatic copy number variations in ALL are not found very frequently. 
There is an average of just 6.4 genetic alterations per case, which when compared to the 
median of 39 per case in solid cancers is significantly less (Mullighan et al. 2007; Zack et al. 
2013).  
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1.7 Prognostic factors 
 
Several of the recurrent genetic alterations can also be linked to prognosis. For example, ALL 
with IKZF1 deletions have a higher frequency of relapse (24% vs 13%) and a reduced 5 year 
event free survival (EFS) (Palmi et al. 2013). RAS pathway mutations, especially KRAS 
mutations are associated with reduced overall survival in ALL (Julie Irving et al. 2014). 
Mutations in the Janus Kinase (JAK) genes which are seen in 2-5% of ALL also confer a poorer 
prognosis in ALL, with patients having a reduced 5 year EFS of around 60%  (Mullighan et al. 
2009).  
Not all prognostic factors denote poorer outcome; patients with trisomies of chromosomes 
4 and 10 have increased prognosis, with a 5 year EFS of between 85-90%, these are found in 
almost a quarter of ALL cases (20-25%) (Salzer et al. 2010).  
Age at diagnosis is an important indicator of prognosis, and infants (<1 year) fare much 
worse than children aged 1-9. This is partly because 80% of infant leukaemia have MLL 
rearranged translocations and these leukaemias have a particularly poor prognosis. The 4 
year EFS is between 30-50%. When these patients are further split according to prednisone 
response, those with a poor response have a 4 year EFS of just 18% (Pieters et al. 2007). The 
prognosis for older adolescents was historically worse with 5 year EFS of 34-60% compared 
to 72-81% for younger children. This is partly due to the increased frequency of the poor 
prognostic translocation t(9;22) coupled with reduced frequency the good prognostic 
translocation t(12;21) (C H Pui et al. 2011). This poor prognosis for adolescents can be 
alleviated by intensive treatment. In one study adolescents (16-20yrs) who were treated 
with a paediatric regimen had overall survival (OS) of 67% compared to 46% for those 
treated on adult protocols (Stock et al. 2008). By giving adolescents intensive chemotherapy, 
which includes  intrathecal triple therapy, intensive dexamethasone (Dex), vincristine and 
aspariginase treatment the 5 year EFS can be increased to 86% in the newest protocols, 
which is more in line with younger paediatric patients (C H Pui et al. 2011).  
Another stratification of risk is white blood cell count at presentation. Patients with <10x103 
blasts/µl at presentation have a 5-year OS of around 90%. However, as the levels of blasts in 
the blood at presentation increase OS decreases, and those patients with >10x103 blasts/µl 
have a lower survival of 66% (Salzer et al. 2010). The presence of blasts in the CNS is another 
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predictive risk factor, and as could be expected those patients with CNS disease at 
presentation have a poorer outcome compared to negative patients (OS 69% vs 86% 
respectively) (Salzer et al. 2010). As well as the number of blasts and their location at 
presentation, the properties of the blasts themselves has prognostic importance. The DNA 
index is the ratio of DNA in leukaemic cells in G0/G1 phases of the cell cycle compared to 
normal cells in G0/G1. In ALL a DNA index of between 1.16 and 1.6 is considered indicative of 
good prognosis whereas a DNA index <1.16 confers a worse prognosis (Salzer et al. 2010). 
Race is another factor that has implications for prognosis. The frequency of ALL in children of 
African descent may be reduced compared to patients of European descent but so too is the 
5 year EFS (61%). The differences in prognosis are thought to be a result of different risk of 
relapse between different ethnic backgrounds. Native American heritage increases the risk 
of relapse significantly, even when adjusted for other relapse risk factors (Lim et al. 2014). 
Sex of the patient is another factor in prognosis, with males having a worse prognosis 
compared to females, 84.7% 5-year OS vs 87.9% respectively (Salzer et al. 2010) . This 
difference can be attributed to several factors including  a higher frequency of CNS relapses 
in males compared to females (Silverman et al. 2010), increased likelihood of males having 
an unfavourable DNA index (<1.16), a higher white cell count at diagnosis and a poor initial 
response to treatment (C H Pui et al. 1999). 
All of these factors are taken into account and patients are stratified into a risk group to 
determine treatment, with lower risk patients receiving less intensive therapy in order to 
reduce the side effects of a lengthy dosing regimen. Even with increased treatment 
compared to standard risk groups very high risk patients still fare worse with a 4 year  EFS 
probability of just 46% (Schultz et al. 2007).  
Despite these poor prognosis factors it should be taken into account that there has been a 
steady increase in survival since the 1950s when ALL was first treated. The improvement of 
treatment regimens and personalised treatment means that for a lot of the subtypes with 
poor prognostic factors survival is increasing.  
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1.7.1 E2A/HLF 
 
Of the factors that are indicative of prognosis, the t(17;19) translocation is one of the 
poorest.  t(17;19) (q22/q23;p13) is a rare event found in <1% of paediatric ALL, but ALL with 
t(17;19) is invariably fatal and  there are no reports of survivors in the literature (Moorman 
2012). The translocation occurs between the amino terminus of E2A on chromosome 19 and 
the carboxyl terminus of HLF (Hepatic leukaemia factor) on chromosome 17. This joins 2 
transactivation domains (TAD) from E2A and the basic leucine zipper DNA binding region of 
HLF (Figure 5), which is important for DNA binding and protein dimerization (Hunger et al. 
1994). It is thought that the E2A/HLF translocation occurs in lymphoid committed progenitor 
cells (Fischer et al. 2015).  
There are two subsets of t(17;19) translocation dependent on which exon of E2A is involved 
in the translocation. Type 1 has a breakpoint in exon 13 of E2A and type 2 has a breakpoint 
in exon 12, both are fused to exon 3 of HLF. These subsets have slightly different clinical 
features with type 1 being associated with disseminated intravascular coagulation and type 
2 with hypercalcaemia, both confer an equally dismal prognosis (Yeung et al. 2006). 
As detailed previously, E2A is vital for early B cell differentiation. The translocation partner 
gene HLF encodes a transcription factor that is part of the proline and acidic rich (PAR) 
subtype of basic leucine zipper proteins. Wild-type HLF binds to DNA as either a homodimer 
or as a heterodimer with other members of the PAR subtype to induce transcriptional 
alterations (Hunger et al. 1992). These transcriptional changes are associated with the 
inhibition of apoptosis, both via the up-regulation of anti-apoptotic genes and the down 
regulation of pro-apoptotic genes (Waters, Sontag, and Weber 2013). Interestingly, under 
normal conditions HLF is not expressed in haematopoietic cells, but in the liver lung and 
kidneys. It is only when HLF is involved in the E2A translocation that it is expressed in 
lymphoid cells (Hunger et al. 1992).  
E2A/HLF is a transcriptional activator and experiments with mutated E2A/HLF reveal a 
possible double mechanism for oncogenesis, firstly the interaction between the TAD1 region 
and the bZIP (basic leucine zipper) to block apoptosis, and secondly the interaction of the 
amino terminal of E2A/HLF with other proteins to repress expression of apoptosis regulating 
genes (Inukai et al. 1998; Yeung et al. 2004). E2A/HLF dysregulates several other genes 
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thought to mediate the leukaemic phenotype of ALL cells such as the ‘haematopoietic 
master regulator’ RUNX1 and the zinc finger transcription factor SNAI2 (snail family zinc 
finger 2), which has anti-apoptotic activity when expressed as a result of E2A/HLF (Takeshi 
Inukai et al. 1999; Dang et al. 2001). Patients that have the E2A/HLF fusion protein as a result 
of the t(17;19) translocation also have recurrent mutations in VPREB1 (Pre B lymphocyte 1), 
part of the pre-BCR. Mutations are also frequently seen in PAX5 and BTG1 (B cell 
translocation gene 1), an anti-proliferative protein (Fischer et al. 2015), providing further 
mechanisms for leukaemogenesis in this subtype. 
 
Figure 5: The t(17;19) translocation that results in the E2A/HLF fusion proteins. The E2A gene 
is located on chromosome 19 and HLF is on chromosome 17. The translocation juxtaposes the 
two transactivation domains (TAD) from the N terminus of E2A with the basic leucine zipper 
domain (bZIP) region at the C terminus of HLF to produce a highly oncogenic protein that 
increases cell survival by inhibition of apoptosis. Black arrows indicate breakpoints and 
dotted lines indicate the new location of the gene fragments (Latif 2012).  
 
1.8 Treatment 
 
Treatment for paediatric patients diagnosed with ALL is a lengthy process lasting 3-4 years. 
There are several stages to treatment, and each is a combination of different cytotoxic drugs 
for varied durations. Each stage of treatment is essential for ALL treatment, but the drug 
regimens differ depending on the risk grouping of the patient. Patients classed as high risk 
receive a more aggressive treatment style than those in standard risk subgroups. In general 
treatment for ALL follows the plan outlined in Table 2. Induction therapy, the first step in 
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treatment of ALL aims to induce a remission, and in over 95% of patients it is successful 
(Cooper and Brown 2015). The drugs used for induction therapy include a synthetic 
glucocorticoid (Dex or prednisone), vincristine, aspariginase and an anthracycline 
(doxorubicin or daunorubicin). In low risk patients the anthracyclines are removed to try and 
limit the toxic side effects of induction therapy  (Cooper and Brown 2015). Dex is the 
glucocorticoid of choice in the treatment of most patients due to its increased CNS 
penetration and longer half-life. In the minority for whom induction therapy is not successful 
allogenic bone marrow transplants are an option. Transplants can slightly improve outcome 
in patients with induction failure in T-ALL but for B-ALL patients the results are mixed and 
seem to be dependent on subtype. For example; in patients less than 6 years old with non 
MLL rearranged leukaemia and induction failure, treatment with chemotherapy has a better 
prognosis than chemotherapy combined with a transplant.  However, patients over 6 years 
did benefit from transplants, but only if the transplant was from a matched, related donor 
(Schrappe et al. 2012). The 10 year survival in patients with induction failure  is around 32%.  
The second phase of treatment, consolidation aims to remove the residual disease and allow 
the restoration of normal haematopoiesis. The drugs used for consolidation are often the 
same as those used for induction phases, with the addition of others to increase efficacy 
such as mercaptopurine, thioguanine, cyclophosphamide and etoposide (Cooper and Brown 
2015).  In high risk patients such as those with a slow early response to induction this phase 
includes an intensification of treatment which can significantly improve outcome (Seibel et 
al. 2008; C.-H. Pui and Robison 2008). During both induction and consolidation phases of 
treatment CNS directed treatment is also given. Intra-thecal administration of chemotherapy 
agents is used rather than CNS irradiation due to the toxic side effects of the latter (Pui and 
Robison 2008).  
The final stage of treatment, maintenance is far less intensive than the previous two stages 
and has been shown to reduce the risk of relapses. This phase lasts 2-3 years, (boys receive 
longer treatment) and involves treatment with mercaptopurine and methotrexate on a daily 
basis (Pui and Robison 2008). 
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Treatment stage Duration Drugs commonly used6 
Induction 3-8 weeks Dexamethasone 
Vincristine 
Aspariginase 
Anthracycline 
Consolidation/Intensification 20-30 weeks Methotrexate 
Mercaptopurine 
Vincristine 
Aspariginase 
Dexamethasone 
Maintenance 2-3 years Mercaptopurine 
Methotrexate 
Table 2: Table 2 details a brief summary of the 3 main stages in the treatment of paediatric B 
ALL. Induction is the shortest treatment period followed by consolidation or intensification 
and lastly the longest phase, maintenance which is used to prevent leukaemic relapse. The 
drugs used in each phase of treatment are often shared but the doses and change between 
them. Induction is the most aggressive phase of treatment and is designed to induce a 
remission. The drugs listed are a selection of the commonly used ones but are not exhaustive, 
subgroup specific treatments are not included (Pui and Evans 2006; Pui and Robison 2008). 
 
1.9  Relapse 
 
Despite high survival rates with modern regimens, treatment failure and relapse still remains 
a problem in ALL. Between 15-20% of patients will relapse at some point during or after 
treatment. Around 70% of these patients will go into a second remission but failure to re-
induce remission or a second relapse reduces prognosis significantly and 5 year EFS after a 
second relapse is just 27% (Bhojwani and Pui 2013).  
The strongest prognostic factor for relapse is minimal residual disease (MRD), where the 
amount of blasts still present in the BM is measured. The presence of MRD after induction 
treatment is inversely correlated with prognosis; patients with MRD 0.01-0.1% have a better 
prognosis than those with MRD >0.1% MRD (5 year EFS - 74% vs 60% respectively) but both 
23 
 
are worse than the prognosis for those patients who are MRD negative after induction (~ 
90% 5yr EFS). Intensive treatment of MRD positive patients does not prevent relapses, but 
there is a delay of approximately 1 year for those patients (Borowitz et al. 2015; van Dongen 
et al. 2015). 
An analysis of 10 ALL trials from 1988-2002 retrospectively looked in a large cohort (n=1,961) 
of relapsed patients to determine factors that influenced survival after relapse. There was a 
clear correlation between the location of relapse and the duration of the first remission with 
survival. Relapse in the BM was a poor prognostic factor, with isolated BM relapses faring 
the worst (24% 5yr EFS) compared to combined BM and extramedullary (39%) or isolated 
extramedullary (59%). Shorter durations of remission were also associated with poor 
prognosis, and a combination of the two factors resulted in just 11.5% 5yr EFS for patients 
with early, isolated BM relapse. The duration of remission being a prognostic factor is not a 
surprising statistic, as relapse whilst the patient is still on treatment would indicate a highly 
resistant disease. The study failed to find any significant increase in the prognosis for 
relapsed ALL in these trials compared to trials carried out from 1983-1989 (Nguyen et al. 
2008b). 
There are multiple theories for the origins of relapse in ALL, with clonal evolution being the 
most prevalent. Using genomic analysis, it has been shown that between 78-94% of relapsed 
ALL cases arise from either a pre-diagnosis (52%) or a diagnosis clone (32%). The emergence 
of the same diagnosis clone, without clonal evolution or the emergence of a distinct 
leukaemia being much rarer events (8% and 6% respectively)  (Mullighan et al. 2008). The 
difference between ALL presentation and relapse has been studied in depth. Interestingly it 
has been found that there is no significant in clonal diversity or mutation burden between 
presentation and relapse, but there is enrichment of certain mutations in relapsed ALL (Ma 
et al. 2015). The lack of difference in clonal diversity may be attributed to the loss of 
presentation specific subclones and the gain, or expansion of relapse specific subclones as a 
result of treatment. It has been found that when investigated using lesion specific PCR 
relapse specific subclones can be detected in 70% of presentation cases, indicating that 
treatment might cause enough of an evolutionary bottle neck for minor subclones to 
become dominant at relapse (Mullighan et al. 2008). The development of relapse in which 
the major subclone has the same CNA as the presentation is a rare event but does still occur. 
In relapses that happen early it was found in that the predominant clone at relapse was the 
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same as the diagnosis clone, but for many of these cases there were also some additional 
CNA indicating clonal evolution between the two timepoints (Yamashita et al. 2015). The 
cases for which relapse from the presentation subclone does occur without clonal evolution 
may indicate induction therapy that has failed to fully eliminate the predominant clone at 
presentation, which then proliferates to become the major subclone at relapse. Or the 
possibility of the presentation subclone being drug resistant before treatment has started.   
1.10 Leukaemic stem cells and clonal evolution 
 
When thinking about relapse in ALL, the leukaemic stem cells which are responsible for 
disease propagation should be considered. Their subsequent clonal evolution results in a 
heterogeneous pool of cells that might have different genetic alterations or treatment 
responses. Whether the leukaemia stem cells were a small subset, a large population, or 
whether they even existed was contested for many years. Leukaemic stem cells were first 
demonstrated experimentally in acute myeloid leukaemia (AML) in 1994 using the 
transplantation of leukaemic cells into immune compromised mice. These leukaemia 
initiating cells were able to home to the BM and repopulate the leukaemia in a similar 
manner to the original disease. This seminal work demonstrated the cells responsible for 
leukaemia in the murine model were the same as those responsible for disease in the 
patient(Lapidot et al. 1994). The finding that one cell in every 250,000 malignant blast cells 
had leukaemia initiating capabilities does not hold true for ALL. Although it was originally 
thought that just a small proportion of ALL cells had leukaemia initiating properties (Cox et 
al. 2004) it has now become apparent that there is a much wider range of cells with the 
potential to initiate leukaemia in ALL. In fact, a diverse range of leukaemic blasts have the 
ability to engraft and recapitulate the original ALL in the NOD/SCID/IL2Rƴ null (NSG) mouse 
model. CD19+ cells with any of CD10high/low, CD20 high/low 
 
or CD34 high/low
  
 result in engraftment 
in up to tertiary mice, interestingly, the injection of both sorted and unsorted cells will still 
recapitulate the entire phenotype of the original leukaemia (le Viseur, Hotfilder, Bomken, 
Wilson, Rottgers, Schrauder, Rosemann, Irving, Stam, Shultz, Harbott, Jurg, et al. 2008; Rehe 
et al. 2013). The frequency of leukaemia stem cells in B ALL has been shown to be as much 
as 1 in 40 for primary engraftment into NSG mice, increasing to 1 in 6 for secondary and 
tertiary engraftment (Rehe et al. 2013).  
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The high proportion of cells with leukaemia repopulating ability is especially relevant for the 
emergence of relapse. As almost all blasts in ALL are able to reconstitute the leukaemia, the 
genetics of the stem cell pool can be diverse. This genetic variation within the population 
provides the ‘units’ for development of the disease through clonal evolution. Clonal 
evolution, which has been demonstrated as the prevalent origin for relapse is a Darwinian 
process in which inter-clonal heterogeneity is the substrate that drives change. The clonal 
architecture in ALL can be linear or branching and is a dynamic process with deletions and 
copy number alterations (CNA) acquired independently in separate subclones in no 
particular order (Anderson et al. 2011; Notta et al. 2011; Waanders et al. 2012). Convergent 
evolution has also been found in ALL samples, with subclones from the same patient having 
different mutations of the same gene (Waanders et al. 2012).  Samples with fewer CNA tend 
to have linear evolution compared to samples with increased CNA having a more complex 
clonal architecture. A more complex branching evolution is also associated with relapse in 
ALL. However, in both linear and branching clonal architecture the terminal clone does not 
always represent the major subclone, in fact there are branches that are evolutionary dead 
ends due to deleterious genetic alterations (Anderson et al. 2011; Landau et al. 2014).  
Experimental evidence for the variegated genetics of leukaemia initiating cells comes from 
murine engraftment experiments, as serial transplantation with a single ALL sample and 
multiple xenografts of a single primary ALL results in different clones engrafting, an 
indication of the many subclones in ALL that are capable of initiating leukaemia (Anderson et 
al. 2011; Notta et al. 2011).  
If variegated genetics provides the units for evolution of ALL, chemotherapy represents the 
evolutionary driver for relapse.  Treatment represents an evolutionary bottleneck in clonal 
evolution with the death of the majority of subclones. Survival of the fittest means that only 
those clones with a genetic alteration which grants them increased fitness allowing them to 
evade chemotherapy will survive to expand and cause a relapse (Figure 6). These relapse 
initiating subclones may be part of the initial diagnosis or even a pre-leukaemic clone 
(Mullighan et al. 2008). Wherever the relapse originates from, high inter-clonal 
heterogeneity increases the chance for one of the subclones to harbour a mutation that 
increases the risk that relapse will occur.  
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1.11 Recurrent genetic alterations at relapse 
 
Analysis of paired diagnosis and relapse samples represents an excellent way to determine 
which mutations are driving relapse. These pairs have been used to determine a specific 
signature of genes which are significantly up or down regulated at relapse. This signature 
includes genes involved in cell cycle, apoptosis, DNA repair, metabolism, B cell development 
and drug resistance genes (Beesley et al. 2005; Bhojwani et al. 2006; Staal et al. 2010; Kuster 
et al. 2011). Interestingly, this signature is different when comparing early or late relapse 
(Hogan et al. 2011). 
Changes to the epigenetic landscape have also been implicated in the emergence of relapse. 
The methylation of cytosine-phosphate-guanine (CpG) sites in the genome is increased in 
relapsed ALL compared to presentation, indicating dysregulation at an epigenetic level has a 
role in the emergence of relapse (Hogan et al. 2011). In fact, treatment of ALL cell lines and 
patient samples either with a DNA Methyltransferase inhibitor or a histone deacetylase 
inhibitor can alter the relapse specific gene signature, reversing it to a diagnosis like 
signature, as well as acting synergistically with chemotherapy or restoring drug sensitivity 
(Bhatla et al. 2012). These drugs might represent a useful addition to treatment protocols for 
relapsed ALL as there is increased drug resistance at relapse, which is increased further with 
subsequent relapses (Styczynski et al. 2015). 
As well as epigenetic alterations throughout the genome there are also recurrent somatic 
mutations associated with relapse. Relapse specific deletions in the DNA mismatch repair 
gene MSH6 (Muts homolog 6) have been found recurrently in ALL. MSH6 is not only a DNA 
repair gene but has also been implicated in drug resistance to mecaptopurines and steroids 
(Hogan et al. 2011). Other recurrent deletions that affect drug resistance have been found in 
BTG1, a co-activator of NR3C1 (Nuclear receptor subfamily 3 group C member 1), and 
TBL1XR1 (Transducin (Beta)-like 1 X linked receptor 1), which is also involved in 
glucocorticoid (GC) signalling at rates of 10-14%. BTG1 and TBL1X1R mutations do not occur 
together. Which indicates that loss of just one is enough to result in GC resistance (Bhatla et 
al. 2014). 
Not only can chemotherapy select for clones that will cause a relapse, such as subclones 
with a mutations resulting in drug resistance, but due to the nature of the drugs used for 
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treatment, some of the commonly used drugs can induce mutations that could drive relapse 
or even second cancers (Godley and Larson 2008).  
 
Figure 6: The scheme shows the intra-disease heterogeneity of ALL. The disease at diagnosis 
is already heterogenous having developed clonally from the leukaemia initiating cell over an 
unknown period of time. The use of treatment acts as an evolutionary bottleneck where only 
cells able to evade chemotherapy survive. These cells then act as the initiating cells for clonal 
evolution and the relapse is often the re-emergence of these cells or subclones derived from 
these with the acquisition of further mutations (Landau et al. 2014; Mullighan et al. 2008).  
 
1.12 Glucocorticoids in ALL  
 
The pro-apoptotic action of synthetic GC on lymphoid tissues has been exploited for the 
treatment ofleukaemia since the late 1950s (Pearson and Eleil 1950). In 1959 prednisone, a 
synthetic GC, was used to induce remission before treatment with 6-mercaptopurine. This 
was the first trial to use synthetic GC in combination with other drugs for the treatment of 
ALL and 67% of patients had induction of remission by prednisone, and although the median 
length of remission was only 29 weeks this represented a major step in the treatment of ALL 
(Freireich et al. 1963). Over the following years treatment protocols were improved and 
prednisone became part of the backbone of ALL treatment. Dex, another synthetic GC was 
first compared to prednisone in the 1970s, it was found that with Dex treatment there was a 
lower incidence of CNS disease (14.3% vs 25.6%) (B. Jones et al. 1991). As well as better CNS 
treatment, Dex has a longer half-life than prednisone and a higher cytotoxicity in patient 
cells than prednisolone (the active metabolite of prednisone) (IC50 0.2 µM vs 3.5 µM). Dex 
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has become the main GC used for ALL treatment. This increase in efficacy is linked to an 
increase in the side effects such as osteonecrosis, mood effects and infections compared to 
prednisone (Inaba and Pui 2010). Not only are synthetic GC indispensable in the treatment 
of ALL, sensitivity to GC is a major prognostic factor, with patients classed as GC poor 
responders having a 5 year EFS of just 55% compared to >80% for the good responders 
(Moricke et al. 2008). 
The anti-apoptotic effects that make synthetic glucocorticoids so useful in ALL are mediated 
through NR3C1, the GC receptor, by a complex process. Both transcriptional modulation and 
cytoplasmic protein: protein interactions are required for the initiation of the apoptosis 
cascade. De novo RNA and protein production appears to be a requirement for GC induced 
apoptosis, cells treated with actinomycin D (transcriptional inhibitor) do not have a GC 
induced increase in cytosolic Ca2+ and the downstream apoptosis pathway (McConkey et al. 
1989). Blockage of several steps can result in inhibition of apoptosis, for example caspase 
activation, aSMase (Acid sphingomyelinase) activity and phospholipase C indicating that the 
process from GC treatment to apoptosis is a multi-stepped process (Cifone et al. 1999; 
Marchetti et al. 2003). The NR3C1 target gene BIM (BCL211, BCL2 like 11), which is up-
regulated by GC treatment is essential for GC induced apoptosis. siRNA (small interfering 
RNA) knockdown of this gene results in GC resistance in lymphoid cells, likely because loss of 
the BIM expression results in lack of antagonism of the anti-apoptotic proteins BCL2 (B cell 
CLL/lymphoma 2), BCL2L1 (BCL2 like 1) and MCL1 (Myeloid cell leukaemia 1) (Abrams et al. 
2004; Schmidt, Rainer, et al. 2006; Bachmann et al. 2005; Jing et al. 2015). 
Interestingly, glucocorticoids have an anti-apoptotic effect in some cells such as granulosa 
cells and liver fibroblasts (Costas et al. 2000; Evans-Storms and Cidlowski 2000; Sasson, 
Tajima, and Amsterdam 2001). This is likely due to differences in the genes activated and 
activity of the different α isoforms of NR3C1. 
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1.13 Glucocorticoid resistance 
 
Although synthetic GC are efficient at the induction of apoptosis in lymphocytes, a number 
of patients become GC resistant after prolonged treatment. The mechanisms of this 
resistance are not well understood but the number of patients developing resistance is 
disparate to resistance to other drugs, with >24-fold increased resistance to GC at relapse 
compared to presentation. With only 0.8-1.9 fold increases at relapse for other commonly 
used drugs (Klumper et al. 1995; Bachmann et al. 2005). 
In cell lines GC resistance may be mediated by deletions or somatic mutations that alter 
ligand binding to NR3C1, NR3C1 translocation to the nucleus or NR3C1 dimer binding to the 
glucocorticoid response element (GRE) sequences. This resistance is dose dependent to the 
levels of NR3C1 expression and can be restored by the re-expression of wild type NR3C1 
(Helmberg et al. 1995; Schmidt, Irving, et al. 2006; Bachmann et al. 2007; Gruber et al. 
2009). 
This is not the case for primary ALL samples, which even at relapse only have approximately 
5% frequency of NR3C1 deletions or mutations (Mullighan et al. 2007). In a small study of 
patient derived xenografts none were found to have deficient nuclear translocation of 
activated NR3C1, and the receptor was transcriptionally active. In selected patient-derived 
xenografts resistance could also be reversed pharmacologically (Bachmann et al. 2007), 
these different mechanisms for resistance in primary derived samples and cell lines 
highlights the need for the use of appropriate models when investigating drug resistance in 
ALL.  
Although deletions are relatively rare in ALL, in blastic plasmacytoid dendritic cell neoplasm 
(BPDCN), an aggressive leukaemia it is much more common, with 28% of cases having 
monoallelic deletion on NR3C1 (Emadali et al. 2016). The high percentage of monoallelic 
rather than homozygous deletions in BPDCN along with the rarity of NR3C1 deletions in ALL 
points to the requirement of NR3C1 for cell viability. This is supported by the fact that NR3C1 
knockout mice die at birth as a result of respiratory failure, showing poor lung development 
as well as lack of adrenaline synthesis, and reduced erythropoiesis and gluconeogenesis 
(Manwani et al. 2010).  
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Changes in the transcriptional activity of NR3C1 are the likely as a cause for GC resistance. 
The inability of NR3C1 to induce transcription of BIM has been found as a mechanism for GC 
resistance at relapse, due to both increased methylation of BIM and also reduced histone 
modifications, this can be reversed by treatment with the HDAC (histone deacetylase) 
inhibitor vorinostat (Bachmann et al. 2010). Deletion of IKZF1, which is correlated with an 
increased risk of relapse, also alters the transcriptional response of cells to GC. IKZF1 
increases NR3C1 transcription and knockdown in GC sensitive cell lines results in gain of 
resistance (Klumper et al. 1995; Marke et al. 2015).  
GC resistance at diagnosis is also an issue. The 10% of paediatric patients that are classed as 
GC poor responders have reduced survival (Moricke et al. 2008). Analysis of the genetics of 
GC poor responders has identified several genes that confer risk, including the expression of 
ABCC3 (ATP binding cassette subfamily C member 3) and GSTT1 (Glutathione S-transferase 
Theta 1)(Anderer et al. 2000; Steinbach et al. 2003). The local chromatin environment of 
NR3C1 target genes is also implicated in GC resistance, GC poor responders were found to 
have significantly reduced H3K9 acetylation of BIM, a gene essential for GC induced 
apoptosis (Bachmann et al. 2010). Interestingly polymorphisms in NR3C1 have not been 
associated with an increase in GC resistance in leukaemia or other diseases, but levels of 
NR3C1 expression are associated with changes in GC sensitivity (Koper et al. 1997; Niu et al. 
2014; Kaspers et al. 1994).  
 
1.14 NR3C1 
 
The nuclear receptor subfamily 3, group C, member 1 protein (NR3C1) is the GC receptor 
which is located on the q arm of chromosome 5 at q31.3. The endogenous GC cortisol binds 
to this receptor and has numerous biological functions.  
There are 9 known alternative first exons, each of which is controlled by a separate 
promoter (Turner and Muller 2005), resulting in a variable 5’ untranslated region (UTR). 
These different 5’ UTRs have been shown to have several implications for NR3C1, including 
changes to the secondary structure of RNA, the half-life of transcripts and the levels of 
NR3C1 protein expressed (Turner et al. 2014).  
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There are two main isoforms of the glucocorticoid receptor (GR), alpha(α) and beta (β), the 
exon and protein structure of these two isoforms is shown in Figure 7. The β isoform was 
originally thought just to be a dominant negative regulator of the α form, but more recently 
it has been found to have transcriptional activity of its own (Lewis-Tuffin et al. 2007; Kelly et 
al. 2008).  The α form is transcriptionally active and has many isoforms as a result of the 
alternate first exons. The α isoforms are all able to translocate to the nucleus upon ligand 
activation but have different transcriptional activity and regulate a different set of genes. 
Less than 10% of glucocorticoid modulated genes are regulated by all of the α isoforms of 
NR3C1 (Lu and Cidlowski 2005).  
 
Figure 7: The structure of NR3C1 from DNA to protein. Top – the exon structure of NR3C1, 
including both exon 9α and β. Middle – the cDNA sequences of the two main isoforms of 
NR3C1, α and β. Bottom – the protein sequence of the same two isoforms showing nucleotide 
length of the final protein. The colours used correspond to the regions of the gene and 
protein, red indicates the 5’ untranslated region (UTR) in which there are many possible 
splice variants. Blue indicates the N terminal transactivation domain, Green shows the DNA 
binding domain and the purple regions denote the exons that make up the ligand binding 
domain where glucocorticoids bind.  
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The alternative exons are expressed differently in different tissues and only the 
hippocampus expresses all of the known isoforms. CD19 positive B cells express all isoforms 
except 1D, and only very low levels of 1E, whereas the liver only expresses exons 1G and 1B 
(Turner and Muller 2005). These differences in tissue expression and the modulation of 
different genes by different isoforms could be the basis for the differential effect of GC in 
different tissues, notably the induction of apoptosis in lymphoid cells.  
As well as a variable N terminal domain, the protein also consists of two other main regions. 
The DNA binding domain (DBD), which contains a zinc finger, is required not only for the 
receptor to bind specific DNA sequences but also for homodimerisation and interaction with 
co-factors. The ligand binding domain (LBD) is where glucocorticoids bind with the receptor 
as well as chaperone and co-regulatory proteins (Zhou and Cidlowski 2005). NR3C1 protein is 
found in the cytoplasm as part of a large complex with several chaperone proteins including 
HSP90, HSP70 (heat shock protein 70/90), p23 (PTGES3, Prostaglandin E synthase 3), and 
several immunophilins including FKBP proteins (Pratt and Toft 1997; Morishima et al. 2003). 
Upon the passive diffusion of glucocorticoids into the cytoplasm they bind with NR3C1 and 
the complex disassembles and NR3C1 translocates to the nucleus. Not all of the chaperone 
proteins are disassociated from NR3C1 upon ligand binding. HSP70 does not disassociate and 
it is thought that it is involved in the DNA binding or transcriptional activity of NR3C1 
(Srinivasan, Patel, and Thompson 1994).  
Translocation of ligand bound NR3C1 to the nucleus occurs within minutes, and the most 
rapidly modulated genes have an increase in mRNA after just 15 minutes (Ringold et al. 
1977). Most genes however take a couple of hours for alterations in mRNA levels to be seen. 
The classical view of NR3C1 gene activation occurs by homodimers of NR3C1 binding to 
specific sequences in promoters called glucocorticoid response elements (GRE) to induce 
transcription of target genes. The classical GRE consist of 2 mirrored short sequences joined 
by 3 nucleotides. Each   is an inverted repeat of the other (Scheidereit et al. 1983). The 
transcriptional response is influenced by the number of GRE in a promoter (Freedman and 
Luisi 1993). As well as the transcription inducing GRE there are also negative GRE (nGRE) that 
repress transcription. The repressive action of nGRE has been shown to result from the 
unique binding of NR3C1 at the sites which inhibits receptor homodimerization, resulting in 
monomers of NR3C1 bound at negative response elements in the DNA (Ratman et al. 2013). 
Binding of NR3C1 monomers at these sites results in the recruitment of a repressor complex 
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that inhibits transcription (Sakai et al. 1988; Surjit et al. 2011). Figure 8 outlines the process 
of glucocorticoid regulation on transcription via the GRE.  
 
 
Figure 8: A simplified schematic showing the mechanism of NR3C1 modulated transcription 
via a classical response element. Briefly, GC (glucocorticoids) enter the cell by passive 
diffusion, once in the cytoplasm GC bind to NR3C1 and most chaperone proteins disassociate. 
Once the chaperone proteins have disassociated NR3C1 translocates to the nucleus where it 
homodimerizes with other GC:NR3C1 complexes. NR3C1 homodimers bind to GRE 
(glucocorticoid response element) sequences and modulate transcription. The DNA 
interaction show is via a classical GRE sequence, several other interactions also occur. 
Adapted from (Bhadri, Trahair, and Lock 2012; Little and Storb 2002).  
 
It has also become apparent that homodimers of NR3C1 binding to the consensus GRE 
sequence is not the only mechanism by which it exerts its effects on gene expression. NR3C1 
also acts via direct protein interactions and with other transcription factors (Yang-Yen et al. 
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1990).There are several mechanisms by which NR3C1 can result in transactivation and 
transrepression of genes, both by direct interactions with the DNA sequence, and by protein 
interactions with other transcription factors (Figure 9). NR3C1 not only induces changes in 
gene expression of its direct target genes but also acts with several other transcription 
factors including AP-1, STAT1-3 and CEBPB (Ratman et al. 2013; Latchoumanin et al. 2007; 
Wu and Bresnick 2007) 
 
Figure 9: Schematic detailing the several different mechanisms by which NR3C1 can induce 
alterations in transcription including activation of genes (top) and repression of genes 
(bottom). The NR3C1:GC complex interacts with both DNA and other transcription factors in 
at least 10 different ways (shown above) to result in either transactivation or transrepression 
of NR3C1 target genes. Adapted from (Ratman et al. 2013).  
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1.15 CRISPR 
 
The use of clustered regularly interspaced short palindromic repeats (CRISPR) technologies is 
rapidly becoming an important technique in genome editing, it is relatively new, only having 
come to the forefront in the past few years.  
Repeats of DNA that would later go on to be determined as CRISPR loci were first found in 
1987 as a coincidental finding whilst sequencing a gene in Escherichia coli (Ishino et al. 
1987). It was not until 2005 that the idea that these repeated elements might have a role in 
immunity was postulated when three different groups independently found that the 
sequences between the spacers were from foreign DNA (Bolotin et al. 2005; Mojica et al. 
2005; Pourcel, Salvignol, and Vergnaud 2005). This role was experimentally proven a few 
years later when after phage exposure, resistant Streptococcus  thermophillus were found to 
have integration of phage DNA into novel CRISPR spacers (Barrangou et al. 2007). This 
immunity is dependent on previously encountered DNA and so can be thought of as similar 
to the adaptive immunity in humans. There are three types of CRISPR-Cas immune systems 
in archaea and bacteria, type I, II and III. 90% of archaea and 40% of bacteria have been 
found to have CRISPR-Cas systems and of those a further 44% have Cas genes associated 
with more than one of these systems. So far 65 Cas proteins have been identified (Makarova 
et al. 2011).  
Type I systems are characterised by the presence of Cas3 proteins. This system uses the 
cascade (CRISPR associated complex for anti-viral defence) complex for DNA targeting, and 
the Cas3 enzyme for DNA degradation (Huo et al. 2014). In type III CRISPR-Cas systems the 
associated protein is Cas10 and they have a targeting system similar to the cascade complex 
of type I.  Type III systems have also been implicated in RNA cleavage, and may have a similar 
function to RNA interference (RNAi) systems in eukaryotes. Type II CRISPR systems have so 
far only been found in bacteria whereas type I and type III systems have also been found in 
archaea (Rath et al. 2015).  
It is the type II CRISPR-Cas systems that have been exploited for genome engineering 
because of the system’s reliance on just one Cas protein for cleavage rather than several as 
in type I and III.  The Cas9 endonuclease cleaves DNA, targeted by short RNA sequences to 
guide Cas9 to the complementary DNA sequence. The Cas9 proteins are large proteins that 
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vary across bacteria with type II systems, which is around 10% of all bacteria (Makarova et 
al. 2011). There are three subtypes of Cas9 proteins, A B and C, which are composed of 
between 1100 and 1400 amino acids that form a 2 lobed secondary structure. There are two 
active sites, the HNH site that cleaves the complementary DNA strand, and the RuvC domain 
that cleaves the non-complementary DNA strand, resulting in double strand breaks (DSB) in 
the DNA. These active sites are in highly positively charged DNA binding groves to facilitate 
binding of the negatively charged DNA. When Cas9 is not in a complex with crRNA to guide I, 
the protein adopts an auto-inhibitory conformation which abrogates nuclease activity   
(Garrett, Vestergaard, and Shah 2011; Gaj, Gersbach, and Barbas 2013; Jinek et al. 2014). All 
Cas proteins need a protospacer adjacent motif (PAM) sequence at the end of the targeting 
RNA andthis differs between the different types of Cas proteins. This results in a vast array of 
targeting options, especially in bacteria that have been found to have more than one 
CRISPR-Cas system.  
There are three main steps in CRISPR-Cas immunity. Firstly the integration of new sequences 
into the CRISPR locus, then the processing of this locus to give crRNA sequences and finally 
targeting by the crRNA to foreign DNA and cleavage by Cas endonucleases. Briefly, foreign 
DNA enters the cell and is targeted by Cas1 and Cas2. These proteins mediate the production 
of novel spacers of around 30bp that are integrated into the CRISPR locus in the genome. 
They are highly conserved across all bacteria and are found in conjunction with all of the 
different Cas systems, mutations that result in disrupted Cas1-Cas2 complexes cause loss of 
spacer acquisition activity (Nuñez et al. 2014). The CRISPR locus is then transcribed with the 
new spacers into the pre-crRNA transcript, which is further modified resulting in short crRNA 
transcripts. These assemble with Cas proteins and upon the entry of the same foreign DNA 
into the bacteria the Cas-crRNA complex is targeted to the DNA by the crRNA and the DNA is 
cleaved (Figure 10).  
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Figure 10: Mechanism of CRISPR-Cas mediated bacterial acquired immunity. Viral DNA enters 
the cell and is targeted by a complex of Cas1 and Cas2 endonucleases. This results in the 
fragmentation of viral DNA and insertion into the CRISPR locus, with short repeat sequences 
known as spacers between viral DNA sequences. This locus is then transcribed by the 
endogenous bacterial transcriptional machinery and cleaved resulting in mature crRNA that 
forms complexes with the Cas enzymes. These crRNA:Cas complexes are then guide the 
targeting of foreign DNA  complementary to the spacer in the complex (Makarova et al. 
2011; Bondy-Denomy and Davidson 2014; Nuñez et al. 2014; Gaj, Gersbach, and Barbas 
2013).  
The lentiCRISPRv2 CRISPR-Cas system which has been developed for genome engineering 
uses the Cas9 from Streptococcus pyrogenes, a type II A Cas9, with around 1400 amino acids. 
The mechanism by which CRISPR-Cas technology has been harnessed for genome 
engineering by the lentiCRISPRv2 plasmid (Figure 11) is outlined in Figure 12 (Jinek et al. 
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2012; Shalem et al. 2014).  Briefly, cells are transduced with plasmids carrying the short 
guide RNA (sgRNA), which is the targeting molecule like the crRNA in the bacterial system. 
The plasmid is integrated into the host genome and the Cas9 and sgRNA are transcribed 
under the control of two separate promoters, the U6 and EFS promoters. The sgRNA and 
Cas9 assemble into a complex and are targeted to the complementary sequence in repaired 
using the cellular machinery for non-homologous end joining (NHEJ) or homologous 
recombination (HR), the two main DNA repair pathways in cells.  
HR is the less error prone of the two systems, and uses a homologous DNA sequence to 
guide repair. Often this will be the sister chromatid, but this system is being utilised with 
short donor guide sequences in CRISPR-Cas systems for site directed mutagenesis (Collonnier 
et al. 2016). HR is active mainly during the S and G2 phases of cell cycle (Grzegorz et al. 
2004). Conversely, NHEJ is active throughout the cell cycle and is more active than HR, 
meaning it is the main pathway by which DSB are repaired. NHEJ re-ligates DSB without a 
guide sequence and has a high frequency of errors. These errors are small, often between 1 
and 10bp but these indels are enough to result in frame shifts or stop codons that would 
result in loss of protein function. The acquisition of indels after NHEJ does not occur at a very 
high rate, only around 5%, but if the target sequence is repaired faithfully the Cas9-sgRNA 
complex can target the sequence again, resulting in an increase in target sites with indels 
over a period of time (Chiruvella, Liang, and Wilson 2013; Jasin and Rothstein 2013; David 
Wyatt 2015). By the introduction of indels CRISPR-Cas9 systems offer gene knockout rather 
than gene knockdown as with the previous generation of genome engineering tools that 
utilised RNAi and shRNA to reduce gene expression. This will be especially useful for the 
investigation of genes in which only a complete loss of protein results in a phenotype.  
The Cas9 from Streptococcus pyrogenes has the PAM sequence of 3’-NGG, and assuming the 
frequency of CG of 5.2% in the genome there would be 1.6x108 predicted NGG sites in the 
genome. This results in the possibility of targeting almost every gene in the genome.  
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Figure 11: Structure of the lentiCRISPRv2 plasmid showing the genes required for lentiviral 
production  such as Psi+ (Psi packaging element), RRE (Rev response element), cPPT (central 
polypurine tract) and WPRE (Woodchuck hepatitis virus posttranscriptional regulatory 
element) and then elements specific to the lentiCRISPRv2 plasmid such as the U6 (U6 
promoter), sgRNA (short guide RNA), spCas9 (Streptococcus pyrogenes Cas9), FLAG (FLAG 
tag) and Puro (puromycin resistance gene) (Sanjana, Shalem, and Zhang 2014; Shalem et al. 
2014).  
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Figure 12: Mechanism of CRISPR-Cas9 mediated double strand breaks (DSB) using the 
lentiCRISPRv2 plasmid. Lentivirus produced using the lentiCRISPRv2 plasmid and packaging 
and envelope plasmids are used to transfect target cells. The lentiCRISPRv2 plasmid DNA is 
incorporated into the host genome. sgRNA and Cas9 transcribed under control of the U6 and 
EFS promoters which are constitutively active. Once transcribed and translated the Cas9 and 
sgRNA form a complex which is then guided to the complementary DNA sequences in the 
host genome. The Cas9:sgRNA complex binds to the DNA and the DNA is cleaved at the two 
active sites in Cas9 resulting in DSB. DSB are repaired by non homologous end joining(NHEJ) 
or less frequently homologous recombination (HR) resulting in the acquisition of indels, or the 
re-formation of the intact targeting sequence (Jinek et al. 2014; Shalem et al. 2014; Sanjana, 
Shalem, and Zhang 2014).   
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1.16 Genetic Screening 
 
Genome editing using CRISPR or any of the other available techniques such as RNAi, Zinc 
fingers, TALENs (Transcription activator like effector nuclease) or transposon directed 
mutagenesis all represent a way to interrogate the function of genes in both normal and 
pathological conditions. CRISPR and RNAi are the most widely used, and each has 
advantages and disadvantages (Table 3), but for all loss of function techniques screening 
works in broadly the same way. There are two main types of screen, positive or negative and 
each looks for a different endpoint (Figure 13). Positive screens are designed to look for 
constructs which are enriched in the sample compared to the baseline (or control), which 
will be targeting genes harmful to cancer propagation. For example, positive screens have 
identified GAS1, (Growth arrest specific 1) a metastasis suppressor CDKN2A (Cyclin-
dependent kinase inhibitor 2A) which is a cell cycle control gene, and genes involved in drug 
resistance such as MEK2/4 (Mitogen activated protein kinase 2/4) (Gobeil et al. 2008; C. L. 
Jones et al. 2015; Wallace et al. 2016). Negative screens on the other hand look for which 
constructs are lost from the baseline as these constructs cannot be tolerated in the cell, so 
the genes they are targeting may be important for leukaemic growth, such as STAT5 (Signal 
transducer and activator of transcription 5), or anti-apoptotic genes such as BCL2 (Wallace et 
al. 2016). 
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Screening 
technique 
Advantages Disadvantages 
CRISPR  Easy to target 
 Less Expensive for library 
 Can target specific exons 
 Complete knockout 
 Less off target effects due to 
requirement of PAM 
 
 Off target effects of Cas9 
 Possible haploinsufficiency 
 In frame mutations/null mutations 
 Requires intact DNA repair pathways 
 Closed chromatin may affect targeting 
RNAi  Easy to target 
 Expensive to buy library 
 Identify genes with 
dose/phenotype relationship  
 Reversible  
 Incomplete mRNA knockdown  
 May affect endogenous RNAi pathway 
 Nuclear transcripts harder to target 
 Binding with mismatches causing off 
target effects 
 Prone to silencing 
Table 3: Comparison of the advantages and disadvantages of CRISPR and RNAi screening 
methods. Both methods have positive and negative features which makes selection of the 
right choice important when designing experiments (Housden and Perrimon 2016; Boettcher 
and McManus 2015; Kuscu et al. 2014) 
There are several factors that should be taken into account when designing screens in order 
to have high statistical power, and to be sure that hits are not false positives. Reproducibility 
between screens can be used to determine the relative statistical power of each screen. 
Statistical power is the chance of calling correctly whether a found difference is actually 
statistically significant. A power of 80 % is considered necessary for genome wide screens 
(Cohen 1988; Stombaugh et al. 2015).  Increased coverage of targeting constructs in screens 
results in more overlap between repeats and better reproducibility. As well as coverage, 
optimisation of the PCR (polymerase chain reaction) steps is also important in ensuring 
reproducibility and in turn statistical power of screens. PCR needs to maintain the coverage 
of the DNA pool as well as keeping amplification steps in the exponential phase (Strezoska et 
al. 2012). 
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As the PCR steps are essential for maintenance of the pool complexity a large number of 
reactions can be required. Considering one molecule of DNA can be synthesised into millions 
of copies in just 30 cycles of amplification, even a tiny contamination can skew results. An 
aerosol from a PCR product can contain as many as 1x106 copies of DNA (Persing 1991) 
which can contaminate the PCR area. Furthermore as dried DNA is less susceptible to 
ultraviolet light, as are short sequences, it can be very difficult to clean an area once 
contaminated (Sarkar and Sommer 1990).  
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Figure 13: The basic premise of positive and negative genetic screens. Both types of screen 
start with a pool of cells transduced with many different constructs. The treatment of the 
cells throughout the screen may also be the same for a positive and negative screen, the 
main difference is when it comes to analysis. A positive screen is designed to identify 
constructs which are enriched at the end, and negative screens are designed to determine 
both the enriched constructs and the depleted constructs. The major reason why a positive 
screen would be chosen instead of a negative screen is the levels of coverage generally 
accepted to be required for a negative screen, which is 1000x coverage. If a whole genome 
screen is being used then the numbers of cells needed rapidly gets unmanageable in vivo.  
Different coloured cells indicate different targeting constructs in each cell.  
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1.17 Previous work 
 
Previous work was carried out in the lab by Dr. Elda Latif (Latif 2012) on paired presentation 
and relapse samples from a case of t(17;19) B cell progenitor ALL; the L707 cells (Table 4). 
The samples were chosen as in the relapse there is a homozygous deletion on the q arm of 
chromosome 5 spanning 6 genes; NR3C1, HMHB1, YIPF5, ARHGAP26, and KCTD16 that was 
identified by Affymetrix SNP6 sequencing (Figure 14). Comparison of the SNP6 data between 
the original patient sample and engrafted samples showed there were no major differences 
between them, indicating the mouse model to be representative of the patient samples.  
L707 presentation cells were found to engraft faster than relapse cells except in the 
presence of Dex treatment, when survival of mice was significantly increased. The relapse 
cells were unaffected by Dex treatment (Figure 15).  
 
 
 
 
 
Figure 14: A circos pot showing the copy number gains (green dots radiating outwards) and 
losses (red dots radiating inwards) compared to normal (grey dots in the centre) in the L707 
Relapse, shown on the left. Constructed using the SNP6 data for the L707 relapse. Data 
produced by Elda Latif and Vikki Rand and circus plot produced by Sirintra Nakjang. The 
expanded section shows the region of the circus plot showing chromosome 5, with 
chromosomal location shown to the right of the SNP6 data. The 5q deletion can be seen in 
this expanded section as the thicker line of red dots on the lower half of the chromosome (the 
q arm) towards the centre of the plot. 
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Figure 15: Survival of mice engrafted with 1x105 L707 presentation (left) or L707 relapse 
(right), cells were injected intra-femorally. Mice were treated with either I.P. Dex (15 mg/kg) 
on weekdays, or saline controls. Treatment was started 2 weeks after intra-femoral injection 
of leukaemic cells. Treatment was continued until mice reached license endpoints and were 
humanely killed. Data produced by Elda Latif (Latif 2012).  
 
To investigate this difference in engraftment time between the presentation and relapse 
L707 cells were injected into NSG mice in a competitive setting. Different ratios of 
presentation: relapse cells were used and it was found that the presentation cells engrafted 
and repopulated faster than the relapse cells at all ratios, which resulted in mice succumbing 
to the disease sooner. This was not the case when Dex treatment was given and the 
sensitivity of the L707 presentation to Dex closed the gap between presentation and relapse 
(Figure 16).  
 
Figure 16: Survival of mice engrafted with ratios of L707 presentation and relapse, 1x105 
cells/mouse. 2 weeks after intra-femoral injection of leukaemic cells treatment was started, 
saline I.P. on weekdays (left) or 15 mg/kg Dex I.P. on weekdays (right). Treatment was 
continued until mice reached license endpoints and were humanely killed. Data produced by 
Elda Latif (Latif 2012). 
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Age 16 years 
Sex Female 
Presentation 
karyotype 
46,XX,der(19)t(17;19)(q2?;p13)[12]/46,idem,fra(10)(q25)[17]
/46,XX[1].ishder(19)t(17;19)(19ptel-
,wcp17+,wcp19+,19qtel+) 
Relapse 
karyotype 
46,XX,der(19)t(17;19)(q2?;p13)[5] 
Treatment 
protocol 
Regimen B, ALL2003 
MRD day 28 Negative 
Relapse <5 months 
Relapse 
treatment 
R3 
FLAG 
Current  Patient died shortly after relapse from intracranial bleed 
Table 4: All available patient information and treatment details for patient L707 including 
age, sex, karyotype of both presentation and relapse. The treatment protocol used at 
diagnosis and the treatments used for the relapse. The patient was negative for MRD at day 
28 but had an early relapse and no second remission was induced. The patient died shortly 
after the second relapse due to an intracranial bleed.  
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 Chapter 2: Materials 
 
2.1 Chemicals 
Standard chemicals and reagents used were purchased from Sigma-Aldrich unless stated 
otherwise.  
2.2  Equipment 
Instrument Manufacturer Software 
1000 electroporator Stratgene, USA  --- 
ABI 7900HT Sequence Detection 
system 
Applied Biosystems, USA SDS 
Avanti J-26 XP centrifuge Beckman Coulter, UK --- 
Centrifuge 5424 Eppendorf, Germany --- 
Centrifuge 5424R Eppendorf, Germany --- 
Class II microbiological safety cabinet  
Medical Air Technology 
Ltd., UK 
--- 
CP 225D Balance Sartorius, Germany --- 
CytoVision Automated Cytogenetics 
Platform 
Leica, UK CytoVision 7.2 
FACS Aria III Beckton Dickinson, UK FACS Diva 
FACS Calibur Beckton Dickinson, UK 
Cell Quest Pro, 
Flowing Software 
FACS Canto II Beckton Dickinson FACS Diva 
FLUOstar Omega BMG labtech, Germany 
MARS Data 
Analysis Software 
GelDoc Imager BioRad, UK Quantity One 
IVIS Caliper Ltd., USA Living Image®  
MCO-18AC-PE CO2 Incubator Panasonic, Japan --- 
Mediphot937 X-ray film developer 
Colenta Labortechnik, 
Austria 
 --- 
Mini-PROTEAN Tetra Cell 2-gell 
system 
BioRad, UK  --- 
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Mini-sub Cell GT BioRad, UK --- 
Multipette stream® Eppendorf, Germany --- 
Multitron Pro, bacterial orbital shaker Infors, UK ---  
Nanodrop 1000 spectrophotometer 
Thermo Fisher Scientific, 
UK 
Nanodrop 1000 
Optima L-100 XP ultracentrifuge Beckman Coulter, UK  --- 
Perkin Elmer GeneAmp 9700 Thermo 
Cycler 
Perkin Elmer, USA --- 
ThermoBrite StatSpin® Abbott Molecular, USA  --- 
Table 5: The equipment used during the PhD, the manufacturer and if applicable the 
software used with the equipment.   
2.3 Lab ware 
Standard lab ware was used throughout the project, separate consumables required for 
specific work are listed below.  
polyallomer Konical ™ (Beckman Coulter, USA)  
0.45 µm Acrodisc® syringe filter (Sigma Aldrich, UK) 
Illustra MicroSpin G-50 columns (GE Healthcare Life Sciences, UK) 
1mm electroporation cuvettes (Peqlab, Germany) 
 
2.4 Buffers 
Luria-Bertani (LB) broth (1l) 
- 25g LB broth powder  
 Contains: 10g/l Tryptone 
     10g/L NaCl 
     5 g/l Yeast extract 
- 1L DI H2O 
Autoclave to sterilise 
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SOB Media (1l) 
- 20g Tryptone 
- 5g Yeast extract  
- 0.5g NaCl 
- 186 mg KCl 
- 1g MgCl2 
- 2.4g MgSO4 
- 1l DI H2O 
Autoclave to sterilise 
LB agar (1l) 
- 25g LB broth powder 
- 12.5g Bacto agar  
- 1L DI H2O 
Autoclave to sterilise 
10x TBE (1l) 
- 108g Trizma (TRIS base)  
- 55g Boric acid  
- 40 ml 500mM EDTA solution  
- Make up to 1l with DI H2O 
0.5x TBE (1l) 
- 50 ml 10X TBE 
- 950 ml DI H2O 
500mM EDTA (500 ml) 
- 84.05g Ethylenediaminetetraacetic acid (EDTA) 
- Make up to 500 ml with DI H2O 
RIPA Buffer 
- 197 mg Tris-HCl  
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- 219.1 mg NaCl 
- 25 mg SDS 
- 0.25 ml Triton-X 
- 5.18 mg Sodium deoxycholate 
- 1 x cOmplete™ EDTA-free protease inhibitor cocktail tablet (Roche, UK) 
- 25 ml DI H2O 
Lammeli Buffer (25 ml) 
- 2.5 g SDS 
- 1.97 mg Tris-HCl 
- 12.5 ml DI H2O 
- 11.5 ml Glycerol 
10% Milk (100 ml) 
- 10 g Milk powder 
- 100 ml PBS 
10X TST (1l) 
- 12.114 g Tris 
- 87.66 g NaCl 
- 10 ml Tween 20 
HeBS 2X Buffer (1 l) 
- 16.36 g NaCl 
- 11.9 g HEPES 
- 0.123 g Na2HPO4 
- 1 l DI H2O 
- Required pH = 7 
- Filter sterilise (0.2 µm) before use 
Special H2O (50 ml) 
- 29.8 g HEPES 
- 50 ml DI H2O 
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- Filter sterilise (0.2 µm) before use 
Polybrene (8 mg/ml, 10 ml) 
- 80 mg hexadimethrine bromide 
- 10 ml DI H2O 
- Filter sterilise (0.2 µm) before use 
Tris-Glycine Buffer (1 l) 
- 30 g Tris 
- 144 g Glycine 
- 1 l DI H2O 
Electrophoresis Buffer (1 l) 
- 100 ml Tris-Glycine buffer 
- 10 ml 10% SDS (1g SDS) 
- 890 ml DI H2O 
Transfer Buffer 
- 100 ml Tris-Glycine Buffer 
- 10 ml methanol 
- 890 ml DI H2O 
Fixative 
- 30 ml Methanol 
- 10 ml Acetic acid 
SOC (super optimal broth with catabolite repression) media (Sigma Aldrich, UK) 
20X SSC (Thermo Fisher Scientific, UK)  
- Diluted 1:10 before use 
Wash Buffer 1 
- 2 ml 20X SSC 
- 300 µl IGEPAL 
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- Make up to 1 l with DI H2O 
Wash Buffer 2 
- 10 ml 20X SC 
- 1 ml IGEPAL 
- Make up to 1 l with DI H2O 
2.5 Kits 
 
NucleoBond Xtra (Macherey Nagel, Germany) 
Nick Translation kit (Abbott Molecular, USA) 
mirVanaTM miRNA Isolation Kit, with phenol (Ambion, Thermo Fisher Scientific, UK) 
BCA Protein Assay Kit (Santa Cruz Biotech, USA) 
RevertAidTMH Minus First Strand cDNA Synthesis Kit (Fermentas, Thermo Fisher Scientific, 
UK) 
Phusion® High-Fidelity PCR Master Mix with HF Buffer (NEB, USA) 
Platinum® SYBR® Green qPCR SuperMix-UDG w/ROX (Fermentas, Thermo Fisher Scientific, 
UK) 
Mix & Go E. Coli Transformation Kit & Buffer Set (Zymo Research, USA) 
NucleoBond Xtra mini kit (Clontech, Japan) 
The following kits were purchased from Qiagen: 
QIAquick PCR Purification Kit, QIAquick Gel Extraction Kit, Miniprep Plasmid Isolation Kit 
Maxiprep Endofree Plasmid Isolation Kit, DNeasy Blood and Tissue Kit, RNeasy Mini Kit 
2.6  Cloning enzymes 
 
T4 DNA ligase 5 u/µl (Fermentas, Thermo Fisher Scientific, UK) 
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FastAP Thermosensitive Alkaline Phosphatase (10 U/µl) (Fermentas, Thermo Fisher 
Scientific, UK) 
T4 Polynucleotide Kinase (10 U/µl) (Fermentas, Thermo Fisher Scientific, UK) 
Esp3I (BsmBI) (10 U/µl) (Fermentas, Thermo Fisher Scientific, UK) 
  
2.7 Tissue culture reagents 
 
RPMI 1640 (R8758) (Sigma Aldrich, UK) 
DMEM (D5671) (Sigma Aldrich, UK) 
low glucose DMEM (D6046) (Sigma Aldrich, UK)  
StemSpan ™ SFEM II (Stemcell technologies, Canada) 
GIBCO™ Foetal calf serum (Thermo Fisher Scientific, UK) 
L-Glutamine (Sigma Aldrich, UK) 
Penicillin-streptomycin (Sigma Aldrich, UK) 
GIBCO™ basic fibroblast growth factor (bFGF) (Thermo Fisher Scientific, UK) 
recombinant IL-3 (R&D Systems, UK) 
recombinant IL7 (R&D Systems, UK) 
Trypsin-EDTA 10X solution (Sigma Aldrich, UK) 
Sodium-pyruvate (Sigma Aldrich, UK) 
VivoGlo™ Luciferin (Promega, USA) 
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2.8 Antibodies 
 
Antibody  Fluorophore 
conjugated 
Clone Supplier Volume per 106 
cells (µl) 
CD19 PE SJ25C1 BD 
Biosciences, 
USA 
10  
Mouse CD45 PE-Cy7 2.5 BD 
Biosciences, 
USA 
2.5 
Mouse Ter119 PE-Cy7 TER-119 BD 
Biosciences, 
USA 
2.5 
Table 6: Antibodies used for FACS analysis of peripheral blood and organs collected from 
mice engrafted with ALL cells.  
Antibody  Source Clone Supplier Dilution  
Anti-α-Tubulin Mouse 
monoclonal 
B-5-1-2 Sigma Aldrich, 
UK 
1:200000 
NR3C1 Rabbit 
polyclonal 
E-20 Santa Cruz 
Biotechnology, 
USA 
1:500 
PLXND1 Rabbit 
polyclonal 
ab96313 Abcam, UK 1:1000 
Anti-mouse IgG-
HRP 
Goat polyclonal P0447 DAKO, Denmark 1:10000 
Anti-rabbit IgG-
HRP 
Goat polyclonal P0448 DAKO, Denmark 1:10000 
Table 7: Antibodies used for western blotting analysis of protein extracted from both cultured 
cells and samples collected from mice engrafted with ALL.  
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2.9 Oligonucleotides and primers 
All oligonucleotides were ordered from Sigma Aldrich 
Gene Forward 5’-3’ Reverse 5’-3’ 
TBP CTGGCCCATAGTGATCTTTGC TCAATTCCTTGGGTTATCTTCACA 
NR3C1 AGGACGCCACCCATTG TGTCTGAAGGGTCCCAGTTTG 
PLXND1 CTCTTAGCTTGTCGGGTCA ACAGTTGTGGAGGAGAGAGC 
GILZ CATGGAGGTGGCGGTCTA TTACACCTCATAACCACCAT 
NFKBIA GAAGTGTGGGGCTGATGTCA TGGCCTCCAAACACACAGT 
FKBP5 CATTATCCGGAGAACCAAAC AATTGGAATGTCGTGGTCTT 
Table 8: Primer pairs used for real-time PCR using cDNA reverse transcribed from mRNA.  
Gene Forward 5’-3’ Reverse 5’-3’ 
ATP10A AGCCCCATGGTGAGTGTACAG GTAGGATTAAATATAGACACCTTCCATGAG 
NR3C1 AGGACGCCACCCCATTG TGTCTGAAGGGTCCCAGTTTG 
Cas9 AGCTGATCCGGGAAGTGAAA GATTTCCTGCTCGCTCTTGG 
Table 9: Primer pairs used for real-time PCR using genomic DNA as the template 
Primer Primer 5’-3’ 
CRISPR amplification 
forward 
ACACTGACGACATGGTTCTACACTTGTGGAAAGGACGAAACACC 
CRISPR amplification 
reverse 
TACGGTAGCAGAGACTTGGTCTGTTGATAACGGACTAGCCTTA 
CRISPR adaptor 
addition forward 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC
TTCCGATCTTCTTGTGGAAAGGACGAAACACCG  
CRISPR adaptor 
addition reverse 
CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGGAGTTCAGA
CGTGTGCTCTTCCGATCTGTTGATAACGGACTAGCCTTA 
 
Table 10: Primers used in the production of the lentiCRISPR amplicon library before next 
generation sequencing was carried out.  
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2.10 Cells 
 
 697 
Pre B ALL cell line derived from the BM of a 12yr old male at relapse. The patient had null 
cell ALL (non B, non T) ALL at presentation but cells cultured at relapse had a pre-B 
phenotype. Carry the t(1;19) translocation (Findley et al. 1982).  
293T 
Cell line derived from embryonic kidney fibroblasts, contains the SV40 T antigen. These cells 
are highly transfectable, which is why they are used in the production of lentiviral particles  
(Pear et al. 1993). 
MS-5 
Murine bone marrow stromal cell line, derived by irradiation of adherent cells from the long 
term culture of C3H/HeNSIc mouse marrow samples. Capable of supporting growth of 
haematopoietic stem cells for more than 2 months (Itoh et al. 1989).  
M210B4 
Murine bone marrow stromal cell line, derived from a C57BL/6J X C3H/HeJ F1 mouse. This 
cell line produces pre-B stimulatory factors and are able to support the proliferation of pre-B 
cells in long term culture (Lemoine et al. 1988).  
L707 
Primary derived cells obtained at presentation and relapse from a 16-year-old female with B 
ALL, passaged through several xenografts. 
MSC 
Primary human mesenchymal stem cells. Collected from the hip of mostly hip replacement 
patients. Collection and purification by Dr. Deepali Pal.  
 
58 
 
2.11 Competent bacteria 
 
STBL3  
E. coli strain with the recA13 mutation that results in reduced recombination of cloned DNA, 
which is required for propagation of lentiviral plasmids.  
E. Cloni 10G 
Specific cloning strain of E. coli with high transformation efficiency. Have the recA1 
mutation, which causes reduced recombination of cloned DNA.  
  
2.12 In vivo model 
 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)  
The NSG (NOD scid gamma) mice are a transgenic line established from the NOD/ShiLtj mice 
with the addition of a scid (severe combined immunodeficiency) mutation and an IL2 
receptor gamma chain deficiency. The resulting mouse is highly immunodeficient, lacking in 
mature B, T and NK cells with deficient cytokine signalling. The NSG mice have 6x higher 
engraftment efficiency than the NOD-Scid mice without the IL2Rgamma chain mutation 
(Shultz et al. 2005). These mice were bred in house, with additional mice purchased from 
Charles River (USA) when additional animals were required.  
RAG2 (BALB/c Rag2-/- gamma c-/-) 
The RAG2 mice are another immune deficient strain. These mice lack the ability to undergo 
VDJ rearrangement and so mice have no mature B or T cells. The loss of the gamma chain, 
which is part of the IL2,4,7,9 and 15 receptors results in a loss of natural killer cells (Colucci 
et al. 1999). These mice were bred in house.  
CD1® IGS 
The CD-1 IGS mouse is an outbred mouse used as a multi-purpose model with no harmful 
genetic phenotype. These mice were purchased from Charles River (USA)  
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 Chapter 3: Methods 
 
3.1 Cell culture 
 
All tissue culture was carried out in a type II fume hood to maintain sterility. Cells lines were 
passaged 3 times a week and primary cells passaged as needed. 
Cell line Disease/model type Media density 
697 pre B ALL  suspension RPMI 1640  
10% FBS 
0.5x106/ml 
SEM pre B ALL  suspension RPMI 1640  
10% FBS 
0.5x106/ml 
HAL-01 pre B ALL  suspension RPMI 1640  
10% FBS 
0.5x106/ml 
293T Human 
embryonic 
kidney 
adherent DMEM  
10% FBS 
1% L-glutamine  
1% Sodium pyruvate 
2.5x105/ml 
MS-5 murine BM 
stromal 
adherent RPMI 1640 
10% FBS 
2.5x105/ml 
M210B4 murine BM 
stromal 
adherent RPMI 1640   
10% FBS 
2.5x105/ml 
Table 11: Information on culture of all cell lines used including disease type, cell type and the 
culture conditions required including the media used, the concentration of supplents 
including FBS and the density that cells were seeded at when split.  
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Cell  Disease type Media density 
L707 Pre B ALL suspension SFEM 
20% FBS 
20 ng/ml IL-3  
10 ng/ml IL-7 
1% pen/strep 
0.5-1x106/ml 
MSC healthy  stromal DMEM  
20% FBS  
bFGF  
1% L-glutamine  
1% pen/strep 
6000-
10000cells/cm2  
Table 12: Information on culture of primary human and primary derived cells including 
disease type, cell type and the culture conditions required.  
3.1.1 Counting cells 
 
Cells were counted using the trypan blue exclusion method. 10 µl of trypan blue and 10 µl 
cells were mixed and pipetted onto a haemocytometer for counting. This method uses the 
ability of viable cells to keep trypan blue out of the cell as a measure of viability. The 
disrupted membrane allows the trypan blue into the cells, showing them as blue, whereas 
live cells stay white. Haemocytometers have 4 squares, each comprised of 16 smaller 
squares; any cells in these 4 large squares were counted and used to determine the 
concentration of cells in the sample, with the following equation: 
Conc= n x df x cf = cells/ml 
Conc = concentration of cells in solution 
n = sum of cells counted 
df = dilution factor  
cf = chamber factor = (desired final volume/counting square unit volume) 
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An alternative method was used for cells collected from mouse organs, especially spleen and 
liver. This used methylene blue, at the same 1:1 ratio as trypan blue. Methylene blue causes 
red cells to lyse, making counting of lymphocytes easier in spleen and liver samples as these 
samples had high levels of red cells in. Methylene blue does not distinguish living from dead 
cells, and so trypan blue counting was also required for these samples.   
 
3.1.2 Culture of suspension cells 
 
All of the leukaemic cells used during the course of this PhD were suspension cells. These 
cells do not need to adhere to a tissue culture flask but grow in a suspension in media. To 
culture suspension cell lines, cells were mixed by shaking the flask and a small aliquot taken 
from the flask using a 5 ml stripette. This was pipetted onto Parafilm and 10 µl taken from 
this and added to 10 µl trypan blue. Using a sterile stripette reduces the risk of infection 
from using a pipette in the flask. Cells were counted using the trypan blue exclusion method 
(3.1.1). Cell number/ml was calculated and cells split to the required density using media 
pre-warmed in a water bath at 37°C. Mycoplasma testing was carried out periodically to 
ensure cells were uninfected, this test was done by Liz Matheson.  
 
3.1.3 Culture of adherent cells 
 
Adherent cells were used as feeder layers and in the production of lentivirus. The culture of 
these cells is different to suspension cells due to them attaching to the surface of the tissue 
culture flasks. To culture adherent cells, old media was removed from flasks using an 
aspirator and glass Pasteur pipette before 10 ml of pre-warmed PBS was added and the flask 
gently swirled to wash cells. This was then removed using a fresh Pasteur pipette and 3 ml 1x 
trypsin-EDTA (0.05% trypsin, 0.02% EDTA) added before incubation at 37°C for 3-5 minutes. 
Once cells were detached 7 ml fresh media was added to the cells in order to inactivate the 
trypsin before 10 µl was taken for counting (3.1.1) 
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3.1.4 Co-culture of leukaemic cells and feeder cells 
3.1.4.1 Growth on murine stromal cell line feeder layers 
 
In order to culture leukaemic cells in a manner that mimics the in vivo niche or to support 
growth ex vivo, feeder layers were used. These cells produce the necessary cytokines 
required to support growth of cell lines at low FBS concentrations, or primary derived cells 
that would usually not proliferate in vitro.  
The MS5 and M210B4 murine BM stromal cell lines were used as feeder layer to support 
growth of 697 cells. As adherent cell lines they were passaged 3 times a week (3.1.3) and re 
seeded in a new 75cm2 tissue culture flask or 96 well plates. If cells were to be used for 
cytotoxicity assays with the 697 cells, they were seeded at 4.5x104/ml the day before use in 
a 96 well plate.  
 
3.1.4.2 Growth on MSC feeder layer 
 
The MSC cells are primary cells, these were obtained from hips removed for hip replacement 
surgeries as a result of osteoarthritis. Dr. Deepali Pal received the hips and did all the 
processing. Cells were retrieved, purified and cultured according to the method in Pal et al 
2016. Briefly, BM was removed from the femoral head and cells were separated using 
Lymphoprep™ (1.077 g/ml). The mononuclear cells remaining after separation were 
collected and washed before culture. MSC adhered to the flask, and after a wash using MSC 
wash buffer 24h later the cells were cultured by Dr. Pal until ready to be split. At which point 
cells were kindly given to me for use. MSC were cultured in the same way as the other 
adherent cell lines used, although with less frequent cell passages required due to slower 
proliferation. MSC were seeded at 6000-10000 cells per cm2 3-5 days prior to use in plates or 
flasks as needed. Once the MSC had reached optimal confluency the cells were gently 
washed with PBS and the leukaemic cells added at a concentration of 0.5x104/ml -1x106/ml 
depending on when they are to be split again or the testing to be done.  
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3.1.5 Thawing cells 
 
Cells were thawed from storage in liquid nitrogen or -80°C by heating cells in a water bath at 
37°C until one ice crystal remained, cells were then pipetted into 10 ml of pre-warmed 
media and centrifuged at 300g for 5 minutes. The supernatant was removed by inversion of 
the tube and cells re-suspended in 5 ml of fresh pre-warmed media. Cells were then counted 
and seeded at a suitable concentration. 
 
3.1.6  Freezing cells 
 
In order to cryopreserve cells, they were split the day before freezing to ensure they were in 
log phase growth when frozen. On the day of freezing cells were counted and centrifuged at 
300g for 5 minutes. The supernatant was discarded and an appropriate volume of freezing 
media (FBS +10% DMSO) added (1 ml per 1x106 cells). Once freezing media was added, cells 
were kept on ice and aliquoted into labelled cryovials. Vials were then transferred to 
polystyrene boxes filled with cotton wool and stored at -80°C. This is to ensure the cells 
freeze slowly and so maintain viability when thawed. After 24 hours at -80°C cells were 
moved to liquid nitrogen for long term storage.  
 
3.2  Flow Cytometry 
 
Flow cytometry was used to determine levels of transduction with fluorescent tagged 
plasmids, determine engraftment in the peripheral blood of mice and sort cells. 
Determination of transduction was done using the FACS Calibur. 500 µl of cells was taken 
from the culture and put into polystyrene FACS tubes (BD). The FACS machine was set up 
before use by filling the sheath tank 2/3 full with FACS flow (BD) and emptying the waste 
tank before putting 100 ml FACS Clean (BD) in. The sheath tank was pressurised and bubbles 
removed from the sheath tubing before the machine was primed twice. After priming, water 
was run through the machine on a high flow rate before samples were run. GFP (Green 
64 
 
fluorescent protein) positive samples were measured on FL1 of the FACS machine, and tRFP 
samples on FL2. If the sample was positive for both, compensation was carried out using 
singly positive samples before-hand to compensate for the bleed through of each 
fluorophore into the other filters.  Samples were always run with a negative control so the 
threshold could be set for positivity, this was set as the top 0.3% of the negative control.  
Analysis of engraftment in the peripheral blood of mice was done using the FACS Canto with 
Dr. Helen Blair. After collection of blood from mice by tail vein venepuncture or cardiac 
puncture antibodies were added to 50 µl of blood. 10 µl of CD19-PE, 2.5 µl mouse CD45-
PECy7 and 2.5 µl Mouse Ter119-PECy7 were added to the sample before mixing and 
incubation for 20 minutes in the dark.  1.2 ml of 1x ammonium chloride solution was used to 
lyse red cells, sample was mixed by inversion and incubated for 5 minutes before 
centrifugation at 400g for 2 minutes. Pellet was washed twice with 1% PBSA (0.2% BSA in 
PBS) before being re-suspended in 500 µl PBSA in a polystyrene FACS tube for analysis. 
Samples were run on the FACS Canto and as no negative control was run when the samples 
were, the same parameters were used each time.  
Cell sorting was done by Hesta McNeill using the FACS Aria. Cells were counted and re-
suspended in PBSA at a concentration up to 107cells/ml in polypropylene FACS tubes (BD). 
Cells were gated on GFP positivity for sorting and were sorted into 15 ml falcon tubes. After 
sorting cells were counted and re-suspended in an appropriate volume of pre warmed media 
before culture as usual, with the addition of 1% pen/strep to the media for 1 week to ensure 
cells remained un-infected after sorting.  
 
3.3  Cytotoxicity testing 
 
Cytotoxicity testing of cells was used to determine the sensitivity to drugs. Cells were 
counted and seeded in a 96 well plate. The compound being tested was added to wells and 
cells were incubated for 96hrs before analysis. For both WST-1 and luciferase assays only the 
internal 60 wells were seeded with cells. This was so that any evaporation that occurred to 
the external wells didn’t affect read-out, and for the WST-1 assay, there were control wells. 
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Cytotoxicity is calculated as the reduction in signal as a percentage of the vehicle treated 
cells.  
3.3.1 WST-1 assay 
 
WST-1 is a tetrazolium salt that when cleaved results in the production of formazan, a dye. 
The cleavage of WST-1 occurs at the cell surface and is dependent on the glycolytic 
production of NAD(P)H, which occurs in viable cells. The amount of formazan dye, and thus 
the colour change from light red to yellow, is directly proportional to the number of cells 
with active metabolism in the sample. Cell Proliferation Reagent WST-1 (Roche) contains 
WST-1 and an electron coupling reagent and is a ready to use solution. Cells were cultured in 
a clear 96 well plate, with the compounds being tested for 96h before the addition of 10 µl 
of WST-1 reagent was added to each well. The plate was incubated for a further 2 hours at 
37°C before the absorbance of the wells was measured using the FLUOstar Omega plate 
reader at a wavelength of 450nm. Control wells containing WST-1 reagent and media but no 
cells were measured and then subtracted as background to control for the colour of the cell 
culture medium. 
 
3.3.2 Luciferase assay 
 
One of the plasmids used throughout much of this PhD is the pSLIEW plasmid. This plasmid 
when used to produce lentivirus and transduced into target cells, encodes the luciferase 
enzyme. This enzyme catalyses the oxidation of luciferin to oxyluciferin along with the 
production of bioluminescence.  This bioluminescence can be used in a number of ways 
including to determine the number of cells transduced using FACS, the levels of engraftment 
in mice injected with transduced cells, using in vivo imaging and for use in a cytotoxicity 
assay.  
In cell lines transduced with the pSLIEW plasmid, the luciferase assay was used to determine 
cytotoxicity. Cells were seeded in white walled 96 well plates and treated with drugs for 96h, 
as with the WST-1 assay. D-Luciferin (VivoGlo, Promega), stored at -20°C was thawed and 
diluted to a working stock of 7.5% just prior to use in tissue culture media. 10 µl of diluted 
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luciferin was added to each well and after 3 minutes the bioluminescence measured using 
the FLUOstar Omega late reader. Bioluminescence is a by-product of the oxidation of D-
luciferin to oxyluciferin by the luciferase enzyme, which is encoded by the pSLIEW plasmid 
(Bomken et al. 2013).  The amount of bioluminescence produced is proportional to the 
amount of luciferase enzyme in the cell culture, and thus is an indirect read-out of the 
number of cells in the well. The luciferase assay is useful for when cells are being cultured 
with a feeder layer as the assay is not affected by different amounts of cells that are not 
transduced with pSLIEW.  
 
3.4 Harvesting cell pellets  
 
Cell pellets for the extraction of RNA, DNA or protein were collected after counting cells. An 
appropriate volume of cells was pipetted into a 1.5 ml collection tubes and centrifuged at 
500g for 5 minutes. Cells were washed once with PBS before removal of supernatant and 
addition of buffers or storage at -20°C depending on downstream use.  
 
3.5  RNA extraction 
3.5.1 Qiagen RNeasy kit 
 
RNA extraction with the RNeasy kit (Qiagen) was done according to the protocol. Cells were 
collected and washed in PBS by centrifugation at 500g for 5 minutes. 350 µl buffer RLT with 
β mercaptoethanol added (β-ME) (1:1000) was then added to cells (up to 3.5x106 cells) 
before storage at -20°C or use straight away. Upon thawing the samples were passed 
through a QIAshredder column by centrifugation for 2 minutes at full speed (16,000g), this 
homogenises the sample.  DNA was precipitated by the addition of 350 µl 70% ethanol 
before being pipetted into and RNeasy spin column. Centrifugation for 15 seconds at >8000g 
ensured the sample passed through the membrane, where the RNA binds. The flow through 
was discarded and the column washed with 700 µl buffer RW1. Centrifugation for another 
15 seconds washes the column before addition of 500 µl buffer RPE and centrifugation twice 
to wash the column. The column was put in a new collection tube before an extended 
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centrifugation to remove any remaining liquid to dry the column and ensure the eluted 
fraction was not contaminated. The dry column was placed in a 1.5 ml collection tube and 50 
µl buffer EB pipetted directly onto the membrane. This was left for 5 minutes before 
centrifugation to elute the RNA. Sample concentration was measured using the Nanodrop 
2000 spectrophotometer and samples stored at -20°C.  
 
3.5.2 mirVana kit 
 
The mirVana kit (Ambion, Fisher Scientific) allows extraction of RNA without loss of 
microRNA, making it ideal for RNA extractions to be used for microarray analysis. The kit 
uses glass fibre filters instead of the silica membranes used for the RNeasy kit. Samples were 
first washed in PBS with centrifugation at 500g for 5 minutes before being disrupted with 
300 µl lysis/binding buffer.  Vigorous vortexing was used to lyse the cells. 30 µl (1/10 
volume) of miRNA homogenate additive was added to the samples before mixing by 
vortexing and incubation on ice for 10 minutes. 300 µl Acid-phenol-chloroform was added to 
the sample followed by further vortexing for 1 minute. This step was to extract the RNA from 
the lysate, and after centrifugation at 10,000g for 5 minutes at room temperature the 
aqueous and organic phases were separated. The aqueous phase, containing the RNA was 
removed and 1.25 volumes of 100% ethanol added to precipitate the RNA. The sample was 
then passed through the filter cartridge by centrifugation for 15 seconds at 10,000g. After 
centrifugation the flow through no longer contains the RNA as it has bound to the column 
and was discarded. The column was next washed with 700 µl miRNA wash solution 1, and 
then 500 µl wash solution 2/3. After the last wash the column was centrifuged in a fresh 
collection tube to ensure there was no residual buffer left. RNA was eluted with the addition 
of 100 µl Nuclease-free water pre-heated to 95°C. The column was incubated for 5 minutes 
before elution to maximise yield. RNA concentration was determined using the Nanodrop 
2000 spectrophotometer before samples were stored at -20°C.  
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3.6 DNA extraction 
 
Extraction of genomic DNA was done using the DNeasy blood and tissue kit (Qiagen). This kit 
works with the same silica based technology as the RNeasy kit. Cells were collected and 
washed in PBS by centrifugation at 500g for 5 minutes. PBS was removed from samples and 
they were stored at -20°C before use. When needed, samples were thawed and 200 µl fresh 
PBS was added, 20 µl proteinase K was added to the sample before the addition of 200 µl 
buffer AL. Samples were mixed by vortexing before incubating at 56°C for 10 minutes. For 
mouse samples, with a lot of cells this incubation was increased to 1 hour to ensure full lysis 
of samples. After incubation DNA was precipitated by the addition of 200 µl of 100% 
ethanol. The sample was pipetted onto a DNeasy spin column and centrifuged at >6000g for 
1 minute. The DNA was then bound to the column, and so the flow through discarded. The 
column was washed with 500 µl buffer AW1 then AW2 before centrifugation for 3 minutes 
to remove residual buffer. DNA was eluted using 200 µl buffer AE that was incubated on the 
column for 5 minutes before centrifugation. Concentration was determined using the 
Nanodrop 2000 spectrophotometer before storage at -20°C.  
 
3.7 Protein extraction 
 
Protein was extracted from cells using the RIPA buffer to lyse cells and collet protein. 
Samples that had been washed in PBS after collection and frozen at -20°C were thawed and 
100 µl ice cold RIPA buffer was added. Samples were vortexed before incubation on ice for 
30 minutes with regular vortexing to aid in lysis of the cells. Samples were then centrifuged 
at 14,000g for 15 minutes in a pre-cooled centrifuge at 4°C. This resulted in pelleting of the 
cell debris, leaving the protein in the supernatant. The supernatant was removed and kept 
on ice whilst protein concentration estimation was done. 
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3.7.1 BCA assay 
 
The bicinchoninic acid (BCA) protein estimation assay uses the measurement of a colour 
change from green to purple in the presence of protein to determine the concentration.  
This change is a result of the reduction of Cu2+ to Cu+ by the peptide bonds present in 
protein. The amount of protein in the solution is proportionate to the amount of reduction. 
These reduced Cu+ ions are then chelated by the bicinchoninic acid to form the purple 
complex that is measured by spectroscopy (Smith et al. 1985).  
A standard is included on each plate in order to quantify the samples, this was made from 
bovine serum albumin (BSA) at concentrations of 125-2000 µg/ml. 10 µl of each of the 
concentrations was pipetted into a clear 96 well plate in triplicate along with 10 µl triplicates 
of each sample, pre diluted 1:10 in H2O. The BCA assay reagents were then mixed at a ratio 
of 1:50 reagent A: reagent B, before 190 µl of the mixture was then added to each well. The 
plate was shaken for 30 seconds before incubation at 37°C for 30 minutes. After incubation 
changes in colour, as measured by absorbance at 560nM was determined using the FLUOstar 
Omega plate reader. The concentration of protein in samples was quantified by comparison 
to the BSA standard.  
After protein concentration estimation, samples were diluted to a concentration of 1 µg/ml 
with Laemmli buffer, and β-ME and bromophenol blue added at a final concentration of 5% 
each.  
 
3.8 Production of cDNA 
 
Reverse-transcriptase polymerase chain reaction (PCR) was used to produce cDNA from 
mRNA using the RevertAid H Minus First Strand cDNA synthesis kit (Thermo Fisher Scientific). 
This kit uses the RevertAid H Minus M-MuLV Reverse transcriptase enzyme, which contains a 
point mutation that removes RNase H activity of the enzyme, resulting in reduced RNA 
degradation, and thus better cDNA yield from long template RNA. The RiboLock RNase 
inhibitor binds RNases thus protecting RNA from degradation at temperatures below 55°C.  
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Random hexamers were added to RNA and RNase free H2O (Table 13) before incubation at 
70°C for 5 minutes in a GeneAmp 9700 Thermo Cycler PCR machine. This step allows for the 
random hexamers to bind to the RNA. After 5 minutes, with the thermo cycler set at 4°C, 8 
µl of PCR master mix (Table 14) was added to each sample. The thermo cycler was then run 
at 25°C for 10 minutes, 42°C for 60 minutes and 70°C for a further 10 minutes before 
samples were removed and 30 µl RNase free H2O added to each before storage at -20°C until 
use.  
 
Reagent Volume (µl) 
RNA (500 ng-1µg) X 
Random hexamers (100 µM) 1 
RNase free H2O X 
Total 12 
Table 13: Reagents used for the first step of cDNA synthesis, the binding of the random 
hexamers to the RNA.  
 
Reagent Volume per reaction (µl) 
Buffer (5X) 4 
dNTP mix (10mM) 2 
RiboLock inhibitor 1 
RevertAid H Minus M-MuLV Reverse 
Transcriptase (200 u/μl)  
1 
Table 14: Reagents used for the second step of reverse transcription, including the reverse 
transcriptase enzyme, dNTPs and Ribolock to inhibit RNases.   
 
3.9 Real-time PCR  
 
To determine the expression of genes real-time PCR was used. This allows for quantification 
of cDNA or genomic DNA in a sample. This was done using a 384 well plate, with 8 µl of  
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PCR master mix (Table 15) per well. This was done with an Eppendorf Multipette stream 
multistepper pipette (Eppendorf). To each well, 2 µl of sample was added in triplicate for 
each primer pair. The plates were centrifuged before use to ensure sample was at the 
bottom of the well and there were no bubbles before being run on the ABI 7900HT 
Sequence Detection system (Figure 17). 
Reagent Volume per reaction (µl) 
SYBrGreen (2X) 5 
Primer Mix (10 µM) 0.3 
RNase free H2O 2.7 
Total 8 
Table 15: Reagents and volumes per reaction for quantitative real-time PCR. Reagents were 
pipetted with a multi-stepper pipette before the addition of cDNA.  
The first step of the PCR run results in denaturing of cDNA, UDG (Uracil DNA glycosylate) 
inactivation and enzyme activation, this consisted of 2 minutes at 50°C and 10 minutes at 
95°C. The second step was 40 cycles of denaturing and hybridisation/amplification steps at 
95°C for 15 seconds and 30 seconds at 60°C, this is when the detector records signal 
amplification as SYBR Green is incorporated into double strand cDNA. The final step of the 
PCR programme is the amplicon disassociation step when the dissociation curve is recorded. 
This consists of 95 for 15°C seconds followed by 1 minute at 60°C.  
 
Figure 17: PCR cycling conditions used for real-time PCR run on the ABI 7900HT Sequence 
Detection system.  
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Data is collected from the PCR machine and analysed using SDS2.3. The Ct (cycle threshold) 
value, which is the cycles needed for the fluorescent signal from incorporated SYBR green to 
exceed a threshold. This threshold was set by the machine, but in analysis could be changed 
if it was too low/high. The Ct values are used with the delta-delta Ct method (ΔΔCt) method 
to determine the expression compared to a control sample. 
This method has 3 steps, first the Ct values of the gene of interest was normalised to the Ct 
of the housekeeping gene. These values are then normalised to the -ΔCt of an untreated 
control sample, resulting in -ΔΔCt values. Each Ct unit represents a 2-fold change in 
expression, so to obtain a relative RNA expression value the inverse of the -ΔΔCt values are 
found. These steps are outlined in the formulas below.  
Ctsample – Cthousekeeping = -ΔCtsample 
-ΔCtsample - -ΔCtcontrol = -ΔΔCtsample 
2-(-ΔΔCtsample) = Relative RNA expression 
 
3.10 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to visualise bands of DNA after PCR amplification or 
restriction digest. Agarose was melted in 60 ml 1x TBE buffer using a microwave before 
adding 6 µl gel red (1:10000), the solution was then poured into a Mini-Sub cell gel tray with 
a gel casting gate with either 8 or 14 wells and left to set.  The amount of agarose used was 
dependent on the size of the band to be visualised. Bands 500-10000bp were run on a 1% 
gel, whereas for smaller bands 200-3000 a 1.5% gel was used.   
The gel was loaded onto a Mini-Sub GT cell (BioRad) and submersed in 0.5x TBE. Samples 
were mixed with 5x gel loading dye before being loaded into the gel. A PowerPac™ basic 
power supply (BioRad) was connected to the cell and used to run electricity through the gel, 
between 60-80V. Once binding buffer reached far enough down the gel the bands were 
visualised using a GelDoc™ XR+ Gel Documentation system.  
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3.11 QIAquick Gel Extraction Kit 
 
To extract DNA bands from agarose gels, the bands were visualised using UV light, a clean 
scalpel was then used to cut out the band, which was put into a 1.5 ml collection tube. These 
tubes were weighed and 3 volumes of buffer QG were added to 1 volume of gel (100 mg gel 
~ 100 µl buffer QG). Samples were then incubated at 50°C for 10 minutes to dissolve the gel. 
Incubation time was increased if the gel was not dissolved in 10 minutes. After the gel has 
dissolved, 1 volume isopropanol was added and the sample mixed by vortexing. This was 
then pipetted into a QIAquick spin column in a collection tube. This was centrifuged for 1 
minute at 17,900g to pass the sample through the column and allow the DNA to bind to the 
membrane. The flow through was discarded and the column washed by centrifugation with 
500 µl Buffer QG and then 750 µl Buffer PE. After the second was the column was 
centrifuged for 2 minutes (17,900g) to dry the membrane and ensure all buffer was 
removed. The column was then transferred to a clean 1.5 ml collection tube and 30 µl Buffer 
EB added to the membrane. This was left for 5 minutes before elution of the sample with 
30s centrifugation. DNA was quantified using the Nanodrop and stored at -20°C until 
needed.  
 
3.12  QIAquick PCR Purification Kit 
 
The QIAquick PCR Purification kit was used for the concentration of several DNA samples as 
well as the clean-up of PCR reactions. It works in a very similar way to the QIAquick Gel 
Extraction kit but. To the PCR products, or DNA to be concentrated 5 volumes of Buffer PB 
were added. This was then pipetted into a QIAquick column and centrifuged to pass the 
sample through the column (1 min, 17,900g). The flow through was discarded and the 
column washed by centrifugation with 750 µl Buffer PE before an extended centrifuge to dry 
the column. 50 µl Buffer EB was used to elute samples after a 5-minute incubation on the 
membrane. Samples were quantified using the Nanodrop and stored at -20°C until needed.  
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3.13 Western blotting 
 
Western blotting was used to visualise protein expression in samples. The pre-cast 4-20% 
Mini-PROTEAN® TGX™ gels (BioRad) were loaded into the Mini-PROTEAN® Tetra Cell tank 
(BioRad), which was then filled with electrophoresis buffer before 15 µg of protein sample in 
Laemmli buffer was pipetted into each well. 5µ Spectra™ Multicolour Broad Range Protein 
Ladder (Thermo Fisher Scientific) was added in order to determine the size of bands. The gel 
was run at 100V for approximately 1h, or until the bands reached the bottom of the gel. 
Following electrophoresis, the gel was removed and put into a tank of ice cold blotting 
buffer whilst the transfer cassette was prepared. This consisted of the cassette, a sponge, a 
piece of blotting paper and the PDVF membrane, which had been submerged in methanol 
before use. The gel, once removed from the plastic case was placed on top of the 
membrane, before another piece blotting paper and a second sponge were placed on top. 
Bubbles were removed from the cassette to ensure an even transfer. This cassette was put 
into the Mini Trans-Blot® Cell (BioRad) with an ice pack and a magnetic stirrer to keep the 
solution cool. Transfer was done at 100V for 1h on a magnetic stirrer plate.  
After transfer the membrane was carefully removed from the cassette and blocked in 10% 
milk for 1h to reduce background signal. After blocking, the membrane was cut if required, 
and incubated with primary antibody in 5% milk for 1hr. Following incubation, the 
membrane was washed in 1X TST for 3 10 minute periods. Incubation with the secondary 
antibody in 5% milk, at a concentration of 1:1000 followed this before another step of 3 1X 
TST washes for 10 minutes each. During the final wash the ECL reagents were prepared in a 
1:1 solution. This was pipetted onto the membrane once removed from the wash and left to 
incubate for a further 5 minutes before x-ray films were used to detect chemiluminesce 
produced by the oxidation of substrates by the horse radish peroxidase (HRP), which is 
conjugated to the secondary antibody. X-ray films were developed using the Mediphot937 X-
ray film developer (Colenta Labortechnik).  
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3.14 In vivo work 
 
All in vivo work was carried under home office personal license F3AC40BF, under the project 
number PPL60/4552. Procedures were checked and signed off by either Helen Blair or Chris 
Huggins before being carried out without supervision.  
 
3.14.1 Animal husbandry 
 
Animal husbandry such as weighing and checking for signs of ill health was carried out at 
least once a week after animals had been injected with leukaemic samples. Once mice were 
on dosing regimens this was increased to everyday, and for mice engrafted with the 697 cells 
this increased to monitoring at least twice a day every day past 21 days of engraftment as 
this was seen to be a very aggressive leukaemia with effects being very swift. End points, as 
defined on the Home Office license were >20% weight loss or >10% weight loss maintained 
for 72h (compared to heaviest weight), tumours >10mm in any direction, (15mm if on 
treatment). As well as these defined endpoints, the health of animals was taken into account 
such as piloerection, anaemia or poor circulation indicated by paleness of the feet ears and 
tail, a starey coat with porphyrin staining around the nose/eyes, loss of skin tone, laboured 
breathing, inability to maintain upright position, reduced movement and as was often seen 
in the case of the L707 cells, hind limb paralysis.  Mice were killed by cervical dislocation, a 
schedule one method.  
 
3.14.2 Intrafemoral injection 
 
The intrafemoral injection was used to engraft ALL cells in NSG mice. The entire procedure 
was carried out in a category II laminar flow hood to maintain sterility and an isoflurane 
anaesthetics trolley was used to administer anaesthetic. Mice were anaesthetised in an 
induction box with 5% isoflurane before being moved to a face mask for maintenance at a 
surgical depth of anaesthesia (~3% isoflurane) throughout the procedure. Mice were 
weighed and 5 mg/kg Carprofen (Rimadyl, small animal injection) was given for analgesia at 
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the start of the procedure.  The leg was shaved and sterilised using Hydrex Derma Pink Spray 
before a 29G insulin needle was used to drill through the kneecap and into the femur. A new 
needle was then used to inject 20 µl of the sample in SFEM II media, into the femur. Mice 
were returned to the home cage and monitored until recovery from anaesthesia. Ear 
notching was used to differentiate mice in a single cage, this was done whilst animals were 
under anaesthetic.  
 
3.14.3 Dosing 
3.14.3.1 Intra peritoneal 
 
Intra peritoneal (I.P.) dosing was used for the administration of both Dex and D-luciferin. It 
done using a 29G insulin needle. The mouse was restrained by grasping the scruff and the 
skin down the back of the body. In order to reduce stress and possible accident a firm hold 
was needed. The needle is then inserted at approximately a 45° angle, bevel upwards into 
the peritoneal area of the mouse. For female mice this was the lower part of the abdomen, 
and for males slightly higher to avoid injecting the testicles. If dosing was done every day, 
then the location of injection was switched sides to avoid excessive bruising and discomfort.  
 
3.14.3.2 Oral  
 
Oral dosing was used for the administration of Dex and Mifepristone. This was chosen on the 
advice of the head technician, who believed that for long periods of dosing oral gavage was 
less stressful for the mice. Oral dosing of drugs was done with a round tipped gavage needle. 
The mouse was restrained in a firm grip and the needle inserted into the mouth, the head 
was gently pushed back and the needle allowed to drop down the oesophagus into the 
stomach. At no time was the needle pushed as this could rupture the oesophagus and cause 
serious injury or death of the mouse. Once the needle had dropped into the stomach the 
drug was given slowly and smoothly before removal of the needle.  
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3.14.3.3 Sub cutaneous 
 
Sub cutaneous dosing of mice was only used for the administration of Carprofen during the 
intrafemoral injection. Mice were anaesthetised at the time, and a 29G insulin needle used 
to inject into tented skin on the scruff. 
 
3.14.4 IVIS imaging 
 
In order to measure bioluminescence of pSLIEW transduced leukaemic cells in mice the IVIS 
(in vivo imaging system) (Caliper) was used.  Mice were injected with 100 µl of D-luciferin 
(VivoGlo, Promega) I.P. After 5 minutes, mice were anaesthetised with isoflurane in an 
induction box (4-5% isoflurane). This timing was kept regular to avoid differences in 
bioluminescence due to changes in blood flow of anaesthetised animals. Once under 
anaesthetic, mice were moved to the IVIS imaging chamber and placed onto the block 
heated at 37°C, in a face mask to continue the delivery of anaesthetic (3% isoflurane). After a 
total of 10 minutes from D-luciferin injection, imaging was started. Length of exposure was 
determined by the IVIS software, Living Image and ranged between 1 second and 5 minutes. 
Once imaging was finished mice were returned to the home cage and monitored until they 
woke from anaesthetic.  
 
3.14.5 Venepuncture of tail 
 
In order to measure leukaemic blasts or drug levels in peripheral blood, venepuncture of the 
tail vein and collection of blood was used. Mice were placed into a restraint tube and a 
scalpel blade was used to nick the tail vein. Heparin coated blood collection tubes were filled 
from the droplet of blood that formed on the tail by capillary action. Once blood was 
collected pressure was applied above the cut to stop bleeding and the mouse released from 
restraint and placed back in the home cage. Mice were checked several times to ensure 
bleeding had stopped. On a single occasion <10% total circulating blood volume was taken, 
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up to 3 times a week. <20% could be taken once in a 28-day period, but 50 µl (<10%) was 
sufficient for FACS analysis.  
 
3.14.6 Cardiac puncture 
 
To get larger volumes of blood cardiac punctures were performed. This procedure is done 
under terminal anaesthetic. Mice were anaesthetised with isoflurane and were at a surgical 
plane of anaesthetic throughout the procedure, which was checked by testing the foot 
withdrawal reflex. A 1 ml syringe with 100 µl heparin (2.5 U/µl) with a 19G needle attached 
was used to withdraw blood. This was done by insertion of the needle between the ribs. 
Upon pulling the plunger back, blood was drawn out of the heart. Once 1 ml had been taken, 
cervical dislocation was used to confirm death. For drug testing the blood was then put into 
a 1.5 ml collection tube and centrifuged at 14000 rpm for 5 minutes. After centrifugation, 
serum was removed from the cell pellet with a pipette and put into a fresh 1.5 ml collection 
tube before being frozen at -20°C. For FACS analysis, 50 µl of whole blood was used for 
antibody staining as previously described.  
 
3.14.7 Collection of samples from mice 
 
Once mice reached endpoints defined in the license they were killed by cervical dislocation 
and organs removed for analysis. The spleen livers BM from femurs were regularly collected.  
The spleen and liver were extracted and weighed before being homogenised using the 
plunger of a 1 ml syringe and passed through a cell sieve with sterile PBS in order to achieve 
a single cell suspension. Cells were then counted using trypan blue and methylene blue 
(3.1.1) before freezing and storage at -80°C.  The BM was collected by removing the femurs, 
and breaking off the kneecap (breaking was used rather than cutting with scissors due to 
reduced frequency of bone shattering using this method). The bone was then flushed with 
PBS using a 19G needle in order to remove the marrow.   
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3.14.8 Histological analysis of samples  
 
When samples were collected from mice, some organs were fixed in formalin and sent for 
staining with haematoxylin/eosin (H&E) and human CD19 to determine morphology and 
engraftment of human cells. All of the work was performed by Anna Long in the histology 
department of the Royal Victoria Infirmary. Samples were decalcified if required using EDTA 
and x-ray of the samples before being set in paraffin wax, sectioned and mounted on slides. 
These slides were then used for staining. H&E works by the binding of 2 dyes to positively or 
negatively charged components in the cell. Haematoxylin is a violet dye, and binds to 
negatively charged molecules such as DNA and RNA as the stain is positively charged. Eosin 
is negatively charged and so binds to positively charged amino acids and stains them pink. 
The L707 presentation cells express CD19 on the cell surface, so organs were stained with an 
anti-CD19 antibody to determine engraftment. Staining was carried out using a Ventana 
BenchMark Ultra machine (Ventana, Roche), and the detection kit used was the Ultraview 
Universal DAB Detection kit. The secondary antibodies in this kit are conjugated to an 
Ultraview HRP multimer. Which catalyses the oxidisation reaction of the DAB (3,3’-
diaminobenzidine tetrahydrochloride) chromogen to produce a brown stain.  
 
3.14.9 Ficoll separation of cells 
 
When cells were collected from the livers of NSG engrafted with 697 cells they were 
separated from the murine cells using Ficoll-Paque Premium (GE Healthcare) which has a 
density of 1.077 g/ml and has been optimised for isolating human mononuclear cells from 
peripheral blood. Livers homogenised by passing through a cell sieve in falcon tubes were 
topped up to 40 ml with PBS and centrifuged for 5 minutes at 500g. Media was removed and 
cells re-suspended in 5-10 ml PBS. Ficoll was extracted from the bottle using a needle and 
added to a 20 ml universal tube, Ficoll was used at a ratio of 4:3 to cells in PBS.  The cell 
suspension was then carefully pipetted onto the Ficoll. The difference in the density 
between PBS and Ficoll means that the layers do not mix. Samples were centrifuged for 40 
minutes at 400g, deceleration was done without a break resulting in a gentle deceleration, 
to avoid mixing of the separated layers.  A glass Pasteur pipette was used to carefully 
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remove the buffy layer, which contained the lymphoblasts. PBS was added to the sample 
before centrifugation at 500g for 5 minutes to pellet cells. PBS was removed and the cells re-
suspended in 2-5 ml media depending on pellet size. Cells were then counted and used for 
downstream applications.   
 
3.15 Production of competent bacteria 
 
The mix and go E. coli transformation Kit (Zymo Research) is a relatively new method of 
making competent cells that does not require a heat shock step in order to transform cells.  
STBL3 bacteria were grown from a stock in a starter culture of 5 ml SOB media for 
approximately 5h before being used to inoculate 500 ml SOB media. The culture was 
incubated overnight in a bacterial shaker (200rpm) at 22°C. Optical density was measured 
the following morning, and once bacteria reached OD600nm of between 0.4-0.6, incubation 
was stopped. Directly after incubation, the culture was placed on ice to cool for 10 minutes, 
and all following steps were done on ice. Bacteria were then pelleted by centrifugation at 
3000rpm for 10 minutes at 4°C. The supernatant was removed and the cells re-suspended in 
5 ml ice cold 1x Wash Buffer. The cells were centrifuged again, the supernatant was 
removed and the cells re-suspended in 5 ml ice cold Competent Buffer. The culture was kept 
on ice whilst bacteria were aliquoted in 100-200 µl aliquots in pre-cooled 1.5 ml collection 
tubes, before storage at -80°C.  
 
3.16 Bacterial transformation 
3.16.1 Chemically competent cells 
 
Transformation of DNA into bacteria that had been made competent using the traditional 
chemical method was done as follows. Cells were thawed on ice briefly and mixed by 
swirling with a pipette tip before 1-10 ng of DNA was added to 50 µl bacteria per 
transformation reaction and the mix incubated on ice for 30 minutes. The bacteria were heat 
shocked by incubation at 42°C for 20 seconds, before being returned to the ice for a further 
two minutes. 950 µl SOC media, without antibiotics was added to the bacteria and the 
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sample was incubated at 37°C for 1 hour in a heat block with shaking at 300rpm. After 1 
hour, 50 µl of the transformed bacteria were spread onto agar plates with the required 
antibiotics and incubated at 37°C overnight. To maintain competency bacteria were kept on 
ice at all times.  
 
3.16.2 Mix and Go 
 
To transform using the Mix & Go bacteria, cells were thawed on ice briefly and 1-10 ng DNA 
added. Bacteria and DNA were left on ice for a further 5 minutes before 50 µl were plated 
directly onto agar plates with ampicillin (100 µg/ml). Plates were then incubated at 37° 
overnight.  
3.17 Production of LB agar plates 
 
LB agar plates were used to grow colonies of bacteria, which were then used to inoculate 
larger volumes of LB. They were made by adding 25 g of LB powder and 12.5 g of Bacto agar 
to a 1 l Duran bottle along with 1 l of DI H2O. This was then autoclaved to sterilise and melt 
the agar. This was cooled to around 50°C before the addition of ampicillin (100 µg/ml) and 
then pouring into 10 cm petri dishes. Pouring was done near a Bunsen burner flame to keep 
the plates sterile. Poured plates were left for 1-2 hr  to set before being dried, inverted in an 
incubator at 37°C. Plates refrigerated for up to 1 month, and were warmed to 37°C before 
use.  
 
3.18 Streaking bacteria 
 
Transformed bacteria and bacterial stocks were streaked on an LB plate in order to pick a 
single colony to expand. This was done by a Bunsen burner flame to keep the LB agar plates 
sterile. 100 µl of transformed bacteria, or 10 µl bacterial stock was pipetted onto the agar. 
This was then spread using glass spreader, sterilised in ethanol and then passed through the 
Bunsen burner flame. Once done, agar plates were incubated inverted at 37°C 
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3.19 Plasmid purification from bacteria 
3.19.1 Miniprep 
 
If small quantities of plasmid were required for cloning or sequencing, then the Miniprep kit 
(Qiagen) was used. This kit is not endotoxin free and so is not suitable for use for plasmids 
that will be used in tissue culture. 5 ml of LB broth (ampicillin 100 µg/ml) was inoculated 
with a single colony from an LB plate and grown overnight in an orbital shaker, 200rpm, 
37°C. The following morning, 1.6 ml of this culture was pipetted into a 1.5 ml collection tube 
and centrifuged for 3 minutes at 6800g to pellet bacteria. After removal of the supernatant, 
250 µl Buffer P1 containing lyse blue and RNase A (each at 1:1000) was used to re-suspend 
the pellet. 250 µl of Buffer P2 was added and the solution mixed by inversion 4-6 times. At 
this point the solution went blue due to the presence of Lyse Blue in Buffer P1, once the 
colour change had occurred mixing was stopped to avoid the risk of shearing the genomic 
DNA. 350 µl Buffer N3 was added to the solution before mixing by inversion 4-6 times. The 
solution went colourless at this point, indicating the SDS had been precipitated. 
Centrifugation for 10 minutes at 17,900g resulted in a compact white pellet, which 
contained the cell debris. The supernatant from this was added to a QIAprep 2.0 spin column 
before centrifugation for 30s at 17,900g to draw the solution through the filter and allow the 
DNA to bind. All following centrifugation steps were also carried out at 17,900g.  The flow 
through was discarded and the column washed using 500 µl of Buffer PB and centrifugation. 
After discarding the flow through the column was washed again with 750 µl Buffer PE. The 
flow through was discarded and the column centrifuged for another minute to fully dry the 
column. The column was then placed in a clean 1.5 ml collection tube before addition of 50 
µl Buffer EB. The columns were left for 5 minutes before centrifugation to elute DNA. DNA 
concentration was quantified using the Nanodrop before storage at 4°C or -20°C as required.  
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3.19.2 Maxiprep 
 
The Endofree Plasmid Maxi Kit (Qiagen) works on the same principles as the Miniprep but 
with an additional endotoxin removal step so that the plasmids can be used in tissue culture. 
From a single colony a starter culture in 5 ml LB was grown for 8h (200rpm, 37°C) before 
being used to inoculate 500 ml LB for overnight growth with the same conditions. This 
culture was then collected the following morning and centrifuged at 6000g for 15 minutes at 
4°C using the Avanti J-26 XP centrifuge. The supernatant was discarded and the bacterial 
pellets re-suspended in 10 ml Buffer P1 with LyseBlue and RNase A by vortexing. 10 ml 
Buffer P2 was then added to the solution and the tube inverted 4-6 times before incubating 
at room temperature for 5 minutes.  At this point the solution turns blue. During the 5-
minute incubation the QIAfilter Cartridge is prepared. 10 ml chilled Buffer P3 is added to the 
solution next, and after mixing by inversion 4-6 times the solution turns colourless. The 
solution is then poured into the barrel of the QIAfilter Cartridge before incubating at room 
temperature for 10 minutes. The cell lysate was passed through the filter by insertion of the 
plunger and removal of the cap, approximately 25 ml of lysate was recovered. 2.5 ml of 
Buffer ER was added after filtering and the solution mixed before incubation on ice for 30 
minutes. This is the endotoxin removal step. During this time the QIAGEN-tip 500 was 
equilibrated by the addition of 10 ml Buffer QBT. The filtered lysate was then added to the 
QIAGENtip 500 and allowed to drip through, at this point the plasmid DNA binds to the resin 
in the tip. The flow-through was removed and the column washed with 30 ml of Buffer QC 
twice. After washing, the DNA was eluted with 15 ml of Buffer QN. This was collected and 
the DNA precipitated by the addition of 10.5 ml isopropanol. This was then centrifuged at 
600g for 1h at 4°C. After this centrifugation the supernatant was carefully removed and the 
pellet re-suspended in 5 ml endotoxin free 70% ethanol before centrifugation at 6000g for 
1h at 4°C. The supernatant was carefully removed and the pellet allowed to dry at room 
temperature before the addition of 500 µl endotoxin free Buffer TE. Plasmids were 
quantified using the Nanodrop before storage at 4°C.  
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3.19.3 NucleoBond Xtra midi 
 
For the extraction of DNA to be used in nick hybridisation to make FISH probes the 
NucleoBond Xtra midi kit (Clontech). This kit is suitable for the extraction of large constructs 
such as the BAC clones that are used in the production of FISH probes. 
500 ml of LB broth was inoculated with a 5 ml starter culture grown from a single colony, 
picked from an LB agar plate streaked from the bacterial stock. This was grown overnight at 
37°C with shaking at 200rpm in an orbital shaker. The following morning bacterial was 
collected and centrifuged at 6000g for 15 minutes at 4°C in the Avanti J-26 XP centrifuge. 
The supernatant was removed and the bacterial re-suspended in 12 ml Buffer RES. Bacteria 
were lysed with the addition of 12 ml Buffer LYS, and the tube inverted 5 times to mix before 
5 minutes incubation at room temperature. During this incubation the column filter was 
inserted into the NucleoBond ® Xtra column and then equilibrated with 25 ml of Buffer EQU. 
Neutralisation of the lysed bacteria was done by addition of 12 ml Buffer NEU and inversion 
of the tube 3 times. This lysate was then poured into the column and allowed to flow 
through. After the lysate had filtered through the column it was washed with 15 ml Buffer 
EQU before removal of the filter from the column. The column, without filter was then 
washed with 25 ml Buffer WASH before elution with 15 ml Buffer ELU pre-heated to 50°C. 
DNA was precipitated from the solution with the addition of 15 ml isopropanol. This solution 
was then centrifuged at 1000g for 30minutes at 4°C. After centrifugation the supernatant 
was removed and 4 ml 70% ethanol used to re-suspend the pellet. This was then centrifuged 
again at 1000g for 5 minutes at room temperature. The supernatant was removed and the 
pellet allowed to air dry before resuspension in 500 µl buffer TE. Samples were analysed 
using the Nanodrop before storage at -20°C before use. 
3.20 Transfection of 293T cells 
 
Once plasmids were extracted using the Maxiprep kit they were used to make lentivirus by 
transfection of 293T cells. The protocol used was described in Bomken et al 2013. 293T cells 
were seeded the day before use at 1.5x105 cells/ml in 10cm tissue culture plates. The 
following day 15 µg transfer plasmid, 20 µg pCMVΔR8.91 packaging plasmid and 5 µg 
pMD2.G envelope plasmid were mixed and made up to 250 µl by the addition of special H2O. 
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To this, 250 µl of 0.5M CaCl2 was added and samples were mixed vigorously. This solution 
was then added to 500 µl 2X HeBS dropwise with bubbling to mix before incubation in the 
CAT II tissue culture hood for 30 minutes. This incubation time allows a precipitate of 
CaPO4/DNA to form. If the incubation is too short this will not form, and if it is too long then 
the precipitate will be too coarse which will result in a less efficient transfection. This 
solution was then gently added to the 293T cells, which were then returned to the incubator 
overnight. The following morning the media was carefully removed and the cells washed 
with 10 ml pre-warmed PBS and removed, before the addition of 10 ml pre-warmed fresh 
media. Plates were returned to the incubator for a further 3 days, before collection of the 
supernatant into 50 ml falcon tubes after this time.  
 
3.21 Collection and concentration of lentivirus 
 
The supernatant from the transfected 293T cells was centrifuged at 3000rpm, 4°C for 15 
minutes to pellet cell debris before being passed through a 0.45 µm Acrodisc® syringe filter 
to remove cell debris too small to be pelleted by centrifugation at 3000rpm. 30 ml of the 
filtered supernatant was then added to ethanol sterilised thickwall-style (open-top) 
polyallomer Konical ™ (Beckman Coulter) tubes. Which were then put into the SW28 
swinging bucket rotor tubes (Beckman Coulter) with Derlin™ PKGED’1 adaptors (Beckman 
Coulter). The use of adaptors stops the tubes from collapsing during centrifugation. The 
tubes containing the samples were weighed to ensure the centrifuge was balanced before 
centrifugation for 2hr at 26000rpm, 4°C in an Optima ™ XL-100K (class S) preparative 
ultracentrifuge (Beckman Coulter).  After centrifugation the supernatant was discarded by 
gentle inversion and the tubes allowed to dry. The lentivirus was re-suspended in an 
appropriate volume of media dependent on the cells in use further downstream.  
3.22 Transduction of leukaemic cells  
 
Transduction of cells was carried out using spinfection with polybrene as a transduction 
agent. Cells were counted and split to 1x106 cells/ml and 1 µl 8 µg/ml polybrene was added 
per ml. 500 µl of cells were pipetted into the wells of a 48 well plate and lentivirus added to 
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each well. Unless primary material was being transduced then several volumes of lentivirus 
were used (1-30 µl). PBS was added to wells around the edge of the plate and plates were 
sealed with Parafilm to avoid evaporation of media. Spinfection was carried out by 
centrifugation at 900g for 50 minutes at 34° C. After centrifugation Parafilm was removed 
and the cells returned to the incubator overnight. The following morning ~350 µl media was 
removed and 500-800 µl of fresh pre-warmed media added. After a further 3 days 
incubation cells were ready for FACS analysis or puromycin selection. 
The protocol with the primary derived L707 cells differed a little from that for the cell lines 
used, mainly in the concentration of cells used for the transduction (up to 5x106/well of a 48 
well plate) and the volume of lentivirus used. The primary derived cells were centrifuged at 
350g for 5 minutes and then re-suspended in lentivirus in order to maximise transduction 
levels.  
 
3.23 FISH 
 
All FISH (Fluorescent in situ hybridisation) protocols were kindly taught by Lisa Jones and Lisa 
Russell, they also provided the reagents for nick translation and FISH that were not included 
in the nick translation kit such as the spectrum red labelled dUTP and sephadex columns.  
 
3.23.1 Nick translation 
 
Nick translation is the method by which Bacterial artificial chromosome (BAC) clone DNA is 
tagged with fluorescently labelled nucleotides for the visualisation of binding of the probe to 
genomic DNA for FISH. This was done with DNA extracted using the NucleoBond Xtra kit 
(Macherey Nagel).  
0.5 ml collection tubes were chilled on ice before use, to these tubes 10 µl dNTP, 5 µl dTTP 
and 5 µl nick translation buffer were added. 2.5 µl of dUTP labelled with spectrum red was 
also added and the sample was mixed by vortexing before centrifugation to remove reagents 
from the sides of the tubes. 17.5 µl of DNA was added to this before gentle mixing using a 
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pipette. 10 µl nick translation enzyme was added to this before incubation at 15°C overnight. 
The following morning, 3 µl of    0.5 M EDTA was added to the samples and left to incubate 
whilst the Sephadex columns were prepared. This was done by removal of the bottom of the 
tube before it was put in a 1.5 ml collection tube before centrifugation for 1 minute at 
4000rpm. The flow through was discarded and the column placed in a 1.5 ml collection tube. 
The entire sample was then pipetted into the centre of the column and spun for a further 2 
minutes at 4000rpm. The column was discarded and to the flow through 10 µl of human cot-
1 DNA, 6 µl of 3 M sodium acetate and 160 µl of ice cold ethanol was added. This was then 
incubated at -80°C for 2 hours before centrifugation at 13000rpm for 30 minutes at 4°C to 
pellet the probe. The supernatant was carefully discarded and the pellet allowed to air dry in 
the dark before resuspension in 14 µl hybridisation buffer. 6 µl of nuclease free H2O was 
added to this before allowing the probes to dissolve at room temperature in the dark. Once 
probes were dissolved they were stored at -20°C until use.  
 
3.23.2 Slide preparation  
 
Samples were thawed using the method described previously (3.1.5) before being 
centrifuged at 1200rpm for 5 minutes. The supernatant was discarded and 10 ml 0.075M 
potassium chloride was added. This was incubated for 10 minutes at 37 °C before 
centrifugation at 1200rpm for a further 5 minutes. The supernatant was discarded and the 
pellet disrupted by vortexing. 1 ml of fixative (3:1 methanol:acetic acid) was added dropwise 
to the pellet whilst vortexing. This was done to avoid clumping of the cells. A further 4 ml of 
fix was added before centrifugation at 1200rpm for 5 minutes to pellet fixed cells. After 
removal of the supernatant 1 ml of fresh fixative was added and cells were stored at -20°C. 
The addition of potassium chloride before fixing causes the cells to swell, which results in the 
plasma membrane erupting when they are dropped onto the slide. This makes probe binding 
more efficient.   
Before use fixed cells were centrifuged at 1300rpm for 2 minutes and 1 ml of fresh fixative 
added. 2.5-3 µl of cells were then dropped onto a pre labelled slide, washed with fixative. 
Slides were allowed to air dry on a damp piece of blue roll and cell density was checked with 
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a microscope. If cells were not dense enough, then the process was repeated. Once the 
desired amount of cells were on the slide it was dried on a hot plate at 60°C for 10 minutes.  
 
3.23.3 Hybridisation 
 
Once cells were made hybridisation was used to mark the DNA with fluorescent probes. 
Homemade probes were mixed to make a working stock of the 3 spectrum red labelled 
NR3C1 probes at a 1:1:1 ratio. This was then used to make a master s containing 1 µl Green 
5p telomere probe (Cytocell), 2 µl pooled Red NR3C1 probe and 1 µl hybridisation buffer for 
each slide. This was then applied to a 22 mm coverslip and the slide gently lowered onto 
this. Bubbles were removed by gently pressing with a pipette tip and the coverslip sealed 
with rubber cement. Slides were transferred to a HiBrite (Abbott Molecular) and hybridised 
at 72°C for 5 minutes and 37°C overnight. 
The following morning the rubber cement was removed from the slide before they were 
immersed in a pot of 2X SSC (sodium citrate and sodium chloride) (Thermo Fisher Scientific) 
to allow to coverslip to soak off.  Once the coverslip had detached, the slides were 
submerged in pre-heated (72°C) buffer 1 for 2 minutes. After 2 minutes, slides were 
removed and put into buffer 2 for a further 2 minutes. DAPI was dropped onto cover slides 
and the slide, once excess buffer 2 was blotted off was lowered onto this, bubbles were 
removed using a pipette tip to gently press the bubbles out. Slides were cleaned using 
ethanol and a lint free tissue before being mounted onto the microscope platform.  
3.23.4 Capture and scoring of cells 
 
Slides were mounted onto the microscope platform for capture using a GSL-120 slide loading 
florescence microscope (Leica) with an 8 bay motorised stage. This microscope is part of the 
Leica CytoVision platform and is able to automatically scan and capture FISH slides. All slides 
were scanned using a 10x objective to determine cell location, before being captured using a 
x60 objective. The scores allocated by the CytoVision 7.2 software were reviewed by myself 
and Lisa Jones, and the average of our findings used for further analysis.  
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Several healthy controls, kindly given by the Leukaemia Research Cytogenetics Group from 
their pool of controls were run alongside the samples in order to determine a lower cut-off 
for positivity (Table 16). The standard cut-off, as used by the Leukaemia Cytogenetics 
Research Group was the average of 3 controls + 3 standard deviations, which for this set of 
experiments was 5.96% (Table 17).   
Control Percentage Abnormal cells 
Control M 5.6 
Control C 5.5 
Control 141701 5.7 
Table 16: Percentage of cells with any abnormal cells (not 2R2G) in healthy control samples 
as determined by FISH. Percentages are the average of 2 scores by different people, 
approximately 1000 cells were scored for each sample.  
 
Average 5.6 
1 standard deviation 0.125 
3 standard deviation 0.377 
Average + 3 standard deviation 5.96 
Table 17: Calculations used to determine the cut-off for hetrozygosity in L707 presentation 
samples treated with Dex in vivo.  
 
3.24 Microarray analysis 
 
3.24.1 GenomeStudio and Excel 
 
Data returned from oxford Genomics in the form of encrypted IDAT (intensity data files) 
files, with a file for each the red and green probes. These were imported into 
GenomeStudio, an Illumina software for the analysis of microarrays. Data was normalised 
using quantile and the background was subtracted. Illumina recommended statistics applied 
to the data before comparisons were run between primary and secondary presentation vs 
primary and secondary relapse. The resulting data, with p.values for both probe binding and 
90 
 
differential expression were exported to Excel for further manipulation. In Excel, the sort 
function was used to select probes dependent on several parameters; p.value <0.01, fold 
change >2 in either direction and probe binding of at least 1 sample >100. This resulted in a 
list of genes with differential expression that were expressed well above background in at 
least one condition and were significantly different between presentation and relapse. No 
further statistics were applied to the data after the Illumina recommended stats in 
GenomeStudio, meaning the data had no corrections for multiple testing  
 
3.24.2 R packages 
 
Microarray data was analysed by myself after completion of the 5-day R and Bioconductor 
course provided by the bioinformatics support unit. Scripts that were adapted for use with 
this data were provided in the hand out from this course (Produced by Dr. Simon Cockell).  
The workflow for microarray analysis is outlined in Figure 18. Raw data in the form of IDAT 
files were imported into R using the read function of the Illumina microarray specific 
programme, Lumi. Data was transformed using variance stabilisation transformation (VST) 
before being normalised using robust spline normalisation (RSN). VST takes advantage of the 
large number of technical repeats in the Illumina microarrays to stabilise variances between 
the bead replicates within a single bead chip (Lin et al. 2008). RSN normalises the data 
between chips, it does this using both quantile and loess normalisation (Du, Kibbe, and Lin 
2016). Quality control and filtering resulted in any probes that failed to meet the detection 
call thresholds applied by Lumi being discarded. This filtered data was used with Limma to 
determine which of the remaining probes were significantly different between conditions 
and a ranked gene list produced. Limma used t-statistics to determine significance, and the 
Benjamini-Hochberg method to correct data and produce a false discovery rate statistic. This 
list was then used for gene ontology statistics to determine which pathways were 
significantly upregulated in the samples.  
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Figure 18: The workflow used for analysis of microarray data using the Lumi and Limma 
method. Input and output files are in yellow boxes whereas the programmes used are in blue 
boxes. The workflow is the gold standard for analysis of microarray data.   
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3.25 GATK whole genome sequencing analysis 
 
The Genome Analysis Toolkit (GATK) is a suite of programmes produced by the Broad 
Institute for the analysis of whole genome sequencing data (McKenna et al. 2010; DePristo 
et al. 2011; Van der Auwera et al. 2013). It is widely considered the gold standard for whole 
genome data variant analysis (Figure 19).  
GATK comprises three main steps;  
1. Pre-processing; this is the process that transforms a raw FASTQ file into an aligned 
BAM file. The alignment used is Barrows Wheeler Alignment (BWA). Duplicates are 
marked and the samples are sorted.  
2. Variant discovery; this is the main step and uses the aligned BAM file to produce a 
list of variants, this is done by looking at regions with genetic variation in order to call 
variants resulting in the production of a VCF call set file 
3. Call set refinement; variants in the form of VCF files are refined, annotated and 
evaluated, this is done using the Variant effect predictor (VEP) programme from 
Ensembl for all variants with more than 10 supporting reads. 
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Figure 19: The workflow for GATK processing of whole genome sequencing data. Yellow 
boxes indicate input and output files; green boxes indicate data manipulation. Workflow 
obtained from the GATK best practices, available on the Broad Institute website (Van der 
Auwera et al. 2013; DePristo et al. 2011; McKenna et al. 2010) 
3.26 RNA sequencing analysis 
 
Raw data was returned from AROS in the form of FASTQ files. Quality control was run on 
these files and the parameters needed for further analysis such as the median insert size, 
standard deviation and pair orientation were determined using the Picard metrics tool. Once 
files had passed quality control, analysis was done using the Cufflinks suite of programmes, 
which was done by myself with significant help from Ben Allen at the bioinformatics support 
unit. The workflow is outlined in Figure 20. Briefly, the reads were mapped to a bowtie2 
generated genome index (hg19) using the programme Tophat. These reads were then 
assembled into transcripts using Cufflinks and the final transcript assembly was done with 
Cuffmerge. To determine differentially expressed transcripts Cuffdiff was used. The output 
from this is a list of differentially expressed transcripts which can be used with CummeRbund 
to generate plots in R as well as for gene ontology. 
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Figure 20: Workflow used for the analysis of RNA sequencing using the Cufflinks suite. Blue 
boxes denote programmes and yellow boxes are input and output files.  
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3.27 CRISPR screen specific methods 
3.27.1 Transduction of electrocompetent bacteria and plasmid collection 
 
The lentiCRISPRv2 GeCKO library is a plasmid library that contains over 122000 sgRNA 
targeting the whole genome. There are 6 sgRNA for each gene and 4 for each miRNA in the 
library, it comes as two separate half libraries, A and B with each library containing half of 
the sgRNA for each target. The plasmid library was designed and used in the papers from the 
Zhang lab at MIT (Shalem et al. 2014; Sanjana, Shalem, and Zhang 2014). The library was 
purchased from Addgene, was transformed into electrocompetent cells as per the library 
protocol (Sanjana, Shalem, and Zhang 2014; Shalem et al. 2014). The E. cloni 10G SUPREME 
Electrocompetent E. coli cells (Lucigen) were used for this. Cells were thawed on ice and the 
entire 25 µl transferred to 1mm electroporation cuvettes (PeqLab), with 75 µl sterile RNase 
free H2O to increase volume to 100 µl. 2µl of the GeCKO lentiCRISPRv2 library DNA (50 ng/µl) 
was added followed by20 minutes incubation on ice before electroporation at 2500V using a 
Stratgene 1000 electroporator. To recover cells from the cuvette, 900 µl SOC media (pre-
warmed to 37°C) was added. A further 1 ml of pre warmed SOC media was also added. The 
samples were incubated for 1hr at 37°C with shaking at 250rpm without antibiotic. For each 
library a total of 4 electroporations were done.  
After 1hr incubation the samples were pooled into the two libraries (8 ml each). 400 µl of 
the transformation mix was pipetted onto LB agar plates containing ampicillin (100 µg/ml) 
and spread. 20 plates were used for each library, resulting in 40 plates in total. As well as 
these 40 plates a dilution plate was made for each library to determine the coverage of the 
library.  10 µl transformation mix was added to 1 ml of SOC media, and 20 µl of this pipetted 
onto an LB agar plate and spread. The colonies on this plate represented a 40,000-fold 
dilution of the un diluted plates. If the colonies on this plate, when multiplied by 40,000 was 
more than 3x106 library coverage would be at least 50X.  
All plates were grown inverted for 14h overnight at 34°C. The lower incubation temperature 
results in reduced recombination within the lentiviral LTR (long terminal repeats). The 
following morning bacteria were recovered from the plates by adding 500 µl LB broth to 
each plate and scraping colonies off before pipetting into a 50 ml falcon tube. The plates 
were washed to ensure maximum colony collection with a further 500 µl of LB broth. All 
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plates were collected and tubes were centrifuged at 6000g for 10 minutes at 4°C to pellet 
bacteria. The supernatant was removed before weighing of pellets and freezing at -20°C for 
use later.  
The dilution plates each had >1500 colonies, which equates to 6x107 colonies total for each 
of the libraries. This represents approximately 490x coverage of the plasmid library.  
Plasmids were extracted from bacterial pellets using the Maxiprep kit (3.19.2), with 14 and 
13 Maxipreps used for library A and B respectively.  
 
3.27.2 Transfection of 293T cells and collection of lentivirus 
 
The lentiCRISPR library was transfected into 293T cells using the protocol described 
previously (3.20). However, it was done on a much larger scale, with 48 100cm tissue culture 
dishes seeded with 293T cells used. These larger TC plates roughly equate to 3 100mm 
plates each, and hold 30 ml of media. The transfection was scaled up to accommodate this.  
Lentivirus was collected as per the original protocol (3.21) and a total of 8 ultracentrifuge 
spins were used over 2 days to concentrate it. The final lentivirus was re-suspended in a total 
of 4.5 ml SFEM II media with 20% FBS.  
 
3.27.3 Transduction and selection of L707 presentation cells 
 
On the day of transduction 3 vials of L707 presentation cells were thawed, after washing in 
pre-warmed SFEM II media and counting, 4.7x107 cells were re-suspended in the 4.5 ml 
lentivirus and a further 11.5 ml media containing 1% pen/strep,20% FBS with 20 ng/ml IL-3 
and 10 ng/ml IL-7. 15 µl, 8 µg/ml polybrene was added to this to aid transduction. Cells were 
then pipetted into 30 wells of 2 48 well plates, approximately 1.5x106 cells/well. Plates were 
wrapped in Parafilm before centrifugation for 50 mins at 900g, 34°C. After centrifugation the 
Parafilm was removed and cells placed in an incubator at 37°C overnight.  
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The following morning, ~350 µl media was removed and 500 µl fresh media added. Cells 
were transferred to 24 well plates and returned to the incubator for 72h. 
After 72h growth to allow the expression of the plasmid, cells were selected with puromycin. 
0.25 µg/ml was added to cells for 48 hr before being increased to 0.5 µg/ml for a further 24 
hr. At this point cells were counted and washed twice in PBS, counted and re-suspended in 
SFEM II media for intrafemoral injection into 15 NSG mice (105 cells/mouse). After 
puromycin selection there were approximately 45% viable cells in the sample.   
 
3.28  Production of amplicon library for lentiCRISPR screen 
 
After DNA was extracted from samples from mice engrafted with L707 presentation CRISPR 
cells it was used in a two-step PCR process to create an amplicon library that was used for 
next generation sequencing. To 0.5 ml PCR tubes 825 ng DNA was added along with 1 µl 
primer mix (50 µM) and 12.5 µl of Phusion® High-Fidelity PCR Master Mix with HF Buffer 
(Table 18). RNase free H2O was used to make this volume up to 25 µl before samples were 
centrifuged and according to the temperatures in Figure 21. A total of 5 reactions was done 
for each sample. This was chosen after discussion about coverage with a bioinformatician, 5 
was determined to give enough coverage without increasing the number of PCR reactions 
too much.  
Reagent  Volume(µl) 
DNA 825 ng 
50 µM Primer Mix 1 
2x Phusion® High-Fidelity PCR Master Mix 
with HF Buffer 
12.5 
H2O Up to 11 
Total 26 
Table 18: Reagents and volumes of each required for the first step amplification PCR of 
genomic DNA for the lentiCRISPR samples before the addition of the barcodes and illumina 
adaptors required for ssequencing on the HiSeq.  
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Figure 21: The GeneAmp 9700 Thermo Cycler settings for both the first and second step PCR 
reactions used in the preparation of the lentiCRISPR amplicon library.  
Due to problems with previous sequencing runs some samples were amplified from pre-
amplified material where there was no DNA left. Each pre-amplified sample was the result of 
5 PCR reactions that were pooled, and where there wasn’t enough genomic DNA left, 1 µl of 
these pooled samples was used for each PCR. The resulting 5 PCR reactions (from genomic 
or pre-amplified DNA) were pooled and concentrated using the QIAquick PCR clean-up kit 
(Qiagen) and eluted in 20 µl of EB buffer and used for the second step PCR to add the 
Illumina adaptors. The second PCR was done in a 0.5 ml PCR tube and all the reagents were 
added before centrifugation and then running on a thermocycler. This PCR used a universal 
forward primer (50 µM), and a barcoded reverse primer (50 µM) so that samples could be 
de-multiplexed after the sequencing run. 1 µl DNA from the pooled first step PCR reactions 
was used (Table 19). The same temperatures were used for the second PCR as for the first 
(Figure 21). 
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Reagent  Volume(µl) 
Pooled, concentrated DNA 1 
Universal forward primer (50 µM) 0.5 
Barcoded reverse primer (50 µM) 0.5 
2x Phusion® High-Fidelity PCR Master Mix 
with HF Buffer 
12.5 
RNase H2O 10 
Total 26 
Table 19: Reagents and volumes required for the second step PCR in which amplified DNA has 
adaptors and a barcode added.  
DNA was amplified using primers located close to the sgRNA region but the amplicon from 
this reaction was less than 100bp, which is the smallest recommended amplicon for retrieval 
using the PCR clean up kit (Qiagen). In order to avoid this issue, the forward and reverse 
primers also had CS1/2 sequences. These sequences were originally designed so that the 
samples could be used with the Fluidigm system, but after this did not work they were kept 
to increase amplicon size. The PCR clean up kit was used to concentrate and purify products 
before the second step of PCR. The second round of PCR added the adaptors and barcodes 
required for multiplexing and sequencing on the Illumina HiSeq2500 (Figure 22).  
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Figure 22: Scheme showing steps in the 2 step PCR process to produce amplicons used for 
next generation sequencing. Genomic DNA is extracted and the 1st step PCR used to amplify 
material. Amplification primers had the addition of CS1/2 sequences in order to ensure the 
amplicon was more than 100bp and so could be used with PCR clean up columns. The 2nd 
step PCR replaces these sequences with the standard Illumina adaptors with a barcode.   
 
Before being sequenced, samples were run on a large 1.5% agarose gel at 70V for 1.5hr and 
the band at 216bp extracted (Figure 23). This was purified using the QIAQuick Gel extraction 
kit (Qiagen), samples were quantified using the Nanodrop and pooled into 7 samples before 
being sent for sequencing by AROS using an Illumina HiSeq2500 with v4 chemistry. 
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Figure 23: Analytical gel of amplified DNA with the adaptors and barcodes added. First 19 
samples are shown. The expected amplicon is 216bp which is reflected by the higher band, 
the lower band reflects primer dimers. The gel shows smeared bands due to the high levels of 
DNA loaded in each well, a consequence of the high concentrations after several 
amplifications and PCR concentration. 
 
3.29 Data Analysis of lentiCRISPR screen 
 
All of the analysis of the raw FASTQ files and MAGeCK (Model based analysis of genome 
wide CRISPR/Cas9 knockout) analysis was done by Dr Matt Bashton. First reads were 
trimmed down from the 50bp read output from the HiSeq2500 to the 20bp sgRNA sequence. 
For trimming the sequence of the CACCG adaptor was used to ensure the sgRNA was 
selected rather than using hard coded bp position, this avoided loss of reads through 
artefacts that resulted in shifts in reads. Once reads were trimmed, a false genome of the 
sgRNA in the screen was created using Bowtie2 and reads were aligned to this. Read 
counting was done using the count function of MAGeCK, before normalisation by mean 
variance.  
The workflow of data analysis is outlined in Figure 24. Once reads had been trimmed, aligned 
and counted they were normalised using median normalisation. Significance calculations and 
ranking is done using mean-variance modelling and modified robust rank aggregation (RRA), 
which utilises an algorithm that assumes sgRNA with no effect will be evenly distributed 
throughout the sample, comparison of actual sgRNA frequency to the model can then be 
used to find which sgRNA have an effect. Genes are also ranked using RRA, dependent on 
the location of the sgRNA for that gene in the list of ranked sgRNA (Li et al. 2014).  
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Figure 24: Workflow of data analysis used for the lentiCRISPR screen. The programme 
MAGeCK is a purpose deisgned software for whole genome screens using lentiCRISPR 
plasmids. Blue boxes indicate functions and yellow boxes indicate output files. Programmes 
used are indicated to the left.  
 
3.30 Cloning CRISPR plasmids 
 
sgRNA constructs were inserted into the lentiCRISPRv2 plasmid using the protocol published 
by the Zhang lab, who created the plasmid (Sanjana, Shalem, and Zhang 2014; Shalem et al. 
2014). In a sterile 0.5 ml tube 1 µg lentiCRISPRv2 plasmid was added to 0.5 µl BsmBI (10 
U/µl), 0.5 µl FastAP (10 U/µl), 1 µl 20 mM DTT (Dithiotheritol), 2 µl 10X Tango Buffer and 
made up to 20 µl with RNase free H2O (Table 20). This was centrifuged to bring the reagents 
to the bottom of the tube before being placed in the GeneAmp 9700 Thermo Cycler for 1hr 
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at 37°C. After restriction, 5 µl loading dye was added and the whole sample run on a 1% 
agarose gel at 70V for 1.5hr. After visualisation using UV two bands were visible at 12.8kbp 
and 2kb. The larger of these two was cut out and extracted from the gel using the QIAquick 
Gel Extraction kit (Qiagen) and stored at -20°C before use.  FastAP was used to de-
phosphorylate the restricted ends of the plasmid which aids in ligation with a 
phosphorylated insert.  
Reagent Volume(µl) 
lentiCRISPRv2 plasmid (1 µg/µl) 1 
BsmBI (10 U/µl) 0.5 
FASTAP 0.5 
20 mM DTT 1 
Tango Buffer  2 
RNase free H2O 15 
Table 20: Reagents and the volumes required of each for BsmBI digestion of the 
lentiCRISPRv2 plasmid.  
Before the oligos could be ligated into the restricted plasmid the sense and antisense strands 
were annealed. 1 µl of both the sense and antisense oligos were added to a 0.5 ml collection 
tube along with 1 µl T4 DNA ligase buffer (10X) and 1 µl T4 Polynucleotide Kinase (10 U/µl) 
(Table 21). This was made up to 10 µl with RNase free H2O and after centrifugation and 
annealed using the following temperature profile; 37°C for 30 minutes, 95°C for 5 minutes, 
70°C for 10 minutes, 25°C for >2hrs. Samples were then taken out of the GeneAmp 9700 
Thermo Cycler and left on the bench overnight. Phosphorylation of the sgRNA was done at 
the same time by the addition of T4 Polynucleotide Kinase (PNK) (10 U/µl), this aids ligation 
into the de-phosphorylated plasmid. 
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Reagent Volume(µl) 
Sense oligo (100 µM) 1 
Anti-sense oligo (100 µM) 1 
T4 DNA ligase buffer (10X) 1 
T4 Polynucleotide Kinase (10 U/µl)   0.5 
RNase free H2O 6.5 
Table 21: Reagents and the volumes required of each to anneal the sense and antisense 
sgRNA oligos before cloning into the restricted lentiCRISPRv2 plasmid.  
Annealed oligos were diluted 1:200 in RNase free H2O before ligation into the restricted 
lentiCRISPRv2 plasmid. Ligation was done at approximately a 1:10 molar ratio, with 50 ng 
restricted lentiCRISPRv2 plasmid, 1 µl of the diluted annealed oligos, T4 DNA ligase (10 U/µl), 
T4 DNA ligase buffer (10X) and RNase free H2O, to make a total volume of 10 µl (Table 22). 
Ligation was carried out on the bench at room temperature overnight. The following day 
ligation products were transformed into stbl3 according to 3.16.2. Bacteria were spread on 
agar plates containing ampicillin (100 µg/ml) and incubated overnight, colonies were picked 
the next morning and used to inoculate 5 ml of LB broth, which was grown for 8h at 37°C 
with shaking at 200rpm. Bacteria was collected and the plasmid DNA extracted using a 
Miniprep kit (3.19.1) Plasmid DNA was sent for Sanger sequencing (Source Bioscience, UK) to 
check the correct insertion of sgRNA before being expanded and a maxiprep (3.19.2) done to 
get DNA for transfection of 293T cells. All single gene knockouts were done with a pool of 6 
sgRNA targeting one gene.  
 
Reagent Volume(µl) 
BsmBI digested plasmid (25 ng/µl) 2 
Diluted oligo complex 1 
T4 DNA ligase (10 U/µl) 0.5 
T4 DNA ligase buffer (10X) 1 
RNase free H2O 5.5 
Table 22: Reagents and the volumes required of each for the ligation of the annealed sgRNA 
oligos into the digested lentiCRISPRv2 plasmid.  
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 Chapter 4: Investigation of mechanism of relapse using paired 
presentation and relapse ALL: The L707 cells 
 
4.1 Introduction 
 
The investigation of the emergence of relapse and the acquisition of drug resistance in ALL is 
an important area of study, as relapse and the often associated loss of chemosensitivity 
represent a significant number of deaths in paediatric ALL cases. The use of matched 
presentation and relapse samples represent an excellent model that has been used for 
several studies including the determination of the origin of relapses inn ALL (Mullighan et al. 
2008), comparison of the immunophenotypic characteristics of presentation and relapse in 
ALL (Eveillard et al. 2013) and investigations into the genesis of therapy resistance (Buijs et 
al. 2014) . The use of matched pairs generally relies on the sequencing of DNA from samples 
rather than the culture of primary material. This is partly because the culture of primary 
material is more troublesome than cell lines due to issues with viability and proliferation in 
vitro. The engraftment of primary ALL samples in immunocompromised mice has proven to 
be invaluable for the evaluation of the disease. This technique has allowed for investigation 
of leukaemic stem cells in ALL (le Viseur, Hotfilder, Bomken, Wilson, Rottgers, Schrauder, 
Rosemann, Irving, Stam, Shultz, Harbott, J??rgens, et al. 2008), drug testing (Leclerc et al. 
2016; Tomkinson et al. 2003) and the expansion of cells for ex vivo manipulation.  Several 
studies have been undertaken to evaluate the correlation between primary samples and 
xenograft samples and the results are encouraging for research using these models. The rate 
of engraftment of relapse samples has been found to be correlated to the length of 
remission, indicating preservation of disease aggressiveness. These rates were stable for at 
least 6 engraftment passages and the immunophenotype was often maintained over several 
passages, as were rearrangements of antigen receptor genes (Lock et al. 2002). Importantly 
for the investigation of the acquisition of resistance, the drug sensitivity profile of xenograft 
cells has been shown to be stable over several xenograft passages (Liem et al. 2004; Lock et 
al. 2002). It should be noted that xenograft models have not been so favourably reported for 
other diseases however. Murine models of hepatocellular carcinoma show very different 
microarray profiles compared to primary tumours even when injected orthotopically (W. 
Wang et al. 2015). The reported success of ALL xenografts could be due to the nature of ALL, 
106 
 
being a haematological malignancy it might be better able to engraft in a way that mirrors 
the original disease. It could also be that there is lesser impact on the cells of the differences 
between the human and murine BM niche.  
The L707 patient samples are a matched presentation and relapse from a patient with pre B-
ALL carrying the t(17;19) translocation. The patient was a 16-year-old female who presented 
with a dexamethasone (Dex) sensitive t(17;19) pre B ALL. The patient was treated according 
to regimen B of ALL 2003 and was MRD negative at day 28. However, the patient suffered a 
relapse within 5 months and despite further treatment (R3 and then FLAG), re-induction of 
remission was not possible. The patient developed encephalopathy and died from an intra-
cranial bleed 2 months after relapse. Cytogenetics for presentation and relapse are detailed 
in Table 23. 
The L707 presentation and relapse cells were investigated by Dr. Elda Latif and all the initial 
data on engraftment and Dex resistance were obtained during her PhD. The percentage of 
leukaemic blasts in the primary patient BM was found to be 99% and 97% for the 
presentation and relapse respectively, and the cells were found to be CD10+, CD19+, 
CD20lo/negative, CD34negative at both presentation and relapse. The intra-femoral injection of 
the primary samples into NSG mice resulted in rapid engraftment, with splenomegaly as well 
as some mice exhibiting ovarian tumours, leg tumours, engraftment of the gastric lining and 
brain stem engraftment (Latif 2012).   
 
Time-point Karyotype 
Presentation 46,XX,der(19)t(17;19)(q2?;p13)[12]/46,idem,fra(10)(q25)[17]/46,XX[1].ishder
(19)t(17;19)(19ptel-,wcp17+,wcp19+,19qtel+) 
Relapse 46,XX,der(19)t(17;19)(q2?;p13)[5] 
Table 23: The karyotype of the L707 cells at presentation and relapse, work carried out by 
NHS cytogenetics services as part of normal treatment protocols (Latif 2012).  
 
Genetic characterisation of the L707 presentation and relapse using the Affymetrix 500k 
array and SNP6 array revealed that there was a 5q deletion at 5q31.3-q32. This deletion was 
present in the relapse and maintained in the relapse xenograft samples with the same 
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breakpoints indicating little change between primary and xenograft samples. The 5q deletion 
spans 6 genes; NR3C1, FGF1, ARHGAP26, HMHB1, YIPF5 and KCTD16 (Latif 2012).   
The aims of this work were to investigate the mechanisms of relapse and Dex resistance in 
ALL. The use of paired presentation and relapse samples represents an excellent way to 
determine the driver genes behind the emergence of relapse in ALL.  To complement this, 
the Dex sensitivity of the presentation, and the resistance in the relapse makes this case a 
useful tool for the investigation of the acquisition of Dex resistance in ALL.  
 
4.2 Differential gene expression profile between presentation and relapse in the L707 
cells  
 
In order to augment the data obtained during Elda’s PhD, and look further into differences in 
the gene expression profile between the presentation and relapse samples, microarray 
analysis was carried out. Samples were collected from mouse spleens and the Ambion 
MirVana total RNA kit was used to extract RNA under instruction from Oxford Genomics, the 
company that carried out the microarray. Samples were originally going to be sorted prior to 
RNA extraction but FACS analysis revealed that the engrafted spleens were ~98% human 
cells, so this was not necessary. 12 samples were sent for analysis, 6 presentation and 6 
relapse representing both earlier primograft and later secondary engraftments of the L707 
cells into NSG mice, these samples were labelled primary and secondary respectively (Table 
24).  
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Array Location Sample Mouse Label 
K1 L707 Presentation primograft  F4033 LN Primary  
K2 L707 Presentation primograft  F4033 NN 
K3 L707 Presentation primograft  F4033 NN 
K4 L707 Relapse primograft F3887 LN 
K5 L707 Relapse primograft F3887 RN 
K6 L707 Relapse primograft F3887 RN 
K7 L707 Presentation secondary xenograft G6766 LN Secondary 
K8 L707 Presentation secondary xenograft G6766 LN 
K9 L707 Presentation secondary xenograft G6766 LN 
K10 L707 Relapse secondary xenograft G6766 NN 
K11 L707 Relapse secondary xenograft G6766 NN 
K12 L707 Relapse secondary xenograft G6766 NN 
Table 24: Array Location, sample type, mouse and labels used for analysis for samples used 
for microarray analysis of L707 presentation and relapse.  
 
4.2.1 Analysis using genome studio and excel 
 
Data was returned from Oxford Genomics in the form of IDAT and GTC files (cluster 
reference information files). These were loaded into GenomeStudio, which was then used to 
run statistics to produce p values for probes. Quantile normalisation was applied to the data, 
the background subtracted and the standard Illumina statistics used (3.24.1) 
The average signals of each sample were compared to check for discrepancies (Figure 25) 
before data was used for further analysis. Samples were found to have similar intensities 
throughout.  
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Figure 25: Plot showing the comparison of the average probe intensity signals between 2 
L707 samples sent for microarray analysis, A and B which correspond to two L707 
presentation samples. The alignment of samples indicates that arrays have similar intensity 
and so do not have significantly different levels of probe binding between them that could 
affect analysis of data. Comparison of 2 samples is shown as a representative, no differences 
were seen in any of the multiple comparisons.  
Once statistics and normalisation had been done in GenomeStudio, data was exported to 
Excel for further manipulation. In order to create a stringent list several parameters were 
applied to the data in order to determine which genes were significantly altered. Firstly, a 
cut-off for differential p values of less than 0.01 was applied, then a fold change of more 
than 2 in either direction. Lastly the probe binding (intensity) in one or both of the samples 
had to be over 100 for the probe to be accepted. This set of parameters was applied to the 
four permutations of comparison (Figure 26) and thus 4 lists of genes differentially 
expressed between presentation and relapse were generated. Comparison of these 4 lists 
showed an overlap of 124 probes common to all lists (Figure 27), from these 124 probes 117 
had gene names.  
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Figure 26: The 4 different assessments made between primary and secondary L707 
presentation and L707 relapse samples in excel to generate a list of significant genes to 
investigate further. Red arrows indicate which samples were compared to one another, 
resulting in a total of 4 lists of genes.   
 
Figure 27: Venn Diagram showing the crossover of genes in each of the 4 lists from the 
multiple comparisons of the primary and secondary engraftment samples for L707 
presentation and relapse. Only probes that had a p value of <0.01, binding of >100 in either 
condition and a 2-fold change in either direction were included in lists, and only probes that 
had associated gene symbols were used for final lists used to produce venn diagram. The 
labels indicate the two lists compared.  
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The resulting list of 117 genes was then used for gene set enrichment analysis (GSEA) to rank 
the genes and determine which pathways were significantly enriched (Figure 28). Analysis 
was carried out with weighted enrichment statistics and genes were ranked using the log2 
ratio of classes. The levels of binding for each of the differentially expressed probes was also 
plotted to determine if there were large differences between the primary and secondary 
samples, which was not found (Figure 29). 
 
4.2.1.1 Genes downregulated at relapse  
 
Of the 37 genes for which expression is decreased at relapse the top 2 as ranked by GSEA are 
NR3C1 and HMHB1 (Figure 28), which is unsurprising due to their deletion in the relapse. 
None of the other genes in the 5q deletion are in the list because the other 4 are not 
expressed at any significant amount in the presentation (Figure 30). As well as NR3C1 and 
HMHB1 downregulation at relapse, there are several genes that are potentially interesting. 
DKK1 (Dickkopf 1) expression is significantly reduced in the relapse. This protein is known to 
be an antagonist of WNT signalling, a pathway activated in many chronic lymphocytic 
leukaemia cases  which is thought to contribute to oncogenesis (Filipovich et al. 2010; D. Lu 
et al. 2004). PEG3 (paternally expressed 3), another potentially interesting gene has reduced 
expression at relapse. This gene is a mediator of apoptosis, and in the absence of TP53 is 
able to induce apoptosis in cooperation with the p53-inducible gene SIAH1A (seven in 
absentia 1A). Loss of PEG3 expression inhibits TP53 induced apoptosis (Relaix et al. 2000), 
indicating a possible reason for loss of this gene at relapse.  
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Figure 28: Ranked list of 117 genes for which GSEA allocated a score with the gene name, 
average probe binding for the presentation and relapse and the average fold increase or 
decrease (average of the 4 permutations of data analysis previously used to generate the list 
input into GSEA. Fold changes for several genes are the averages of several probes for the 
same gene that scored as significant). Genes and values shown in green indicate genes for 
which expression is higher in the presentation than the relapse. Genes and values in red 
indicate genes for which expression is higher in the relapse than the presentation. Genes are 
ranked in order, i.e. NR3C1 is the most significant of the lost genes and HIST1H4A is the most 
significant of the increased genes.  
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Figure 29: Scatter plot showing the probe binding for the differentially expressed probes as determined using the protocol described (p<0.01, >2 fold difference, probe 
binding >100 in either presentation or relapse. Present in all 4 lists). Presentation samples are show in green and relapse in red. For both, the lighter shade represents 
the primary timepoint and the darker shade the secondary. 
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Figure 30: Probe binding (as a surrogate for mRNA expression) of the 6 genes in the relapse 
specific 5q deletion at presentation and relapse. Only NR3C1, HMHB1 and YIPF5 are 
expressed in the presentation, with YIPF5 expression levels still very low compared to NR3C1 
and HMHB1.  Gene expression in L707 Presentation is shown in green and expression in L707 
relapse in red.  
 
4.2.1.2 Genes upregulated at relapse  
 
In the genes upregulated at relapse there is a large proportion of histone genes, which were 
all replication dependent (Marzluff et al. 2002) rather than the histone genes which are not 
cell cycle regulated. This indicates that the L707 may have altered cell cycle, and although 
the increase in histones might indicate that there is an increase in cell cycling, the fact that it 
has been found by others in our lab that the L707 relapse, when in culture on a MSC feeder 
layer in vitro has an increased number of cells in G0 and has slower proliferation (Pal et al. 
2016), this would indicate that the increased histones somehow result in the opposite; 
reduced proliferation.  
Gene ontology analysis of the genes down regulated at relapse shows several significantly 
enriched gene sets, including DNA methylation, (FDR=0.000381), the nucleosome 
(FDR=1.67e-17) and chromatin (FDR=7.53e-9), all of which suggest an altered transcriptional 
profile in the L707 relapse. These gene sets are all enriched due to the presence of a number 
of histones in the genes upregulated at relapse.  
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Running gene ontology on both the upregulated and downregulated genes similar pathways 
are enriched as for the downregulated genes alone. These include the nucleosome core 
(FDR=2e-14) and the histone core (FDR=2.3e-14), somewhat interestingly systemic lupus 
erythematosus is also highly enriched for in the gene list (FDR=2.6e-12), an autoimmune 
disease which does have an increased risk of haematopoietic malignancies, in particular 
lymphoma associated with it (Sultan, Ioannou, and Isenberg 2000; Abu-Shakra, Gladman, 
and Urowitz 1996) 
When gene ontology analysis is run again with the larger list of all genes differentially 
expressed in any of the 4 lists (2122 genes) rather than the shortened list, the categories are 
very similar ( 
Table 25). 
Term p Value Benjamini score  
Nucleus 9.90E-22 6.20E-19 
Phosphoprotein 4.50E-19 1.40E-16 
Protein-DNA complex 5.30E-12 6.00E-14 
Nucleosome 1.50E-16 2.90E-11 
Nucleosome assembly 1.10E-11 2.70E-08 
 
Table 25: Top 5 gene ontology hits when all genes are used to generate the input data for 
GSEA to determine enriched pathways between the L707 presentation and L707 relapse 
rather than the 4 lists generated through excel analysis. Table shows the gene ontology term 
as well as the p value and Benjamini score (corrected p value), Hits are ranked by p value. 
 
4.2.2 Microarray analysis using R 
 
Analysis using excel produces a list of genes that are differentially expressed between two 
conditions. This however has no corrections for multiple testing, and relies on the user 
creating several lists and then comparing those. Analysis using statistical programmes 
provides a better option. This is because the significance determined using statistical 
programmes will take into account all biological and technical repeats, as well as correcting 
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for multiple testing. Data was re-analysed using the R programmes Lumi and Limma (3.24.2). 
These programmes are just some of the vast array available for this type of analysis but are 
the most commonly used analysis programmes (Eijssen et al. 2015) 
Raw IDAT files were imported into R using the Illumina microarray specific programme, Lumi. 
Data was analysed in the standard way for microarray, with the VST method of 
transformation and RSN normalisation (Figure 31).  At this point, 7 probes were excluded 
due to low bead numbers in one or more of the samples. 61% of probes then failed to meet 
the detection call threshold applied after normalisation. This is lower than would have been 
expected but there was enough data remaining to continue with analysis.  
Principal component analysis (PCA) (Figure 32) shows the presentation samples cluster, with 
the primary and secondary samples clustering closest. There is more variance between the 
primary and secondary samples in the relapse.  
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Figure 31: Intensity box plots for each of the 12 microarray samples before normalisation 
(top) and after robust spline normalisation (bottom).  Plots show the median intensity (bold 
line) as well as the upper and lower quartiles (top and bottom of box) for probe intensity for 
each sample. The error bars represent the extremes at the upper and lower ends. As can be 
seen, robust spline normalisation results in more evenly distributed probe intensity between 
samples.  
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Figure 32: Principal component analysis of the microarray samples after quantile 
normalisation. Presentation samples are shown in blue and relapse samples in red with the 
darker shade representing the primary time point samples (labelled early) and the lighter 
shade representing the secondary timepoint samples (labelled late). The two principal 
components contributing the most to the total variance between samples are shown on the x 
and y axis, with the percentage contribution to the differences shown.  
 
4.2.2.1 Genes down-regulated at relapse 
 
Expression of 4825 genes are significantly different (p<0.01) between the presentation and 
relapse when analysed . The most significant of these genes is TCEA3 (Transcription 
elongation factor A3) with an adjusted p. value of 9.05e-14. TCEA3 has been found to be 
significantly enriched in mouse embryonic stem cells and is implicated in differentiation, 
although it appeared to have no effect on proliferation in these cells (Park et al. 2013). 
TCEA3 has also been found to be repressed upon treatment with Dex in breast cancer cells 
(Kinyamu et al. 2008).  
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NR3C1, the most significant using the genome studio and excel analysis is the 16th ranked 
gene, the 3rd most significant of genes lost at relapse with an adjusted p. value of 2.8e-11. 
This is still highly significant but highlights the differences when analysis data using Excel or 
the statistical programmes designed specifically for analysis of microarray data.  Another 
gene of interest that is lost in the relapse includes CEBPB (CCAAT/enhancer binding protein 
beta) (adj. p.value = 4.93e-8). CEBPB has been implicated in ALL with an IGH translocation, 
but is usually found to be upregulated in these cases (Akasaka et al. 2007). PEG3 and DKK1 
are both still significantly down regulated at relapse, but using this method of analysis are 
further down the ranked list (position 25 and 103 respectively), again highlighting the 
differences in the analysis compared to using Excel.  
 
4.2.2.2 Genes up regulated at relapse 
 
The 3 most significant genes upregulated at relapse are SNORD3D, 3A and 3C. These are all 
small nucleolar RNA, they are non-coding RNA that have vital roles in the processing of 
ribosomal RNA. Although not a lot is known about them, these RNA are highly conserved 
across eukaryotes indicating an important function (Scott and Ono 2011). These RNA 
molecules have been found to associate with AGO (Argonaute) and may have RNAi 
capabilities (Ender et al. 2008).  
Similar to the Excel analysed data a large proportion of the highly significant genes are 
histones including genes from the HIST1 and HIST2 loci. These genes are replication 
dependent histones, which are unusual genes in so much as the mRNA does not  have a 
polyA (polyadenylated) tail but a stem-loop and the genes are encoded by exons without 
introns (Marzluff et al. 2002). These proteins are increased 35 fold when the cells enter S 
phase, thus gaining the name replication dependent histones. The histones that are not 
regulated with the cell cycle are more classical as they do have a polyA tail.  How an increase 
in these histones results in a phenotypic change in the L707 relapse is not known, but the 
fact that all of the significantly upregulated histones are replication dependent, and the fact 
that so many are high in the ranked list indicates that they play some role. One option is that 
the L707 relapse cells were in a different phase of cell cycle when they were collected, but 
this is unlikely as there were 3 replicates for each presentation and relapse.   
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Of the 1459 gene ontology biological process IDs tested, 142 were returned as significant 
(p<0.01), and after multiple testing correction using an FDR of 0.05, 91 were left. The top 
enriched gene ontology term is chromatin silencing, followed by nucleosome assembly and 
chromatin assembly. These terms are similar to the results from the upregulated genes at 
relapse in the excel analysis. The similarity between the analysis results indicates that the 
excel analysed data, which was used throughout most of the PhD is a good indicator of the 
gene expression profile differences between the L707 presentation and relapse.   
What can be taken from this microarray analysis, either the genome studio and excel or the 
R method is that the L707 relapse shows an alteration in the gene expression profile 
consistent with an altered chromatin landscape, and it is likely that this alters the 
transcriptional profile.  How this change in gene expression results in relapse is harder to 
pinpoint , and although one mechanism for Dex resistance is the loss of NR3C1 in the 
relapse, it is possible that there are other mechanisms, as well as mechanisms that drive the 
emergence of relapse.   
 
4.3 Whole genome sequencing: Genetic differences between presentation and relapse 
 
Whole genome sequencing was carried out on the L707 presentation and relapse cells by Dr. 
Lisa Russell in conjunction with Illumina. Bam files and output from mutation analysis were 
returned. However, the alignment did not appear to be good quality so the files were re-
analysed by Dr. Matt Bashton. Briefly, this involved extracting FASTQ files from the BAM files 
and, sorting and re-running the alignment protocol. The type of alignment used was 
Barrows-Wheeler alignment (BWA-mem) and hg19 was the reference genome. Aligned BAM 
files were then used with the GATK method of analysis (3.25), which was run using scripts 
from Dr. Sirintra Nakjang. Variant discovery was used to produce a list of variants, which are 
then refine, annotated and evaluated using the online Variant effect predictor (VEP) 
programme from Ensembl (McLaren et al. 2016). The average read depth of the sequencing 
for both the L707 presentation and L707 relapse was approximately 35X.  
Due to the lack of germline material for patient L707, variants that are disease specific 
cannot be determined. However, looking at those that are relapse-specific could elucidate 
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possible mechanisms of relapse and drug resistance, and looking overall may give clues to 
possible oncogenic driver mutations. Without germline material it can also not be 
determined for all variants whether they are constitutional or somatic variants other than by 
looking in the literature for those that have been reported before. The variants that have 
been identified before and that were flagged up by the variant effect predictor have been 
further investigated using the 1000 Genomes data available on the online database Ensembl 
(Aken et al. 2016). For the rest this has not been done as it was beyond my limited 
bioinformatics skill.  
 
4.3.1 Relapse specific SNP 
 
Of the 2355169 single nucleotide polymorphisms (SNP) that were above the thresholds used 
to remove false positives during analysis, 0.365% (8610) were unique to the L707 relapse, 
and of these 58% (4999) had >10 reads each. This list of variants was then used with the 
online VEP programme to annotate and give a predicted effect. 
The most frequent effects of SNPs unique to the L707 relapse were intron variants (47%) 
intergenic variants (16%) and non-coding transcript variants (13%). Of those that were 
predicted to have coding consequences the majority were missense variants or synonymous 
variants, 7% were gain of a stop codon (Figure 33). Just 33/4999 of the annotated variants 
scored moderate or high in the effect predictor, mapping to 9 genes, including 2 genes with 
existing variants known. 
 
 
Figure 33: Charts showing the predicted consequences of SNPs unique to the L707 relapse. 
Consequences were determined using the online tool Variant effect predictor (VEP). The left pie 
chart shows all consequences; the right chart shows only the consequences predicted to be 
coding consequences.  
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In all of the SNPs unique to the L707 relapse there were 4 that were associated with existing 
variants, affecting 3 genes. The catalogue of somatic mutations in cancer (COSMIC) database 
was used to look these up and they were all found to be associated with carcinoma (Table 
26). These three genes all have roles that could be important in the emergence of relapse in 
the L707 cells. CLEC1A (C-type lectin domain family member 1A), the SNP in which is 
associated to invasive breast cancer, is part of the c-type lectin family of genes, these genes 
have diverse roles in cell adhesion and signalling and the innate immune response 
(Drickamer 1999). TRRAP (Transformation/transcription domain associated protein) is a part 
of the histone acetyl transferase (HAT) complex. TRRAP is responsible for the recruitment of 
HAT to the chromatin (Murr et al. 2007). It is thought that deregulation of this protein 
contributes to cancer, and this SNP is associated with renal cell carcinoma.  The last of the 3 
genes with cancer associated SNPs is NDUFB11 (NADH:Ubiquinone oxidoreductase subunit 
B11), a mitochondrial enzyme. Disruption of metabolism as a result of de-regulation in the 
mitochondria is associated with cancer and the progression of leukaemia (Basak and 
Banerjee 2015) 
 
SNP Gene Mutation Consequence Associated disease 
COSM5811821 CLEC1A c.423G>C Stop gained Liver Cancer 
COSM485794 TRRAP c.10339G>C Missense variant Renal clear cell carcinoma 
COSM485795 TRRAP c.10426G>C Missense variant Renal clear cell carcinoma 
COSM1468092 NDUFB11 c.161C>T Missense variant Colon adenocarcinoma 
Table 26: Known variants in the SNPs with predicted moderate or high impact unique to the 
L707 relapse. SNPs with associated COSMIC identifiers were found using VEP and the 
identifier looked up using the COSMIC database. The table shows the SNP identifier from 
COSMIC, the gene affected, the mutation and the consequence as well as the associated 
disease.   
 
4.3.2 Relapse specific indels 
 
In the L707 relapse, 254,349 indels were called over thresholds, and of these 3.4% (8656) 
were unique to the relapse. 31% of these indels (2693) had more than 10 supporting reads 
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for each variant, the allele frequency for the majority of these was 1 or 0.5. Predictions of 
the effects of these variants showed similar effects to the unique SNPs with most being 
intron variants (50%), non-coding transcript variants (15%) and downstream gene variants 
(8%) (Figure 34). Of these indels, 82 scored high or moderate for impact, with a total of 26 
genes affected, and within this list 2 indels were found to be existing variants affecting the 
genes LILRB4 (Leukocyte immunoglobulin like receptor B4) and STRN (striatin) ( 
Table 27). LILRB4  is an immunoglobulin like receptor. This gene family encodes cell surface 
receptors important for the recognition of HLA proteins and modulation of the immune 
system (Cella et al. 1997) . STRN is a calmodulin binding protein that has roles in oestrogen 
receptor signalling, a steroid receptor related to NR3C1 (Lu et al. 2004). 
 
 
 
 
 
Variant Gene  Mutation Consequence % in population 
rs146936423 LILRB4 G/T Frameshift variant 1% 
rs763151379 STRN G/A Frameshift variant 0.9% 
 
Table 27: Known variants found in the list of indels with predicted moderate or high impact, 
unique to the L707 relapse. Variants were identified using VEP. The table shows the variant 
identifier, the gene affected, the change in nucleotide sequence, the consequence of the indel 
and the percentage of the variant present in the population as determined from the 1000 
genomes data available on the online Ensembl database (Aken et al. 2016) 
Figure 34: Charts showing the redicted consequences of indels unique to the L707 relapse, 
determined using VEP. The left pie chart shows all consequences and the right chart shows only 
consequences predicted as coding consequences.  
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4.3.3 SNPs and indels in both L707 presentation and relapse 
 
Although there is no remission or germline sample to compare the presentation and relapse 
to, some information can be gained from the SNPs and indels that are shared between the 
two. These majority of these variants will be germline, but some will be oncogenic, and 
looking at the genes affected may provide a route for carcinogenesis in patient L707.  
 
4.3.3.1 Shared SNP between L707 presentation and relapse 
 
There are 4,646,346 SNP that are found in both presentation and relapse and 99% of these 
have a least 10 supporting reads. Only the predicted high impact consequences were looked 
further into due to the large size of the dataset. There were 13586 SNPs with more than 10 
supporting reads that were predicted to have a high impact, representing 0.29% of the total 
SNPs in the sample. Of these SNPs 28% were loss of stop codons and 26% were gain of stops 
(Figure 35). The 13586 SNPS correspond to 1988 different genes and within this gene list 
there are several interesting hits that could possibly account for oncogenic transformation 
(Table 28). One of these interesting hits is BRCA2 (Breast cancer 2), a known tumour 
suppressor that is important in haematological malignancies as well as ovarian and breast 
cancer (Friedenson 2007). Protein association and gene ontology analysis reveal that the 
TP53 signalling pathway is enriched in this set of genes (FDR=0.003).   
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Figure 35: Coding consequences of the SNPs shared between presentation and relapse. Only 
SNPs with more than 10 supporting reads and predicted high impact are shown. All 
combinations of impact types with less than 2% of the total are grouped together (other 
combinations) 
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Location Consequence Gene Info  
15:41821752-
41821752 Splice donor variant MAPKBP1 MAPK signalling 
5:68294662-
68294662 Stop gained PIK3R1 PI3K-AKT signalling 
1:243499744-
243499744 Stop lost AKT3 PI3K-AKT signalling 
3:142507966-
142507966 Stop gained ATR 
Phosphorylates CHEK1, 
cell cycle arrest 
11:125635478-
125635478 Stop lost CHEK1 
checkpoint protein, cell 
cycle arrest 
2:219078116-
219078116 Stop gained NHEJ1 
Non homologous end 
joining protein 
13:32339465-
32339465 Stop lost BRCA2 tumour suppressor 
11:44573235-
44573235 Splice donor variant CD82 
metastasis suppressor 
gene 
2:101887152-
101887152 Stop lost MAP4K4 
MAPK signalling, 
associated with 
leukaemia 
14:95133457-
95133457 Start lost DICER1 microRNA processing 
Table 28: Selected SNP shared between the L707 presentation and relapse that when input 
into VEP have predicted high consequence and have been associated with cancer in the 
literature (Fu et al. 2015; Casazza et al. 2010; Chang et al. 2003; Breaks et al. 2006; Vago et 
al. 2014; Marjon et al. 2015; Bai et al. 2013; Friedenson 2007) 
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4.3.3.2 Shared Indels between L707 presentation and relapse  
 
The indels that are shared between the L707 presentation and relapse show a similar 
distribution of types as the indels that are specific to the relapse with 50% being intron 
variants. Of those that have coding consequences 79% were frameshift variants (Figure 36). 
There were 16009 indels with a high predicted impact, which related to 2028 genes. In this 
list of genes, 116 were known variants and there were several genes that have been 
associated with cancer and could possibly account for leukaemic transformation of cells. For 
example, TP53, known as the ‘Guardian of the Genome’ is a tumour suppressor gene and 
has a shared indel between L707 presentation and relapse. Two TP53 related genes TP53RK 
(TP53 regulating kinase) and TP53BP1 (TP53 binding protein 1) also have indels with a 
predicted high impact. MDM2 (Mouse double minute 2 homolog), the negative suppressor 
of TP53 also has high impact predicted indels. Although it is just speculation, this could imply 
a role for deregulated TP53 in the oncogenesis of the L707 cells.   
 
Figure 36: Coding consequences of indels shared between L707 presentation and relapse with 
more than 10 supporting reads and predicted high impact. Data generated using VEP. All 
combinations of impact types with less than 2% of the total are grouped together (other 
combinations).  
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4.3.3.3 Identification of deletion breakpoints 
 
With the re-aligned BAM files, we were able to run Pindel, a programme designed to analyse 
paired end reads from WGS (Whole genome sequencing) to determine breakpoints of 
deletions, insertions inversions and other structural changes in DNA. Once breakpoints had 
been found using Pindel, Dr. Alex Elder designed primers and used PCR to generate small 
amplicons for sanger sequencing of the breakpoint.  All of the following work on the 
breakpoints was done by him.  
From the PCR analysis of the breakpoints and the reads in the WGS it can be seen there are 2 
major products resulting from likely 2 separate deletions (Figure 37). One complex deletion 
product, with a duplication and inversion as well as the deletion and one a simple product, 
with just a deletion.  At the breakpoints for 2 of these genetic alterations there are small 
insertions of 2-3bp (Table 29) 
 
 
Figure 37: Breakpoints in the 5q deletion present in the L707 relapse; Top - WGS reads of the 
breakpoint (top) with corresponding genes (below) and sections of heterozygous and 
homozygous loss (below). Coloured blocks represent regions of DNA that are in a different 
orientation or location in the L707 relapse compared to the presentation.  Two deletion 
products are made as a result of the deletion.  
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Table 29: Sequences of the breakpoints in the relapse specific 5q deletion. Colours correspond 
to the schematic of the deletion in Figure 37. Black letters represent small insertions between 
the breakpoints of the deletion.   
 
4.4 Emergence of resistance in the L707 cells 
 
An interesting question in the field of relapse in ALL is whether the relapse clone already 
existent in the presentation sample or are the relapse specific molecular alterations induced 
by chemotherapy. The question remaining after investigation of the L707 presentation and 
relapse by microarray and whole genome sequencing was where was the relapse clone 
emerging from. One previous sample of the L707 presentation was found to have a 
heterozygous deletion of NR3C1 and so this was investigated further to elucidate the genesis 
of the relapse.  
 
 
 
Breakpoint Sequence 
1 CCCAAGCATAGGGCTTCACAGTGTCGTAATCAGTTAGTTCTCCATTTCTG 
2 CTGTGAAGCTTCGGCACAGTCTGGGACAGGTTGGGTTACCCACAAAGGGAAGCCC
ATCAG 
3 TTACTGTATCTGTGTCCTTAAGTACCACTGCTGTTTTTAAAATGGTAATCATTAAAAAA
GACTGAATTAAAGTATTAA 
4 GAAGACGTGTCTGGTGTTTCCTTATTTTTATTTCAGAGATCATCAGCACTCTAATGAA
T 
5 AAAAGAAGTTATTCATCTCGGGGTAGAAAAAATACTGGACTAGTTAGAAATGGCAA
A 
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4.4.1 Previous work  
 
Dr. Elda Latif, previous to my starting, carried out experiments whereby L707 presentation 
cells were engrafted in NSG mice and then treated with Dex (15 mg/kg). These samples were 
then tested by FISH to determine the effect of Dex dosing. One of these mice was found to 
have 16% heterozygous deletion of NR3C1. As a result of this a larger experiment was 
carried out to screen for this emergence of the deletion induced by Dex treatment in the 
L707 presentation.  
11 NSG mice were injected with 104 L707 presentation cells, either from KD2 (3rd passage 
xenograft) or KD68 (5th passage xenograft). Mice were left to engraft for 2 weeks before 
treatment was started with 10 mg/kg Dexamethasone I.P. every weekday. This was 
continued until mice reached license defined endpoints and were humanely killed. Samples 
collected from mice were fixed in methanol and acetic acid before being used for 
fluorescence in situ hybridisation (FISH).  
The probes used to detect NR3C1 were made in the lab, using the bacterial artificial clones 
(BAC) RP11-790H04, RP11-926806 and RP11-614D16. These probes were the same probes 
used for the original study and were designed by Elda Latif and Lisa Russell. A 5p telomere 
probe (CytoCell) was used as a control.  
FISH was carried out according to the protocol detailed previously (3.23). A high number of 
cells was used to increase the likelihood of finding a very rare clone in the population. The 
average of three healthy controls + 3 standard deviations was used to determine the cut-off 
for positivity, which was 5.9%.   
After the first experiment was scored some mice were found to have low levels of 
heterozygous NR3C1 deletion, although not over the cut-off for positivity determined using 
the negative controls (Table 30). Despite no samples being overtly positive, 2 samples, KD71 
and KD77 were thawed and re-injected. Mice were dosed in the same way as with the first 
experiment and samples collected for FISH. These samples when tested by FISH were found 
to have increased levels compared to the initial sample, indicating further selection. 
However, only one of these samples, KD139 was positive above the cut-off for NR3C1 
heterozygous deletion (Figure 38).  
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Mouse Sample % heterozygous del.  
--- Control M 1.5 (5.6 % total abnormal) 
--- Control 141702 1.9 (5.7 % total abnormal) 
--- Control C 0.9 (5.5 % total abnormal) 
KD70 L707 Presentation – from KD2 (3rd passage xenograft) 4.2 
KD71 L707 Presentation – from KD2 (3rd passage xenograft) 1 
KD73 L707 Presentation – from KD2 (3rd passage xenograft) 1.4 
KD74 L707 Presentation – from KD2 (3rd passage xenograft) 2 
KD75 L707 Presentation – from KD68 (5th passage xenograft) 2.6 
KD77 L707 Presentation – from KD68 (5th passage xenograft) 3.1 
KD78 L707 Presentation – from KD68 (5th passage xenograft) 2.5 
KD79 L707 Presentation – from KD68 (5th passage xenograft) 2.95 
KD137 L707 Presentation – from KD71 (4th passage xenograft) 5.1 
KD138 L707 Presentation – from KD71 (4th passage xenograft) 4 
KD139 L707 Presentation – from KD77 (6th passage xenograft) 7.4 
Table 30: Percentage of cells with heterozygous deletion of NR3C1 in all L707 presentation 
samples tested. Mouse number, the sample (passage of L707 presentation injected into mice) 
and the percentage of cells with heterozygous deletion of NR3C1 as determined by FISH are 
shown. The 3 control samples used to determine the cut off are also shown, with both the 
percentage of cells with a heterozygous deletion and the total percentage of abnormal cells 
that was used to determine the cutoff for positivity, which was the average + 3 standard 
deviations. All but one case fall below the cutoff for positivity (5.96).  
The cut off for positivity was calculated using the standard method employed by the 
Leukaemia Research Cytogenetics lab at Newcastle under the advice of Dr. Lisa Russel. 
Despite the majority of samples not passing the cut-off there is the suggestion of a minor 
clone with heterozygous deletion of NR3C1 and it could be that more rounds of Dex 
treatment are needed to increase this further and the initial sample with 16% heterozygous 
deletion was an anomaly. In the cells with the higher percentages of heterozygous deletion, 
PCR used by Alex Elder to identify the previously defined relapse breakpoints in the samples 
but none of the breakpoints were present.  
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4.5 Summary 
 
The L707 cells represent an interesting case to use for the study of acute lymphoblastic 
leukaemia and the acquisition of dexamethasone resistance at relapse. There are several 
genes highlighted by the analysis of this data that should be investigated further in my 
opinion. Firstly, the role of the replication dependent histones in the L707 relapse cells. The 
fact that so many of these genes are significantly upregulated leads to the hypothesis that 
they are having an effect and are not just a side effect of other expression profile alterations. 
It would suggest that these cells are in cell cycle more often, but that does not fit with the 
reduced proliferation and fitness of these cells in vivo compared to the presentation. The 
down-regulation of TCEA3, the most significant of all downregulated genes may be a result 
of Dex treatment of these cells (Kinyamu et al. 2008), but whether the downregulation of 
this gene is a driver event is unknown.   
 
Figure 38: Representative images of the FISH carried out on the L707 presentation cells from 
mice treated with Dex or saline. Arrows point to NR3C1 probes (red), the control probe used 
was a 5 telomere probe (green). Images were generated using the CytoVision Automated 
Cytogenetics Platform and analysed in CytoVisionV7.   
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The enrichment of genes associated with chromatin silencing, nucleosome assembly and 
chromatin assembly may indicate a change in the transcriptional landscape of the L707 
relapse and altered epigenetics. Considering NR3C1 is known to interact with proteins that 
alter the structure of chromatin (Johnson et al. 2008) this change in chromatin associated 
pathways could be the readout from loss of NR3C1 signalling. It could be a separate entity. 
Alterations in the epigenetic landscape of ALL at has also been reported, and epigenetic 
reprogramming using a DNA methyltransferase inhibitor can revert the relapse specific 
epigenetic landscape to a presentation signature (Bhatla et al. 2012). This change is also 
accompanied by a reversal in chemo-resistance. Altered epigenetics could be important for 
the acquisition of resistance (Bhatla et al. 2012). Whether this occurred before or after the 
5q deletion that resulted in dexamethasone resistance is not known, but considering the 
suggestion of the emergence of a heterozygous clone in the L707 presentation with Dex 
treatment, it could have occurred concurrently or after.  
Unfortunately, the drug sensitivity of the L707 to other commonly used chemotherapeutic 
drugs was not tested. This would be a good experiment to do in order to determine if the 
alterations in chromatin associated pathways at relapse have an effect on overall drug 
resistance.  
The whole genome sequencing of the L707 cells not only allowed identification of the 
relapse specific 5q deletion breakpoints but also allowed for investigation into possible 
oncogenic SNPs and indels, as well as those that could be driving relapse. Unfortunately, 
without a remission sample to test any oncogenic mutations are purely speculative. The 
most attention-grabbing SNPs and indels that are present in both the presentation and 
relapse that could possibly be driver mutations are BRCA2 and TP53, both well known to be 
involved in various cancers. Of the relapse specific SNPs and indels several have been 
associated with cancer, for example TRRAP, NDUFB11 and CLEC1A for which the variants are 
recorded in COSMIC. These are not the only genes that have links to cancer. RNF20 (Histone 
H2B E3 ubiquitin ligase ring finger protein 20), which has a predicted high impact frameshift 
variant in the relapse is a regulator of chromatin that has been found to be necessary for 
leukaemogenesis induced by MLL fusion genes (Wang et al. 2013). PDS5A (precocious 
dissociation of sisters 5A), another gene with a predicted high impact indel has been found 
as a novel translocation partner of MLL in AML. This gene is a cell cycle gene and has been 
associated with several cancers (Put et al. 2012). None of these variants present an obvious 
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case for the emergence of relapse. However, further investigation using targeted 
mutagenesis and knockout studies would be helpful to determine if they are actually driver 
mutations. From the WGS data it would seem likely that NR3C1 deletion appears to be the 
main driver of relapse in the L707 samples. There are several possible contributing factors 
too but these are unproven as of yet.  
The presence of two breakpoints in the relapse indicate that this deletion likely occurred as a 
two-step process, which is supported by the emergence, albeit slightly limited, of a 
heterozygous clone in the presentation. The lack of proof that the heterozygous deletion has 
the same breakpoints as either of the relapse breakpoints provides an interesting point. If 
the breakpoints were not the same it could imply that NR3C1 is targeted somehow in this 
case. NR3C1 deletions being relatively rare, the presence of another deletion occurring, that 
is not related to the ones seen in the relapse would be very unlikely. In order to investigate 
this further the clones with the heterozygous deletion would need to be expanded further to 
allow for genomic sequencing to determine the breakpoint.  
The treatment of L707 presentation cells with dexamethasone and the subsequent trend 
towards an increase in cells with a heterozygous deletion of NR3C1 represents a mechanism 
for relapse. However, this data is not very convincing as only one of these samples shows a 
population with a heterozygous deletion over the cut-off. Also, despite knowing the 
breakpoints in the relapse 5q deletion, these could not be found in the samples with 
heterozygous deletion. This could be indicative of the levels being too low to test, or that the 
breakpoints are not the same in these cells as the relapse.  
What can be taken from this data is that the L707 presentation are an excellent model of B-
cell ALL due to the low variation between the primary and secondary xenograft passages. 
The L707 relapse do not appear to be so closely related when investigating the expression 
pattern using PCA. The underlying cause for relapse has not been definitively proven, but the 
acquisition of Dex resistance with the deletion of NR3C1 is likely a driver, along with altered 
chromatin assembly and the likely resulting changes in epigenetic programming.  
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 Chapter 5: Role of NR3C1 in proliferation and engraftment of ALL cells 
 
5.1 Introduction 
 
The hyper-activation of NR3C1 by synthetic glucocorticoids and subsequent apoptosis this 
induces has been used in the treatment of ALL for decades. The role of NR3C1 in the 
transduction of Dex signalling has been thoroughly investigated. It is known that Dex binds 
to the receptor and results in  homodimerisation, nuclear translocation and activation or 
repression of target genes via action at GRE sequences (Bhadri, Trahair, and Lock 2012). The 
pathway by which Dex initiates apoptosis in ALL cells after binding to consensus GRE 
sequences has several components that are known to be essential for apoptosis, including 
BIM transcription (Abrams et al. 2004), caspase activation (Cifone et al. 1999) and an 
increase in cytosolic Ca2+ (McConkey et al. 1989). Inhibition of any of the steps in this 
pathway reduces apoptosis in ALL cells. Altered function of downstream targets of NR3C1, 
such as the reduced acetylation of BIM are often the source of Dex resistance in ALL 
(Bachmann et al. 2010). Deletions and mutations that affect NR3C1 are relatively rare in ALL, 
with a frequency of just 5% even at relapse (Mullighan et al. 2007). When this is compared 
to the relatively high frequency of GC resistance at relapse (>24 fold compared to 
presentation), it appears there is a disparate increase in GC resistance compared to other 
drugs, but a lack of causative mutations in NR3C1, the effector of Dex induced apoptosis 
(Bachmann et al. 2005; Klumper et al. 1995).  
As deletions are relatively rare it would imply that they are disadvantageous for ALL cells 
except in certain situations where the disadvantage is negated by other factors. However, as 
all ALL patients will be given Dex as part of treatment, the reasons why this deletion is not 
more common is still unknown. The hypothesis that loss of NR3C1 is a disadvantage to the 
cells can be investigated using the L707 relapse cells. These relapse cells have a deletion on 
the q arm of chromosome 5 that results in homozygous loss of NR3C1, as well as 5 other 
genes. These cells engraft and proliferate slower than the L707 presentation in vivo (Latif 
2012), which was presumed to be a result of the loss of NR3C1.  
The mechanism by which loss of NR3C1 could result in a reduction of fitness of ALL cells is 
not fully understood, but as GC signalling is one of the most ubiquitous signalling pathways it 
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is hypothesised that loss of the gene is not well tolerated. Glucocorticoid signalling via 
NR3C1 and cortisol, the endogenous ligand, is involved with several key processes including 
metabolism, the immune system, stress response and learning and memory (Miller, Chen, 
and Zhou 2007; Sapolsky, Romero, and Munck 2000). It is not hard to see why loss of this 
gene is a poor evolutionary choice for most cells.  
In order to investigate the role of NR3C1 in proliferation and engraftment of ALL cells, and 
whether loss results in reduced fitness, the inducible shRNA plasmid pTRIPZ was used. This 
plasmid induces mRNA knockdown of target genes. This is achieved using short hairpin RNA 
(shRNA) technology, which utilises the RNA interference (RNAi) pathways within the cell to 
produce degradation of target mRNA and knockdown of expression. shRNA constructs are 
delivered to cells lentivirally and integrate into the genome where they are transcribed by 
the endogenous cellular machinery.  The pri-miRNA produced by transcription of this 
sequence is then cleaved by Drosha, which results in a 2 nucleotide 3’ overhand, which 
targets the molecule for export to the cytoplasm. Here it is further processed by Dicer, 
resulting in the production of mature siRNA that is able to reduce mRNA expression (Silva et 
al. 2005; Y. Lee et al. 2003). The degradation of mRNA occurs when the mature siRNA is 
loaded into the RNA induced silencing complex (RISC), which then binds to the 
complimentary mRNA sequences resulting in cleavage by the AGO family of endonuclease 
proteins (Taxman et al. 2010).  
The pTRIPZ plasmid has several features to increase efficiency including the use of a 
humanised shRNA backbone in an HIV-1 derived plasmid. By inserting the shRNA sequence 
into this miR-30 pre-microRNA backbone, delivery of the pre-miRNA precursor was found to 
be 80% more effective in reduction of the target gene mRNA (Boden et al. 2004). Another 
feature of the pTRIPZ plasmid that makes it a very useful tool is the use of the rtTA3 (reverse 
tetracycline transactivator 3), which is a mutant version of the wildtype tetracycline 
transactivator. This protein has several mutations that increase the transcriptional activity, 
resulting in increased doxycycline sensitivity, as well as a modifications that result in activity 
only in the presence of doxycycline, not the absence like the wildtype protein (Das et al. 
2004).  
Another method by which to reduce NR3C1 signalling is through pharmacological inhibition 
rather than mRNA knockdown. This was done using mifepristone, an anti-glucocorticoid 
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compound. Originally developed in 1981 as a synthetic NR3C1 antagonist.  Mifepristone was 
quickly discovered to have anti-progesterone activity and found use as an abortive drug. It is 
this use for which the drug is well known and is its major use, but its actions as an anti-
glucocorticoid have also been used for Cushing’s disease (Johanssen and Allolio 2007).  
When mifepristone was first synthesised, two other known anti-glucocorticoid drugs, 
deoxycorticosterone and progesterone had been found to have partial agonist activity 
against NR3C1 (Rousseau et al. 1973), but mifepristone was found to be much better, with 
only slight agonist activity reported at concentrations > 5 µM (Bourgeois, Pfahl, and Baulieu 
1984). This was put down to contamination with an agonist in the preparation or an off-
target effect. The affinity of mifepristone for NR3C1 is 3-4 fold greater than that of Dex, and 
around 18 fold more than the affinity of cortisol. Mifepristone exerts its actions by inhibiting 
the dissociation of heat shock proteins from NR3C1, resulting in significantly reduced nuclear 
translocation and thus transcriptional activation of target genes (Johanssen and Allolio 
2007).  
The hypothesis that led to this work being carried out was that loss of NR3C1 is infrequently 
seen in ALL because the gene is required for cellular function. Only in the presence of Dex 
treatment does loss of this gene become an advantage, and even then it is a rare 
occurrence. The reduced proliferation of the L707 relapse in vivo appeared to support this 
hypothesis as the relapse specific 5q deletion covers NR3C1, giving a possible cause for this 
reduced fitness. This led to the idea that reduction of NR3C1 signalling in cells without a 
deletion, using a GC antagonist such as mifepristone, may result in the L707 presentation 
having a similar engraftment and proliferation phenotype as the L707 relapse in vivo.  
The aims of this study were to investigate the effect of knockdown of NR3C1 mRNA in vitro 
and in vivo in response to Dex as well as determine if mifepristone treatment had any effect 
on the survival of mice engrafted with ALL cells.   
 
5.1.1 shRNA constructs  
 
When the PhD project was started only the SNP6 data were available for the L707 and from 
this it appeared that there were only 5 deleted genes in the 5q deletion of the L707 relapse 
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not 6. These 5 genes were FGF1, ARHGAP26, NR3C1, HMHB1 and YIPF5, but not KCTD16, and 
so for this reason, KCTD16 was not investigated as part of these experiments. The hypothesis 
behind using a pool of shRNA targeting these genes was to determine which were enriched 
or lost, which would give an indication of which genes were leukaemic driver genes and 
which were passenger deletions.  
All available pTRIPZ constructs (Figure 39) were purchased for NR3C1, HMHB1, FGF1, 
ARGHAP26, and YIPF5. Bacterial stocks were amplified and plasmid DNA extracted which 
was then used for lentiviral production. The 697 cells were used for the pTRIPZ pool as they 
are a Dex sensitive ALL cell line and the titre of pTRIPZ was not high enough to transduce the 
primary derived L707 presentation cells. 697 cells were transduced with this pool and 
puromycin (0.6 µg/ml) used to select transduced cells. This concentration of puromycin was 
selected based on a puromycin kill curve done with the 697 cells (Figure 40). Selection was 
continued for approximately 3 weeks, until 697 cells were ~90% RFP positive based on FACS 
analysis before experiments using the pool were started.   
 
 
Figure 39: Sequence of pTRIPZ plasmid. Doxycycline, a tetracycline antibiotic, binds to rtTA3 
(reverse tetracycline transactivator) which in turns activates the TRE(tetracycline responsive 
element). The TRE then drives expression of tRFP (turbo red fluorescent protein) and the 
shRNA construct.  The rtTA3, as well as the lentiviral integration, resistance and stabilisation 
components; IRES (internal ribosome entry site), PuroR and WPRE (Woodchuck hepatitis virus 
posttranscriptional regulatory element), are expressed under the drive of the constitutively 
active UBC promoter.   
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Figure 40: Puromycin kill curve for the 697 cells used to determine the lowest concentration 
of puromycin required to kill all non transduced cells. Cells were incubated with puromycin 
for 48h before WST-1 assay, data was analysed using a 4 parameter dose response curve, 
n=1. -0.5 Log[puromycin]µM is 0.3 µg/ml which was initially used with transduced cells but 
cells were found to select slowly so the concentration was increased to 0.6 µg/ml for 
puromycin selection. 
 
5.1.1.1 Pool Validation 
 
The addition of doxycycline to 697 cells transduced with pTRIPZ plasmids will induce shRNA 
expression and gene knockdown. This is done by the activation of the rtTA3 by doxycycline 
and subsequent activation of the TRE which drives expression of the shRNA. Before this was 
tested in a large experiment cytotoxicity assays were carried out to determine the sensitivity 
of the transduced cells to Dex as well as the levels of NR3C1 mRNA knockdown caused by 
each single constructs for NR3C1 targeting shRNA. The 697 pTRIPZ cells had no change in 
Dex sensitivity compared to un-transduced 697, with an IC50 of 18.3nM compared to 20.5nM 
in the un-transduced cells. This was changed if the cells were treated with Dox (Figure 41). 
When the individual NR3C1 targeting shRNA were tested separately they did show 
knockdown of mRNA when treated with doxycycline compared to un treated controls. The 
untreated controls also showed knockdown in NR3C1 mRNA compared to cells transduced 
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with pTRIPZ constructs targeting AML1/ETO, which the 697 cells do not have (Figure 42). 
This implies that the constructs are leaky and expression is driven even in the absence of 
doxycycline. No effect on proliferation was seen in 697 cells with NR3C1 knockdown (data 
not shown). The apparent disparity between levels of knockdown and effect on Dex 
resistance could be attributed to the shRNA affecting the protein more than it does the 
mRNA.  
When the 697 cells transduced with the full pool of pTRIPZ constructs was treated with Dex, 
the cells treated with doxycycline were resistant.  No resistance was seen in cells not treated 
with doxycycline. The lack of resistance in 697 pTRIPZ cells not treated with doxycycline 
would indicate that the leakiness of single NR3C1 shRNA seen by qPCR does not affect drug 
response.  
Investigation of the NR3C1 targeting shRNA individually shows that some are more efficient 
than others with NR3C1-sh1 and sh5 not showing the same level of increase as sh2-4 in the 
Dex + Dox group, which have around 2 fold increase compared to control (Figure 44).  
This disparity between the mRNA levels and the resistance to Dex could be accounted for by 
an inhibition of protein translation by the shRNA. A decrease in protein expression without 
an accompanying reduction in mRNA has been found in several studies investigating RNAi 
(Nottrott, Simard, and Richter 2006; Maroney et al. 2006). For these reasons despite 
apparent leakiness the 697 pTRIPZ pool cells were used for further experiments.  
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Figure 41: Cell survival of 697 and 697 pTRIPZ pool cells with and without Dox treatment (2 
µg/ml) in response to Dex treatment. Viability was measured using WST-1 assay after 96h 
treatment and data analysed using a 4 parameter dose response curve . 697 pTRIPZ pool 
cells do not show any increase in Dex compared to the untransduced 697 cells resistance 
unless they are also treated with Dox, n=1.   
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Figure 42: NR3C1 mRNA expression in 697 cells transduced with NR3C1 targeting shRNA, 
with and without Dox (2 mg/ml). Although the constructs when treated with Dox were not 
significant compared to the constructs without Dox (due to the leakiness of construct) using 
one way ANOVA. NR3C1-sh2, sh3 and sh5 had a significant (p<0.05) reduction in NR3C1 
mRNA with Dox treatment compared to AML1/ETO with Dox treatment (one way ANOVA).  
The decrease in NR3C1 mRNA in many of the constructs not treated with Dox indicates 
leakiness of the construct and aberrant expression of the shRNA which resulted in reduced 
NR3C1 mRNA in the absence of Dox induction, n=3, error bars show mean SEM.  
 
5.2 Induced NR3C1 targeting shRNA are enriched only in the presence of Dex.  
 
In order to determine the contribution of the 5 genes within the 5q deletion seen in the L707 
relapse, to Dex resistance, the cells were treated with combinations of Dex and Dox over a 
short time period. Cells were dosed with Dex for 10 days, and if they were also receiving 
Dox, a further 3 days before the Dex treatment to induce shRNA expression. Analysis of pool 
complexity at the end of the 10-day testing period was used to determine which shRNA 
levels were changed between baseline and the end point. The enrichment or depletion of 
constructs would indicate loss of gene expression or the incompatibility of reduced 
expression with survival respectively. Cells were tested using 4 different treatment groups as 
shown in Table 31 
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Group Treatment 
Control 0.05% ethanol 3 times a week  
Dox 0.6 µg/ml Dox media 
Dex and Dox 20 nM Dex 3 times a week, 0.6 µg/ml Dox media 
Dex 20 nM Dex 3 times a week 
Table 31: Table showing the different treatment groups and the treatments those cells 
received in the testing of the pTRIPZ transduced 697 transduced cells.   
After samples were collected genomic DNA was extracted and a 1 step PCR process to create 
an amplicon library. The Decode PCR primers provided with the Decode Pooled Lentiviral 
shRNA Screening library, which are designed to amplify pGIPZ and pTRIPZ constructs were 
used amplify the region around the shRNA and add the Illumina adaptors and barcodes. 
Barcoded primers meant that samples could be run together on the Illumina MiSeq and then 
de-multiplexed to determine changes in pool complexity between samples.  
Files were returned in the form of FASTQ files and were de-multiplexed and counted by Dr, 
Simon Cockell from the Bioinformatics Support Unit. Data in the form of count tables was 
used for analysis. It was normalised by using the sample count as a percentage of total 
reads. The fold change between the baseline and experimental samples was calculated, and 
these values were used to determine which shRNA were enriched and which were depleted.  
 
5.2.1 NR3C1 targeting shRNA are enriched when cells are treated with Dex and Dox 
 
NR3C1 targeting shRNAs are enriched in the Dex + Dox treatment group compared to all 
other treatment groups, to a much greater extent than the other targeting shRNA (Figure 43-
44). There is also a smaller increase in NR3C1 targeting shRNA in the Dex only treatment 
group. The increase in NR3C1 targeting shRNA in the Dex + Dox group indicates the NR3C1 
targeting shRNA are having the expected effect and knockdown of the gene results in 
increased Dex resistance in these cells. However, as there is no change in the levels of any of 
the other shRNA constructs, this implies that they have no effect in the 697 cells. As there 
was only one repeat statistical analysis could not be carried out. 
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Figure 43: Fold change of the shRNA count number in the 697 cells transduced with pTRIPZ 
constructs when treated with Dex/Dox combinations over a 13 day period. Separate 
constructs for the genes with more than one targeting shRNA are shown as an average. Fold 
change was calculated using the normalised reads in the baseline compared to the 
normalised reads at the endpoint. NR3C1 targeting constructs are increased in both the Dex 
+ Dox and Dex groups, n=1.  
The apparent disparity between the mRNA knockdown of NR3C1 for each shRNA (Figure 42) 
and the shRNA which are enriched most in the screen in Dex + Dox treated cells (Figure 44) 
further lends credence to the theory that the mRNA knockdown is not totally indicative of 
the levels of protein down regulation in the 697 cells. The shRNA with the most enrichment 
are sh-2-4, wheras the shRNA showing the highest levels of mRNA knock down are sh-3 and 
sh-5. This contradiction in results could have been better explained if a western blot had 
been carried out on the 697 transduced with each shRNA.  
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Figure 44: Fold change of the shRNA count number for the 5 separate NR3C1 targeting 
shRNA constructs and the 3 control shRNA in 697 cells over a 13-day period with 
combinations of Dex and Dox. Fold change was calculated using the normalised reads in the 
baseline compared to the normalised reads at the endpoint, n =1. 
The screen was run a second time to verify the results as well as determine the effect of 
varying the dose of Dex. When this was done, three concentrations of Dex were used, 10 
nM, 20 nM and 50 nM, equating roughly to the IC-25, IC-50 and IC-75 values. The other 
treatment conditions were kept the same as the first experiment. There was a substantial 
increase in NR3C1 targeting shRNA in all 3 groups treated with Dex and Dox but as only one 
repeat was done statistics could not be done on the data to determine the significance. One 
thing noted with this experiment is there was also an increase in NR3C1 targeting shRNA in 
the Dex only groups (Figure 45). Upon further investigation this appears to be a result of the 
pTRIPZ plasmid containing the UBC (Ubiquitin C) promoter to control expression of rtTA3, 
which is activated in response to Dex treatment (Marinovic et al. 2002a). It was 
hypothesised that increased expression of UBC driven rtTA3 may be enough to activate the 
TRE in the absence of doxycycline. This was not tested however. There also appears to be 
loss of MLL/AF4 targeting constructs when cells are treated with Dex alone.  The cause for 
this is not known as the 697 cells do not express the MLL/AF4 fusion protein.  
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Figure 45: Fold change of the count number for all constructs for the second in vitro run 
including 3 concentrations of Dex. Dex + Dox, and Dex only treatment groups have increased 
NR3C1 shRNA expression. Fold change was calculated using the normalised reads in the 
baseline compared to the normalised reads at the endpoint, n=1. 
 
The same trend seen with first screen was also seen in the second screen, with an increase in 
NR3C1-targeting shRNA in both Dex and Dox and Dex only treatment groups (Figure 46).  The 
increase corresponds with an increase in Dex concentration. The same pattern of shRNA 
increases is seen, with levels of sh2-4 being the most increased. This is likely as a result of 
increased efficiency of those shRNA compared to sh1 and sh5. Indeed, NR3C1-sh3 has the 
highest level of NR3C1 mRNA knockdown when investigated singly.  
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Figure 46: Fold change in the count number for the 5 separate NR3C1 targeting shRNA and 
the 3 control shRNA in 697 cells treated over a 13-day period with combinations of Dex and 
Dox for the second run of the experiment. Fold change was calculated using the normalised 
reads in the baseline compared to the normalised reads at the endpoint, n =1.  
 
5.2.2 Survival of mice is not affected by induction of shRNA constructs 
 
The same experiment was done in vivo using 17 male NSG mice. Each mouse was 
intrafemorally injected with 104 transduced 697 cells and then split into 2 groups given 
either Dox containing food or normal food. These two groups of mice were then split further 
into control or Dex treatment groups, resulting in 4 different treatment groups. Dox food 
was given from 8 days after intrafemoral injection, and Dex (10 mg/kg) I.P. every weekday 
was started 2 days after that. Mice were monitored every day and were humanely killed 
when they reached license endpoints. As can be seen from Figure 47, Dex treated mice died 
slightly earlier than control mice, but not significantly earlier than any other treatment 
group. However, with such small group numbers the significance of this data is questionable. 
What was found with this experiment is that the 697 cells engraft and result in death very 
quickly, as 4 of the mice were found dead, which prompted the increase of checking to twice 
daily after 21 days.  
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Figure 47: Survival of mice in the 4 different treatment groups. Mice were either fed with Dox 
containing food or normal food starting 8 days after intrafemoral injection. Mice were also 
treated with Dex (10 mg.kg) or saline I.P. every weekday started 10 days after intrafemoral 
injection. Dex treated mice die significantly earlier (p<0.05) than the other treatment groups 
when analysed using the Log-rank (Mantel-Cox) test. The other treatment groups are not 
significantly different from each other.  
 
5.2.3 The in vivo screen shows no correlation with treatment group and expression of 
NR3C1 expressing shRNA constructs 
 
When the data from the in vivo experiment were analysed it was found there was no 
consistent pattern between any of the groups (Figure 48-49). Some cells were tested for 
tRFP expression after collection from the mouse and this may provide a reason for why there 
was no increase in NR3C1 targeting shRNA in either the Dex + Dox treated mice or the Dex 
only mice. The tRFP expression was reduced from what would be expected in a spleen with 
high levels of engraftment (Figure 50), indicating that the tRFP and shRNA expression has 
been silenced. This is a problem that has been reported before with the use of the UBC 
promoter in our lab in vivo (unpublished data).  
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Figure 48: Fold change of shRNA counts from 697 cells engrafted into NSG mice. Control 
shRNA and the averages of targeting shRNA for each gene are shown. There is no correlation 
between any of the groups, as there is in vitro. This indicates that either the Dex or Dox is not 
reaching the cells or the cells are not reacting in the same way they do in vitro. Fold change 
was calculated using the normalised reads in the baseline compared to the normalised reads 
at the endpoint. 
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Figure 49: Fold change of shRNA counts from 697 cells engrafted into NSG mice. Control 
shRNA and the 5 NR3C1 targeting shRNA are shown. There is no correlation between any of 
the groups in NR3C1 targeting shRNA in the Dex + dox mice as there is in vitro. This indicates 
that either the Dex or Dox is not reaching the cells or the cells are not reacting in the same 
way they do in vitro. Fold change was calculated using the normalised reads in the baseline 
compared to the normalised reads at the endpoint.   
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Figure 50: FACS analysis of 697 cells after puromycin selection before injection into mice, and 
spleen samples after collection from mice. Mouse spleens were very heavily engrafted upon 
collection, the amount of tRFP negative cells in samples treated with doxycycline is higher 
than expected indicating that the expression of tRFP and the shRNA under the same 
promoter is being silenced in these cases. 
What can be taken from this experiment is that in vitro, the NR3C1 targeting shRNAs result 
in Dex resistance when induced by Dox treatment. These constructs are slightly leaky, and 
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there is an increase in NR3C1 targeting shRNA expression when cells are just treated with 
Dex. This does not appear to alter the Dex resistance of the sample, which has a similar 
cytotoxicity profile to the un-transduced 697 cells.  
In vivo is a different story, and no useful data can be gleaned from this experiment other 
than the pTRIPZ plasmid is susceptible to silencing in vivo and should be avoided for future 
experiments. Despite a lack of data to support the original hypothesis, the use of the 697 
cells for this experiment led to the incidental finding that the 697 cells appear to be Dex 
resistant in vivo. This led to further experiments to investigate this. It is also possible that the 
lack of changes in the enrichment of constructs may not just be a result of silencing but 
because the cells are not responding to Dex treatment in the murine microenvironment.  
 
5.2.4  Mifepristone acts as a partial agonist at NR3C1 in the 697 cells 
 
The next hypothesis was that if loss of NR3C1 is a disadvantage to cells, except in the 
presence of dexamethasone, then antagonism of the receptor may also be a disadvantage. 
To study this, mifepristone, a progesterone and glucocorticoid receptor antagonist with high 
binding affinity for NR3C1, was used (Bourgeois, Pfahl, and Baulieu 1984). Mifepristone 
treatment has been shown to be of use in spontaneous murine leukaemia, with treated mice 
having significantly better survival (Check et al. 2009).  
Before the study was taken into mice, the effect of both Dex and mifepristone on the 
expression of several NR3C1 inducible genes was tested in the 697 cells to ensure they were 
having the desired effect. Treatment with 10nM or 100nM Dex increases the expression of 
GILZ (Glucocorticoid induced leucine zipper), NFKBIA (NFKB inhibitor alpha) and FKBP5 
(FK506 binding protein 5), to different extents with GILZ being the most induced. This 
induction of expression is rapid and occurs within 2hr, whereas FKBP5 is slower to respond 
(Figure 51). As well as the induction of target genes there is also an auto induction of NR3C1 
expression when cells are treated with Dex.  
Mifepristone when tested had a somewhat surprising effect, Although NFKBIA expression in 
response to mifepristone reduced, as would be expected with an antagonist, with a steady 
decrease in both NFKBIA and NR3C1 mRNA over the time period. When GILZ was measured 
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it was found that within the first few hours after drug exposure there was an increase in GILZ 
mRNA. By 24hr this was reduced, as was NR3C1 expression, but there was an initial increase 
induced by mifepristone. FKBP5 expression had an initial decrease before recovering 
expression in response to mifepristone (Figure 52).  
From this data it would appear that mifepristone is not a NR3C1 antagonist as there is little 
evidence for NR3C1 inhibition in cells treated with Mifepristone. Mifepristone does appear 
to be a partial antagonist with agonist activity at some concentrations and time points. The 
partial agonist activity of mifepristone has been reported in two kidney cell lines, and is 
reported to occur when there are high levels of NR3C1 present, which is sufficient to drive 
the formation of NR3C1 dimer DNA complexes, which can then become transcriptionally 
active (Zhang, Jonklaas, and Danielsen 2007).  
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Figure 51: Response of NR3C1 target genes and NR3C1 to Dex treatment over a 24 hr period 
in the 697 cells, bars show mRNA level relative to GAPDH and control samples. A – The 
increase in GILZ mRNA is rapid and sustained over 24 hr. B- NFKBIA expression increases are 
much smaller than with GILZ, but there is an increase in expression correlated with increased 
dose, the auto induction of NR3C1 by Dex can also be seen. All data is relative to samples 
taken at 0 hr. n = 1.  
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Figure 52: Response of NR3C1 target genes and NR3C1 to Mifepristone treatment over a 24 
hr period in the 697 cells, bars show mRNA level relative to GAPDH and control samples.. A – 
There is an initial increase in GILZ mRNA before it is reduced by 24h. There is little increase in 
NR3C1 and this too is reduced by 24 hr. B – NFKBIA expression reduces over the time period 
but it is not a large difference. C – FKBP5 expression shows an initial decrease before 
recovering somewhat. All data is relative to samples taken at 0 hr. n =1.  
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5.2.4.1 Mifepristone is not toxic in mice up to doses of 100 mg/kg 
 
Despite the apparent initial agonist activities of mifepristone, the reduction in GILZ mRNA by 
24h was determined to be sufficient to warrant taking the hypothesis further and testing 
mifepristone in vivo.  
As this drug is widely used for a number of medical conditions it has a well-known safety 
profile and so only a small toxicity study was needed to determine the concentrations that 
were tolerated in the NSG mice.  
6 male NSG mice were intrafemorally injected with 1x105 L707 presentation cells, and 2 
weeks later dosing with mifepristone was initiated for 3 mice. Three doses, 10, 30 and 100 
mg/kg mifepristone were used. This was given in suspension in olive oil by oral gavage, with 
a dose escalation every 7 days to determine the highest tolerated dose. There was no effect 
of mifepristone dosing on the weight of treated mice compared to controls (Figure 53), and 
although mice tolerated the highest dose the suspension was very viscous and hard to 
administer, so to avoid possible injury from dosing with a thick liquid 30 mg/kg was chosen 
for further experiments.  
 
Figure 53: Weight of mice normalised to weight at the start of the experiment. Black arrows 
indicate start of dosing and the concentration of mifepristone given at these time points and 
for the next 7 days. The drop in weight seen in all but one mouse before the 10 mg/kg dosing 
was started was due to a blocked water bottle. 
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5.2.4.2 Mifepristone does not increase survival of mice engrafted with L707 presentation 
cells 
 
Once the lack of toxicity of mifepristone in the NSG mice had been established, a larger 
study was run to determine mifepristone treatment had any effect on survival of mice 
engrafted with L707 presentation cells. The hypothesis was that treating the L707 
presentation with mifepristone may result in a phenotype similar to the L707 relapse, with 
longer survival periods of mice.  
11 male NSG mice were each injected with 5x105 L707 presentation cells transduced with 
the luciferase expressing lentiviral plasmid, pSLIEW. 13 days later, imaging was carried out 
using the in vivo imaging system (IVIS) to ensure mice were engrafted (Figure 54). Once 
engraftment was established dosing was started with either Dex (15 mg/kg), mifepristone 
(30 mg/kg) or control (olive oil). Dosing was done by oral gavage and was given every 
weekday. The different groups were separated by cage as mifepristone is excreted in the 
faeces and as mice are coprophagic, mixing mifepristone treated mice with other treatment 
groups might result in other mice also being dosed with mifepristone.   
Survival of mice was increased significantly with Dex treatment as had been seen before, but 
mifepristone had no effect on survival (Figure 55).  
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Figure 54: Representative IVIS image of 3 mice showing bioluminescence in the mouse 13 
days after injection with L707 presentation pSLIEW cells. Bioluminescence is produced by the 
oxidation of uciferin to oxyluciferin, catalysed by luciferase, which is encoded in the pSLIEW 
plasmid which was used to transduce the L707 presentation cells before they were intra-
femorally injected into the mice.  Engraftment can be seen in the injected femur (right) and 
the contralateral femur as well as several other locations. This indicates that the leukaemia 
has spread beyond the site of injection.  
 
Figure 55: Survival of mice engrafted with L707 presentation pSLIEW cells. There is no effect 
of mifepristone (30 mg/kg) dosing on survival, Dex (15 mg/kg) treated mice survive 
significantly (p<0.05) longer than control and mifepristone treated mice. Dex and 
mifepristone groups n=4, control group n=3. Statistical analysis done using Log Rank 
(Mantel-Cox) test.  
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After mice were killed, FACS analysis was used to determine levels of CD19 positive human 
cells in the spleens as these were to be used for microarray analysis and needed to have low 
levels of murine cells that would contaminate the results. The percentage of L707 
presentation cells was high in the spleens, with an average of 97% between all the spleens 
tested by FACS (Figure 56). The levels of GFP in the samples was very low, with an average of 
just 0.22% of cells expressing GFP, indicative of very low transduction levels with pSLIEW of 
these cells. This low amount is sufficient for mice engrafted with these cells to be analysed 
using IVIS imaging.  
 
Figure 56: Two FACS plots showing the levels of CD19-PE and GFP positive cells. The majority 
of cells are CD19 positive, but only a small fraction is positive for GFP (average 0.22%). R3 
shows CD19 positive cells, red cells within that show GFP positivity. There was no difference 
seen between the spleens of the Dex treated or Control spleens. Representative images, all 
plots showed a similar picture.  
RNA was extracted from the spleen samples using the MirVana kit (Ambion). This RNA was 
then sent to Oxford Genomics for microarray analysis to determine the changes in the gene 
expression profile of the L707 presentation cells when treated with Dex, mifepristone or 
controls.  
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5.2.5 Microarray analysis  
 
Data was returned from Oxford Genomics in the form of Illumina IDAT files. These were 
analysed in two ways, firstly using Genome studio for normalisation and then Excel to 
determine which genes have altered expression, and secondly in R using the microarray 
analysis programmes Lumi and Limma.  
 
5.2.5.1 Control vs Dex treatment shows reduction the anti-apoptotic gene BCL2 but no 
significant enrichment of pathways 
 
The genes that are differentially expressed between control and Dex treatment samples 
should give an indication of how Dex is resulting in apoptosis in the L707 presentation cells. 
Using the thresholds determined previously (>2 fold change in expression, p<0.01, binding 
>100 in either control or Dex treatment), 375 genes score as differentially up or down 
regulated; 144 are upregulated in Dex treatment compared to controls, and 231 are 
downregulated in response to Dex.  
Two of the proteins upregulated in response to Dex are S100A8 and S100A9 (S100 Calcium 
binding proteins A8 and A9). These genes have been shown to result in glucocorticoid 
resistance when expression is increased in MLL rearranged ALL (Spijkers-Hagelstein et al. 
2012). These proteins supress the glucocorticoid induction of increased cytosolic calcium 
ions required to initiate apoptosis.   
Gene ontology of the 144 genes upregulated with Dex treatment shows that positive 
regulation of biological processes (FDR=3.04e-5), cellular response to chemical stimuli 
(FDR=3.04e-5) and signal transduction (FDR=1.77e-4) pathways are enriched in the list.  
The 231 genes that are downregulated more than 2 fold in response to Dex treatment have 
no pathways significantly enriched. Despite this, there are several genes which indicate the 
Dex treatment is having an effect, other than the increase in mouse survival. BCL2, an anti-
apoptotic protein is reduced 2.2 fold in the Dex treatment samples. This gene has been 
reported to have a reduction in response to Dex in chondrocytes (Zaman et al. 2014). When 
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investigated in the gene expression data BCL2 was found to be expressed at similar levels in 
the presentation and relapse.  
 
5.2.5.2 Control vs Mifepristone treatment shows little change in gene expression profile 
 
When looking at the cells which pass the thresholds in the mifepristone treatment group 
compared to control, only 6 genes have a p value of < 0.001. If this is relaxed to 0.005 then 
the number of probes increases to 9, equating to 7 genes, this is still far less than was 
expected. This list of genes does not have any enriched pathways associated with it.  
The reasons for this lack of differentially expressed genes in the cells treated with 
mifepristone were unclear at the time of initial microarray analysis and so the data was not 
used for any further experiments.  
 
5.2.5.3 Microarray analysis using R shows 2 samples do not cluster with the rest 
 
Analysis of the microarray data using the R programmes Lumi and Limma sheds a little more 
light on the apparent lack of data shown using Genome studio and Excel for analysis.  
The data was imported into R and 3 probes were removed due to low numbers of beads in 
at least one sample. VST and RSN were used to transform and normalise the sample (Figure 
57-58) before the clustering of samples was determined using PCA (Figure 59). It was found 
that the Mifepristone 1 and Dexamethasone 3 samples did not cluster with the other 
samples the way they were expected. This lack of clustering could possibly account for the 
lack of data found when all samples were analysed using Genome Studio and Excel. For 
further analysis these 2 samples were removed, which resulted in far closer clustering of 
treatment groups (Figure 60). The reason for these two samples not clustering together is 
not known.  
When array quality control metrics were run on the arrays, only 35% of probes were left 
after filtering. This is lower than was expected and could indicate a poor array run but at the 
point of analysis it was too late to repeat the experiment.  
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As can be seen from the heat map (Figure 61), when the top differentially expressed genes in 
the Dex treatment group are used, the control and Dex samples have separate gene 
signatures. Mifepristone treated cells look more similar to the controls, indicating that the 
highly differential genes for Dex are not also differentially expressed in mifepristone treated 
cells.  
 
 
Figure 57: The Density plot of the raw microarray data for the L707 presentation cells treated 
with Dex, mifepristone or controls before normalisation. The plot gives an indication about 
the distribution of the intensity of probe binding (signal) across the chip. If chips have very 
different distribution patterns then they are normally removed from the data analysis. No 
chips were removed from the analysis at this point.    
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Figure 58: The Density plot of the microarray data for theL707 presentation cells treated with 
Dex, mifepristone or controls after robust spline normalisation (RSN) has been used. The plot 
shows that after normalisation the distribution of intensity, and thus probe binding across 
the chip is the same for all chips meaning they can be analysed together.   
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Figure 59: Principal component analysis showing all 10 samples run on the microarray  for 
the L707 samples treated with either Dex, mifepristone or controls.  The top 2 principle 
components are shown, including the percentage contribution of each to the distribution. 
Two samples, Dexamethasone 3 and Mifepristone 1, do not cluster closely with samples in 
the same group, the reason for this is not known.  
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Figure 60: Principal component analysis of the microarray data for the L707 samples treated 
with either Dex, mifepristone or controls with the two outlying samples, dexamethasone 3 
and mifepristone 1 removed. The top 2 principle components are shown, including the 
percentage contribution of each to the distribution. Samples cluster closer with samples of 
the same treatment.  
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Figure 61: Heat map for the top 1000 differentially regulated genes in L707 presentation 
treated with Dex compared to L707 presentation cells treated as controls. Clustering shows 
that L707 cells with mifepristone treatment cluster with controls closer than dexamethasone 
treatment, this indicates that there may not be a lot of changes induced by mifepristone in 
the L707 presentation cells.  
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5.2.6 L707 Presentation; control vs Dex treatment 
 
Once the two anomalous samples were removed from the data analysis was done to 
determine the differential gene expression in response to treatment with Dex and 
mifepristone. Analysis of the genes that are differentially regulated in response to Dex in the 
L707 presentation cells will give an indication of the pathways activated in these cells that 
result in apoptosis.  
 
5.2.6.1 Up regulated genes in response to Dex  
 
It is known from the survival data that treatment with Dex prolongs survival, so looking at 
genes which are upregulated should give an indication into how the cells are responding and 
what pathways are resulting in apoptosis.  
1610 probes score as significant (P<0.05), which is 13% of all probes that passed through 
data filtering, but when applying fold change thresholds to this the number reduces 
dramatically. A p value of 0.05 was used rather than the 0.01 as with the other analyses as 
there were so few probes significant with the lower p value that no genes scored as 
significant.  14 genes are upregulated >2 fold in the L707 cells in response to Dex treatment, 
and these account for just 0.11% of the total probes that passed filtering. These 14 genes 
show an interconnected network of protein interactions (Figure 62).  
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Figure 62:Protein interactions between the 14 genes with >2 fold increase in expression in 
response to Dex treatment in the L707 presentation cells. Interactions were determined using 
the online database Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), 
version 10.0. The types of interactions are shown in the legend below the 
Within these upregulated genes several pathways are significantly enriched including 
response to drugs (FDR=4.07e-5) and the immune response (FDR=7.36e-5). The upregulation 
of an immune response pathway could be linked to the presence of Activator protein (AP-1) 
subunit genes in this list, Fos, Jun and FOSB. AP-1 is involved in the immune response by way 
of induction of inflammatory mediators. If AP-1 is knocked down using RNAi then cells have 
been found to have reduced levels of IL6, IL8 and CD38, all inflammatory cytokines.  In the 
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same study that showed this, it was also found that AP-1 protein subunits were regulated by 
the MAPK (Mitogen activated protein kinase) pathway member MAPK3K8 (Wang et al. 
2013).  Both MAPK pathway genes and AP-1 are some or the many factors that interact with 
NR3C1 to alter the activation and repression of target genes. In the case of AP-1 this occurs 
by AP-1 recruiting the glucorticoid interacting protein (GRIP1) to initiate transrepression of 
target genes (Glass and Saijo 2010). Using ChIP seq it was been found that AP-1 was present 
in a high proportion of NR3C1 binding sites and that loss of AP-1 signalling resulted in a 
significant reduction in NR3C1 regulation of transcription indicating an interaction of the two 
transcription factors (John et al. 2011; Biddie, John, and Hager 2010).  
As was seen with the analysis done using GenomeStudio and Excel, the calcium binding 
proteins S100A8 and S100A9 have increased expression in response to Dex in the L707 cells.  
These genes are 2 of the most differentially regulated genes with a fold change of 4.3 and 5 
respectively. The Two other proteins in the list of upregulated genes are heat shock proteins, 
which form complexes with NR3C1 in the cytoplasm, HSPA1A and HSPA1B (Heat shock 
protein 1A and 1B). These proteins have been shown to be involved in the NR3C1 mediated 
regulation of genes (Prota et al. 2012).  
 
5.2.6.2 Downregulated genes in response to Dex  
 
The downregulation of genes in response to Dex is another indication of how the drug is 
affecting the cells. Just 8 probes have >2 fold decrease in expression in Dex treated samples, 
0.06% of the total probes that passed filtering. These 8 genes include 5 protein coding genes, 
2 SNORD RNA genes and one probe without a gene symbol. The 5 protein coding genes do 
not show enrichment of any pathways but includes 3 genes, PROM1 (promonin 1), SNORA79 
(small nucleolar RNA, H/ACA Box 79) and LOC100132810 which are all significantly reduced 
in the L707 relapse, which might indicate a role for these genes in the L707 response to Dex 
in these cells.  
If the thresholds are relaxed to include genes with >1.5 fold reduction, then the list of 
upregulated probes is increased to 19. These 19 probes include 10 protein coding genes, 5 
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RNA genes and 3 probes without gene symbols. There is still no enrichment of pathways in 
the gene list.  
When the data is used for KEGG pathway analysis there are 17 significantly enriched KEGG 
pathways in the differentially expressed genes. These included TP53 signalling pathway, 
pathways in cancer and MAPK signalling pathway.  
 
5.2.7 Control vs Mifepristone treatment  
 
Although treatment with mifepristone did not result in a change in survival of mice, 
investigation of the differentially expressed genes may still prove interesting.  
782 probes are significantly (p<0.05) differentially expressed between control and 
mifepristone treated mice. Of these, only 6 probes have>2 fold increase in expression, and 
none have >2 fold decrease. If the parameters are relaxed to include probes with >1.5 fold 
change then the number of upregulated probes increases to 14 probes, but still no probes 
that are downregulated.  
The probes that are upregulated >1.5 fold with mifepristone treatment have several 
interconnecting protein associations (Figure 63). This list also includes 5 genes that are also 
upregulated in response to Dex, indicating similar pathways may be modulated in the L707 
cells in response to these 2 drugs, possibly as a result of the partial agonist activity of 
mifepristone.  
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Figure 63: Protein association of the genes upregulated >1.5 fold in response to mifepristone 
treatment in the L707 presentation cells. Interactions were determined using the online 
protein interaction database, STRING (version 10.0), and the types of interaction are shown 
in the legend below. 
 
From this data it would appear that treatment with mifepristone has little effect on the L707 
presentation cells. Although pharmacokinetic studies have not been done to ensure that the 
drug has high bioavailability in vivo, the use of this drug orally in patients implies that it has a 
good oral bioavailability profile and the lack of differentially expressed genes stem from the 
L707 cells not having a large response. Possibly due to the dual action of the drug as an 
agonist and antagonist.  
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5.3 Summary 
 
From the data obtained during these experiments it would appear that although NR3C1 
knockdown results in Dex resistance in vitro, when cells are tested in vivo there is no 
enrichment of NR3C1 targeting constructs as is seen in vitro. This is highly suggestive of a 
loss of shRNA expression in vivo, which is supported by the finding that cells collected from 
the spleens of mice treated with doxycycline do not show high levels of tRFP expression. 
Another possible cause for this lack of library enrichment could be because there is a lack of 
Dex sensitivity of the 697 cells in vivo (Chapter 7). The cause for this silencing is not known, 
but it has been reported before in the lab (unpublished data). Furthermore, the use of the 
pTRIPZ plasmid with Dex may not be advised, as Dex activates the UBC promoter (Marinovic 
et al. 2002a). This could account for why in Dex treated in vitro samples there is an increase 
in NR3C1 targeting shRNAs. The hypothesis as to how this results in increased leakiness of 
shRNA expression is that over activation of the UBC promoter may be enough to drive rtTA3 
expression, so that in the absence of Dox the TRE is activated, and transcription initiated 
(Figure 64).   
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Figure 64: The hypothesised reaction of the UBC promoter in response to Dex treatment in 
ALL cells transduced with the pTIPZ plasmid. This shows how induction of shRNA expression 
can be bought about in the absence of Dox (Marinovic et al. 2002).  
The response of the 697 cells to Dexamethasone was as expected according to the literature, 
with an auto induction of NR3C1 (Van Galen et al. 2010), and an upregulation in GILZ, FKBP5 
and NFKBIA (Rainer et al. 2012). GILZ appears to be the most responsive of these genes, with 
more than 10-fold increase in mRNA expression even with just 10nM at 2h. Despite this 
increase, GILZ was not one of the significantly increased genes in the microarray analysis of 
Dex treated mice vs controls. One possible reason for this could be that increases in GILZ 
expression is transient, and by the time mouse samples are collected the effect has returned 
to normal levels. Another possibility is that GILZ is only upregulated in response to Dex at 
these levels in vitro and the response in vivo is different.  
Another interesting finding from these experiments is that mifepristone acts as a partial 
agonist of NR3C1 within the first few hours of treatment. There is a basis for this in the 
literature; in an early paper on mifepristone the drug was found to have weak glucocorticoid 
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agonist activity but this was put down to the presence of an agonist impurity in the 
preparation or a non-specific effect (Bourgeois, Pfahl, and Baulieu 1984). Since then it has 
been found that increased NR3C1 levels are sufficient to cause the formation of 
transcriptionally active NR3C1 complexes in the presence of mifepristone, driving expression 
of NR3C1 target genes (S. Zhang, Jonklaas, and Danielsen 2007). Despite this finding, 
mifepristone was still tested in vivo because it was thought the antagonist activity at 24h 
could be sufficient for any effect on survival to manifest. The toxicity study with mifepristone 
confirmed that it was non-toxic in NSG mice but no differences in survival were found for 
mifepristone treated vs control mice, it was only when mice are treated with Dex that there 
was any increase in survival.  
Despite no change in survival, mifepristone treated samples were still sent for microarray 
analysis along with the Dex treated and control samples. From this it can be seen that 
mifepristone does not result in many genes being significantly differentially regulated, but of 
those that are, several are also genes that are differentially regulated in Dex treated samples 
such as S100A8, S100A9, which have both been implicated in Dex resistance in ALL (Spijkers-
Hagelstein et al. 2012) and JUN (Jun proto-oncogene). This indicates some cross over of 
pathways involved in the cellular response to these two drugs. The differential expression of 
these in both mifepristone and Dex treated samples gives further credence to the hypothesis 
that mifepristone is acting as a partial agonist at NR3C1.  
The genes differentially regulated in mifepristone treated cells does not have complete 
crossover with Dex treated samples however. In Dex treated L707 presentation cells there is 
upregulation of JUN and FOS (Fos proto-oncogene). These genes are part of the AP-1 
(Activator protein 1) transcription factor which has roles in cell cycle, the glucocorticoid 
response and oncogenesis (Helmberg et al. 1995; Bakiri et al. 2000; Yang-Yen et al. 1990; 
Kappelmann, Bosserhoff, and Kuphal 2014). These roles are initiated by the interaction 
between AP-1 and NR3C via intermediary proteins GIP1 and NTRIP6, which are required for 
NR3C1/ AP-1 driven transrepression of AP-1 target genes (Glass and Saijo 2010). The ability 
of NR3C1 to repress other transcription factors is not limited to AP-1, it is also known to 
modulate the expression of NF-κB target genes. This was in part discovered by the inability 
of NR3C1 to bind to NF-κB and induce repression of target genes when there was a loss of 
acetylation either through targeted mutagenesis or siRNA knockdown (Ito et al. 2006). 
Acetylation of NR3C1 was required for the two transcription factors to form a complex which 
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in turn represses NF-κB activity. Interestingly, the differentially expressed genes S100A8 and 
S100A9 are both NF-κB target genes (Nemeth et al. 2009) 
The microarray analysis of Dex and mifepristone treated L707 presentation cells as well as 
controls did not yield as many results as was expected. The removal of the 2 anomalous 
samples will have reduced the power of the comparison, but not so much that there should 
be so few differentially expressed genes between the treatment groups. The lack of genes 
significantly down regulated by mifepristone is further support for the lack of effect of this 
drug in ALL cells, but the lack of other known NR3C1 target genes in the Dex treated samples 
implies that perhaps the microarray data quality was not high enough, which is supported by 
the fact only 35% of probes passed filtering.  
The original hypothesis that NR3C1 is infrequently deleted because it results in reduced 
fitness has not be proven or disproven by this set of experiments. The loss of NR3C1 mRNA 
does result in Dex resistance but no alteration in proliferation. Loss of NR3C1 signalling 
pharmacologically through use of mifepristone has no effect on survival. This indicates that 
further work would be needed to prove this hypothesis.  
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 Chapter 6: In vivo lentiCRISPR whole genome screen to determine genes 
implicated in dexamethasone treatment and the emergence of relapse 
 
6.1 Introduction 
 
Genome editing using CRISPR Cas9 is a relatively new technique that has really taken off in 
the past few years with several high profile papers being published (Sanjana, Shalem, and 
Zhang 2014; Shalem et al. 2014; Chen et al. 2015). The system utilizes the Cas9 
endonuclease from Streptococcus pyrogenes (S. pyrogenes) to induce double strand breaks 
(DSB) in DNA; these are then repaired by homologous recombination or non-homologous 
end joining. The result of these repairs are either the repair of the target sequence or the 
creation of an indel, which may lead to disruption of gene function. The Cas9 enzyme is 
directed to the DNA using specific short guide RNA (sgRNA) sequences that can be targeted 
anywhere in the genome with a protospacer adjacent motif (PAM) sequence. The Cas9 
endonuclease from S. pyrogenes is specific to the PAM sequence NGG, and  by taking the 
frequency of GG dinucleotides as around 5.2% in the 3 billion base pairs that make up the 
human genome, the number of possible PAM sites recognisable by S. pyrogenes is over 161 
million (Scherer 2008; Integrated DNA Technologies 2016). This number of possible sites 
means that virtually any gene in the genome will be targetable using the CRISPR Cas9 
system.  
The CRISPR Cas9 system was chosen over other whole-genome screening methods for 
several reasons. With RNAi-mediated screens, especially in vivo we have found silencing of 
the construct to be a problem (unpublished observations). This was demonstrated by the 
data in chapter 5, which found that when 697 cells that were transduced with the inducible 
lentiviral plasmid pTRIPZ and grown in vivo, there was a loss of tRFP expression in vivo 
despite mice being treated with Dox to induce expression. This was not seen when the same 
cells were grown in vitro suggesting a role for the murine microenvironment in facilitating 
silencing of the construct. Using CRISPR negates the risk of silencing as once Cas9 has caused 
a DSB and the gene is knocked out, it is a stable effect that is passed on to all daughter cells. 
This could result in problems such as off target effects, but as we felt siRNA and methods 
using transient Cas9 expression were not a viable option in primary derived cells, due to 
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both the high levels of cell death with electroporation of primary cells seen in our lab 
(unpublished results) and the transient effects, the lentiCRISPRv2 GeCKO plasmid library was 
chosen as the best choice.  
The lentiCRISPRv2 GeCKO library is a commercially available CRISPR sgRNA library (Chen et 
al. 2015; Shalem et al. 2014). The library contains over 122000 sgRNA, with 6 sgRNA per 
gene, 4 for miRNA and 1000 non targeting controls. The lentiCRISPRv2 is a single plasmid 
system with both the sgRNA and Cas9 enzyme encoded by the same plasmid, this means 
that only one type of antibiotic selection, and one round of transduction is needed, both of 
which are preferable for use in primary ALL cells.  
Although cell lines are often the model of choice for research due to their availability and 
relative ease of culturing in vitro, these may not be the best models to investigate the 
acquisition of Dex resistance. Several studies found that cell lines have increased sensitivity 
to cytotoxic agents compared to matched primary material (Stein et al. 2004; Wang et al. 
2002), and that in cell lines there is no correlation between target expression and drug 
sensitivity (Jaeger, Duran-Frigola, and Aloy 2015) There is also evidence that following 
prolonged Dex exposure, cell lines have an increase in the acquisition of deletions or 
mutations in NR3C1 (Hala et al. 1996). Considering that deletions or mutations in NR3C1 are 
relatively rare in ALL, even at relapse when resistance to glucocorticoids is increased(Irving 
et al. 2005), this further supports the theory that cell lines may not be the best model for 
these investigations. As a result, it was decided that to investigate acquisition of drug 
resistance in ALL, drug naïve primary cells were the best model. It was hypothesised that if it 
was possible to transduce primary derived cells with the lentiCRISPRv2 plasmid (Sanjana, 
Shalem, and Zhang 2014; Shalem et al. 2014), with a high enough viral titre, it would 
represent a robust model in which to carry out a genome wide CRISPR screen. The use of 
primary cells may be a better model but there are technical issues with using them, most 
notably the amount of cells needed for a screen. For this reason, primary derived cells that 
have been grown in vitro after injection into NSG mice were used. Although primary derived 
cells are not directly primary cells, they still retain the characteristics of the primary sample. 
The cells chosen for this screen, the L707 presentation cells, do not proliferate in vitro 
without the support of a feeder layer and have a phenotype more similar to primary cells 
than a cell line. The L707 presentation xenograft cells have maintenance of genomic 
deletions from the patient sample and the phenotype of the cells once engrafted remains 
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stable over several engraftment passages (Latif 2012). This suggests that the primary derived 
L707 presentation cells are an accurate representation of the primary material.  
The aims of this screen were  
 to prove the feasibility of a genome-wide lentiCRISPR screen in primograft ALL cells in 
vivo, and  
  to investigate mechanisms of Dex resistance in matched presentation and relapse 
ALL cells.  
6.2 Transduction pilot 
 
An initial transduction pilot was done before the screen was undertaken to determine the 
feasibility of the whole-genome approach in primary derived cells. L707 Presentation cells 
were transduced with lentiCRISPRv2 empty vector lentivirus and samples were taken at 3 
and 5 days post transduction. As the plasmid does not contain a fluorescent marker for 
quantification of transduction, qPCR was used. Levels of cas9 DNA in the genomic DNA of 
samples were determined as a measure of transduction. Compared with the un-transduced 
L707 Presentation and SEM cells the transduced cells had significantly increased Cas9 DNA 
levels, over 1000 fold more than in the controls (Figure 65). This PCR represents the proof of 
concept that a sufficient viral titre could be achieved to go ahead with a full genome screen.  
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Figure 65: Relative Cas9 DNA levels in samples transduced with the lentiCRISPRv2 plasmid at 
3 and 5 days post transduction. Negative controls of L707 Presentation and SEM cells without 
virus were also tested. L707 Presentation without virus was used as the control for -ΔΔCt 
calculations along with GAPDH levels. Data shows technical repeats of a single transduction, 
not biological repeats and error bars show SEM.  
 
6.3 in vivo screen  
 
Approximately 4.7x107 freshly thawed L707 Presentation cells were transduced with 
concentrated lentivirus before being grown in vitro and puromycin selected (0.25-5 µg/ml). 
The cells were then intra-femorally injected into 15 NSG mice and dosing with Dex started 
the next day (every weekday, 15 mg/kg for 5 weeks, 10 mg/kg thereafter. This was 
continued until the mice reached endpoints as defined on the license and were killed by 
cervical dislocation. Samples were extracted from several organs and DNA extracted before 
PCR was used to prepare amplicon libraries for next generation sequencing using an Illumina 
HiSeq2500.  
Treatment with Dex is known to significantly prolong the survival of mice engrafted with the 
L707 presentation cells (Latif 2012). The treatment of mice engrafted with L707 CRISPR cells 
significantly increases survival compared to these mice, but as treatment is started straight 
away this is not a true comparison (Figure 66). No other experiments with the L707 
presentation used Dex treatment straight away after engraftment and so the L707 
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presentation + Dex after 2 weeks represents the best data to compare the survival of mice 
engrafted with the L707 Presentation CRISPR cells to.  Three mice did die earlier than 
expected, and on examination this was due to suspected liver toxicity, and this prompted 
the decrease in Dex dose and these mice were excluded from survival analysis.  
 
 
Histology was done on the samples collected from the mice engrafted with L707 
presentation CRISPR cells to determine if there were differences between the organs, or any 
abnormalities not normally seen in mice engrafted with L707 presentation cells. The spleens 
of NSG mice engrafted with L707 presentation CRISPR cells show the highest level of 
engraftment of human cells, which considering the splenomegaly seen in these mice is 
unsurprising (Figure 67). The BM in the vertebra (Figure 68) and tibia (not shown) were also 
highly engrafted with L707 presentation cells. The infiltration of human cells into the liver is 
more variable, with large areas not showing expression of CD19, indicating no human cells 
(Figure 69). This pattern of engraftment in the mouse implies that the BM is colonised first, 
Figure 66: Survival of mice engrafted with L707 Presentation cells; L707 Presentation (red), 
L707 Presentation + Dex (15 mg/kg) after 2 weeks engraftment (blue) and L707 Presentation 
CRISPR + Dex (15 mg/kg, then 10 mg/kg) (green). Censored mice are shown as black bars. 
Both L707 Presentation + Dex and L707 Presentation CRISPR + Dex have significantly longer 
survival than the untreated L707 Presentation (p<0.005). L707 Presentation + Dex and L707 
Presentation CRISPR + Dex do not have significantly different survival. The L707 presentation 
+ Dex engrafted mice were left for 2 weeks before dosing was started (I.P. every weekday) but 
the L707 Presentation CRISPR mice did not have a gap before treatment.  
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closely followed by the spleen and then later on the liver, but before the liver can reach 
significant levels of engraftment the mice succumb to the disease. In mice engrafted with 
L707 presentation CRISPR cells, several mice were killed due to loss of hind limb mobility, 
likely as a consequence of vertebral collapse resulting from high levels of engraftment in the 
vertebral BM. This was the same as for previous mice engrafted with L707 presentation 
without transduction, which suggests that the engraftment phenotype of these cells was not 
altered by the transduction with the CRISPR library.  
 
 
Figure 67: Histology of a section of spleen from an NSG mouse engrafted with L707 
presentation CRISPR cells treated with Dex, left – H&E staining shows gross morphology is 
very homogenous in the spleen, Right – CD19 staining shows the entire spleen is heavily 
engrafted with human cells. Sectioning and staining was carried out by the histopathology 
department at the RVI hospital.  
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Figure 68: Histology from the spine of a mouse engrafted L707 presentation CRISPR cells 
treated with Dex. The muscle around the spine as well as the BM of the vertebra can be seen. 
Left – H&E staining shows muscles are not engrafted but the BM is homogenous with small 
lymphocyte like cells, Right – CD19 staining shows that the BM of the vertebra are engrafted 
with CD19 positive human cells.  Sectioning and staining was carried out by the 
histopathology department at the RVI hospital. Sectioning and staining was carried out by 
the histopathology department at the RVI hospital 
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Figure 69: Histology from the liver of a mouse engrafted with L707 presentation CRISPR cells 
treated with Dex. Left – H&E staining shows engraftment of cells is not homogenous in the 
liver with areas of different cellular composition. Right –CD19 staining shows that only some 
areas of the liver are engrafted with human CD19 positive cells. The majority of the liver is 
not-engrafted. Sectioning and staining was carried out by the histopathology department at 
the RVI hospital. 
 
6.3.1 Sample preparation  
 
The sequencing run and data described in this chapter are from a second sequencing run as 
the initial one failed to produce usable data. This is thought to be a result of using a custom 
primer and the Fluidigm adaptors rather than the standard Illumina primer and adaptors. 
The custom primer likely did not have the right thermodynamic properties and as such there 
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was no hybridisation and the chemistry used with the HiSeq2500 did not work. As a result, 
not all samples sent for sequencing were amplified from genomic DNA, some were from pre 
amplified DNA from the first run.   
 
6.3.2 Analysis 
 
When data were returned originally analysis was carried out but it was found that levels of 
NR3C1 and some non-targeting control (NTC) sgRNAs were unusually high (Figure 70). 
Plasmids containing these NR3C1 and control sgRNAs had been cloned in the lab for use in 
experiments knocking down NR3C1 individually before the library preparation Given that the 
NTC were high in the list of hits along with NR3C1, this implied that there was a PCR 
contamination and the results for these constructs could not be trusted. High sensitivity of 
PCR to contamination by other sgRNA plasmids used in the same lab space has also been 
reported by other groups using the GeCKO library in the institute (unpublished results). As a 
result, the analysis was re-run without the 6 NR3C1 targeting sgRNA and the 20 NTC that 
were used. All data reported has had these 26 sgRNA removed.  
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Figure 70: A -  The number of reads for the top 10 highest reads for KD93 spleen in the 
contaminated analysis before removal of NR3C1 and NTC reads (red) and after these reads 
were removed (green). B – the names of these 10 genes for the contaminated reads (red) and 
reads after the contaminants were removed (green).  
 
6.3.2.1 Data Analysis: Reads and coverage  
 
Two types of analysis were used with this data. Firstly analysis of the normalised reads in 
excel which gives an overall view of the level of sgRNA lost and the coverage in different 
mice and organs, and secondly, analysis using the CRISPR specific statistical programme 
MAGeCK (Li et al. 2014), which allows for significance to be calculated for enriched and 
depleted sgRNA, genes to be ranked and enrichment of pathways to be determined.   
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AROS returned the data in the form of de-multiplexed FASTQ files, and analysis of the raw 
reads showed that all samples except one had >1 million reads, and only 3 were < 5 million 
reads (Figure 71). The high levels of reads for most samples means that even with reads 
removed there are enough left for statistical analysis. The differences in the number of reads 
between samples is not an issue due to the median normalisation that is used.  
 
Figure 71: The reads per sample in the raw sequencing data returned from the HiSeq2500 
sequencing run from AROS. The sequencing depth was varied between the samples but only 3 
samples had <5 million reads and these were still analysed with the rest. 
Coverage is an important issue in whole genome screens, and especially so with negative 
screens which look at drop out of sgRNA. This is due to the requirement of a high number of 
each sgRNA in the baseline in order to determine which drop-outs are significant and often 
1000-fold coverage is the requirement. However, 1000-fold coverage in this screen would 
have required 1220 mice and assuming 30% transduction, the transduction of >4x10^8 cells, 
which was not achievable with the number of cells, mice and time available. Instead, a 
positive screen was used to look for which sgRNA constructs were enriched in samples after 
treatment. 15 mice were injected with 105 L707 presentation CRISPR cells each, and the 
original pool had a complexity of ~122000 constructs. This results in 0.8-fold coverage per 
mouse, and when all mice are pooled a total coverage of 12.3-fold. With low coverage this 
screen was designed not to be negative, but a positive screen, identifying constructs that are 
enriched in samples compared to baseline.  
Count data was used to investigate the coverage and loss of sgRNA in the mouse organs and 
a 10 read cut off was applied to the data to eliminate sequencing artefacts. Using this cut-
off, the baseline maintains 94% coverage of the original GeCKO plasmid library (Figure 72). 
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This reduction in library complexity was to be expected, as with genome wide screens some 
constructs will be lost, partly due to actual drop out of constructs that negatively affect the 
cell and partly due to low read counts as a result of not having high coverage.  The reduction 
in sgRNA from the baseline sample to the mouse organs ranges from 11% to 88% of the 
baseline sample (Figure 73). This variation is seen both between different mice, and within 
the organs from one mouse. As might be expected, those samples with more reads also had 
a higher percentage coverage (Figure 74). There does not appear to be any patterns in the 
coverage when looking at different organs.   
 
Figure 72: The reduction in the number of sgRNA found in the original GeCKO library (grey), 
number of sgRNA with >10 reads in the baseline sample (Green) and the combined mouse 
samples( blue). The reduction between the library and the two samples indicates a loss of 
complexity, which was expected. The loss is not too severe meaning there was engraftment 
of almost all sgRNA in the mice. 
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Figure 73: The reduction in sgRNA coverage in the organs of 4 representative mice compared 
to baseline. All sgRNA reads are included in charts, and loss in complexity between baseline 
and samples is shown by a reduction in the area of the plots. This shows the difference in the 
sgRNA distribution in the separate organs of the mice compared to the baseline sample.  
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Figure 74: A comparison of sgRNA in separate organs. sgRNA with > 10 reads as percentages 
of the original GeCKO library are shown in red, and as a percentage of the baseline are 
shown in blue. The total reads for each sample is shown above those samples in black.   
Principal component analysis (PCA) of the samples shows there is no clustering pattern, 
some samples show close association between different organs, but others do not (Figure 
75). This would imply that despite the pool being spread across several mice, the inter 
mouse effect is not as significant as it could have been.  
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PCA plot — Mouse samples 
Figure 75: Principal component analysis plot for samples in the screen using the two principal components that contribute most to sample 
variance. Baseline sample is shown in black and each mouse a different colour, separate organs for each mouse are not differentiated by 
colour. Plot was produced by Dr. Matt Bashton. 
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6.3.2.2 Enriched sgRNA 
 
sgRNA that are enriched in the mouse samples indicate genes with knockout by CRISPR 
induced indels, that has led to reduced sensitivity to Dex or enhanced growth in vivo. This list 
of genes can be used to determine which are important for engraftment and Dex response in 
vivo in the L707 presentation.  
Of the top ten significantly enriched sgRNA (Figure 76) there are two non-targeting controls. 
This could be because they have off-target effects on cell function not calculated for when 
the sgRNA were designed using an algorithm. When the sequences are searched for using 
the online BLAST (Basic Local Alignment Search Tool) web interface (Madden 2002), 
NonTargetingControlForHuman_0823 (NTC_0823) has 95% sequence homology with 
PTPRN2 (Protein tyrosine phosphatase, receptor type N2), a protein with a similar sequence 
to known receptor protein tyrosine phosphatases. The other highly scoring NTC, NTC_0737 
has 80% sequence homology to CNTN5 (Contactin 5) (Figure 77). Alternatively, because the 
NTC are a single sgRNA rather than a pool of 6 like protein coding genes, less of an increase 
is needed for them to score as highly significant. The top hit for a protein coding gene is 
MSRB2 (Methionine Sulfoxide Reductase B2). This gene is the catalyst in the reduction of 
methionine sulphoxide to methionine, and is thought to be protective against oxidative 
stress induced damage in cells (Sreekumar et al. 2005).  
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Figure 76: RRA (Robust rank aggregation) scores for positive selection of sgRNA in mouse 
samples vs baseline. Only the top 10 enriched sgRNA are shown as data points on the trend-
line.  A higher RRA score is associated with a reduced number of genes, with the vast 
majority of genes having a very low score. Data was produced using the in built functions of 
MAGeCK by Dr. Matt Bashton. 
 
Figure 77: Sequence homology, as determined using the NCBI blast online database. The top 
sequence shows the homology between 19 bp of NTC_0823 and PTPRN2, which is 95% and 
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the lower sequence shows the homology between 16bp of NTC_0737 and CNTN5, which is 
80%. The homology between the NTC and known genes indicates that these may not be non 
targeting.  
Analysis of all the genes with significantly enriched sgRNA with an FDR <0.05 after 
corrections for multiple testing (Figure 78) does not show any enrichment of gene ontology 
terms, or protein interactions between the genes, and when all the enriched sgRNA are 
analysed for pathway analysis, those that are significant include genes downregulated by 
NR2E1 (Nuclear receptor subfamily 2, group E member 1) and Multiple myeloma pathways. 
After corrections for multiple testing none of these pathways have an FDR <0.05.  
The protein coding genes with significantly enriched sgRNA in the mouse samples compared 
to baseline, as determined by robust rank aggregation were investigated further. This was 
done using publically available ENCODE Chromatin immunoprecipitation (ChIP) data 
obtained by treating the A549 human alveolar adenocarcinoma cell line with 100nM Dex and 
then testing for the presence of NR3C1 bound to the DNA (ENCODE project Consortium 
2013) (GEO:GSM803371). Six of the genes investigated have NR3C1 binding at the start sites 
of the genes in the presence of Dex; MSRB2, MSL1 (Male specific lethal 1) and RRBP1 
(Ribosome binding protein 1), IKBIP (I Kappa B kinase interacting protein), POT1 (protection 
of telomeres 1) and MAPKBP1 (Mitogen activated protein kinase binding protein1) (Figure 
79). This data combined with the fact that these genes have enriched sgRNA, and so 
decreased expression, indicates that these genes are likely to play a role in the response of 
Dex that is disadvantageous to the cells. However, it is important to note that the ChIP-seq 
data was obtained using an alvelolar adenocarcinoma cell line, and it is known that smooth 
muscle cells have a differential response to Dex compared to lymphocytes.  
Some of the genes identified as significant using the MAGeCK analysis did not have any 
NR3C1 binding in the presence of Dex (Figure 80) which could indicate that these are not 
direct targets of NR3C1 but downstream targets, or that they are not affected by Dex 
treatment but are important for leukaemic growth.   
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Figure 78: Plot showing the increase in sgRNA reads between the baseline to the endpoint 
samples (Dex) for all of the genes with significantly (p<0.05) upregulated sgRNA calculated 
using the robust rank aggregation (RRA) score in the MAGeCK analysis pipeline. Only genes 
with an FDR < 0.05 after correcting for multiple testing are shown.  
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Figure 79: Genes with enriched sgRNA and NR31 binding at the transcription start site as 
determined by ChIP-seq. Traces produced using publically available ENCODE ChIP-seq data 
for A549 cells, a human alveolar adenocarcinoma cell line, treated with 100nM Dex. The top 
part of each trace shows the gene and direction or transcription. The traces below that show 
two repeats of the ChIP seq with peaks for NR3C1 antibody binding. The blue peaks at the 
gene transcription sites, marked by the red boxes indicate locations of NR3C1 binding to the 
DNA. (ENCODE project Consortium 2013)   
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Figure 80:  Genes with enriched sgRNA but no NR3C1 binding as determined by ChIP-seq 
data. Traces produced using publically available ENCODE ChIP-seq data for A549 cells, a 
human alveolar adenocarcinoma cell line, treated with 100nM Dex. The top part of each 
trace shows the gene and direction or transcription. The traces below that show two repeats 
of the ChIP seq with peaks for NR3C1 antibody binding. These traces show two genes, 
DDIRAS1 and MS4A6E that do not have NR3C1 binding sites at the transcriptional start site 
or anywhere within the gene. (ENCODE project Consortium 2013). 
Of the genes with significantly enriched sgRNA, 9 are expressed in the L707 presentation and 
relapse as determined by the microarray data. Interestingly, MSRB2, the top protein coding 
gene hit for the CRISPR screen has a reduction in the relapse compared to the presentation. 
This reduction, is 0.45 fold but may indicate that the enrichment of this sgRNA is mirroring 
the phenotype in the relapse. Several of the top hit genes are not expressed, which indicates 
that theses sgRNA may be high ranking because they have little effect in the cell. MS4A6E 
(Membrane spanning 4-domains A6E), TMEM182 (Transmembrane protein 182), IGF1R 
(Insulin like growth factor) and MRAS (Muscle Ras oncogene homolog) are not expressed in 
either the L707 presentation or relapse. All of the other genes have no difference in 
expression between the presentation and relapse.  
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6.3.2.3 Depleted sgRNAs 
 
Depletion of an sgRNA indicates that the cell cannot function without the gene targeted by 
that sgRNA. Although there is not as high coverage in the screen as would usually be 
required to determine dropout with significance, looking at those genes for which sgRNA are 
lost can still reveal some targets of interest.  
The top hit for depletion of sgRNA is PLXND1 (Plexin D1) (Figure 81). In several cancers 
PLXND1 and its ligand, SEMA3E (semaphorin 3E) expression are associated with increased 
invasiveness and malignancy (Casazza et al. 2010). Indeed PLXND1 has been postulated as a 
dependence receptor which when activated by ligand binding increases invasiveness, but 
without ligand binding can induce apoptosis by its interaction with NR4A1 (Nuclear receptor 
subfamily 4, group A member 1), and orphan receptor (Luchino et al. 2013). PLXND1 as well 
as 3 other of the top genes with depleted sgRNA have NR3C1 binding sites in the region near 
the transcriptional start site of the gene (Figure 82).  
 
 
198 
 
 
Figure 81: RRA scores for depletion of sgRNA in mouse samples vs baseline. Only the top ten 
depleted sgRNA are shown as data points on the trend-line. A higher RRA score is associated 
with fewer genes, the majority of shRNA in the screen will have a lower score which is why 
there is a correlation between the number of genes and a low RRA score.  Data was produced 
using the in built functions of MAGeCK by Dr. Matt Bashton.  
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Figure 82: Traces for the genes with depleted sgRNA that have ChIP-seq peaks at the 
transcription start site. Produced using publically available ENCODE ChIP-seq data for A549 
cells, a human alveolar adenocarcinoma cell line, treated with 100nM Dex. The top part of 
each trace shows the gene and direction or transcription. The traces below that show two 
repeats of the ChIP seq with peaks for NR3C1 antibody binding. The blue peaks at the gene 
transcription sites, marked by the red boxes indicate locations of NR3C1 binding to the DNA. 
(ENCODE project Consortium 2013) 
200 
 
Unlike the enriched sgRNA analysis, when using the pathway analysis function of MAGeCK, 
several pathways had an FDR < 0.05. It should be noted that the pathway analysis takes into 
account the entire data set and so the top genes may not correlate as strongly as expected 
to the list of pathways. TP53 targets is one of these pathways. TP53 is well established as a 
tumour suppressor, and loss of genes associated with this pathway indicates a loss of 
tumour suppressive control in the L707 cells (Baker et al. 1989; Zilfou and Lowe 2009). 
Another significantly enriched pathway was EED (embryonic ectoderm development) 
targets. EED is a polycomb protein that forms part of the cellular machinery that represses 
transcription, it is also implicated in the proliferation of haematopoietic cells and loss of 
expression results in increased myeloid and lymphoid proliferation (Lessard et al. 1999). This 
pathway and the associated gene signature is correlated with an immature stem cell like 
phenotype (Ben-Porath et al. 2008), which implies that these sgRNA are not compatible with 
proliferation and engraftment in vivo due to their role in the L707 presentation cells as 
promoting the leukaemic phenotype. It should be noted that none of the genes in the top 10 
depleted constructs appear to be associated with this pathway, so any investigations arising 
from the gene ontology output from MAGeCK, gene expression may have to be checked 
separately using alternative methods first.  
PLXND1 mRNA is expressed in both the L707 presentation and relapse, but there is little 
difference between the expression, with just a 0.2-fold reduction in expression in the 
relapse. PLXNA1 is expressed at very low levels (average probe binding in presentation 31) in 
the presentation but is completely lost in the relapse. Considering the low expression in the 
presentation is, this might be an artefact of the microarray. The other genes with depleted 
sgRNA also show very low or no expression and only PLXND1 shows probe binding >100.  
Although the low coverage means that loss of sgRNA data is not as robust as it could be, the 
results warrant further investigation, especially the loss of sgRNA targeting PLXND1 as this is 
expressed in both the L707 presentation and relapse.  
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6.3.3 Functional validation of targets 
6.3.3.1 NR3C1 
 
The results from the screen were further investigated to determine which genes may have 
an effect on dexamethasone resistance. Several genes were chosen for this from the ranked 
MAGeCK gene lists. Lentivirus was made from pools of sgRNA ordered based on sequences 
in the GeCKO library and transduced into the L707 Presentation cells, which were then 
puromycin selected whilst on MSC feeder cells. The cloning of these single sgRNA was the 
source of the PCR contamination in the screen, as the NR3C1 targeting sgRNA were used in 
the lab before the samples from the screen were sent away for sequencing.  
As detailed previously, the L707 Presentation cells are Dex sensitive. They have an IC50 of 
approximately 28 nM when treated with Dex in vitro whilst growing on an MSC feeder layer 
(Figure 83). After 96 hrs treatment of the L707 presentation with 25 nM Dex, 58% of cells are 
still viable, which is significantly less than the L707 relapse (87% survival).  This resistance in 
the relapse is likely to be a direct result of the 5q deletion in the L707 relapse cells, which 
includes NR3C1. L707 Presentation CRISPR-NR3C1 cells showed Dex resistance at similar 
levels to the L707 Relapse cells (80% survival) at 25 nM, but were less resistant than the 
relapse at higher concentrations (Figure 84). This could possibly indicate a heterozygous 
mutation of NR3C1 rather than a homozygous loss. To determine any off target effects of 
Cas9 or transduction in general, cells were transduced with a pool of 6 non-targeting control 
CRISPR plasmids and tested in the same way. The Dex response of the L707 presentation 
control CRISPR-NTC (Non targeting control) cells was not significantly different from the L707 
Presentation indicating no effect of Cas9 or transduction (Figure 84). Despite a significant 
gain of resistance in the L707 presentation CRISPR-NR3C1 cells there was no significant 
decrease in mRNA, although there was a trend for reduced mRNA in transduced cells (Figure 
85). There was also no decrease seen in protein levels. A possible cause for this is that the 
sgRNA target the DNA binding and ligand binding domain, and instead of causing knockout 
of the gene entirely are just causing mutations in these critical regions for Dex response. This 
would explain the Dex resistance as well as lack of reduction in protein and also account for 
the modest loss of mRNA as the primers used span exons 2 and 3, separate from the sgRNA 
binding locations.  
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This data supports the idea that the NR3C1 deletions are the major causes of Dex resistance 
in the L707 relapse cells.  
 
Figure 83: Survival of L707 presentation cells grown on an MSC feeder layer when treated 
with Dex over a 96 hr time period. L707 presentation cells were grown on MSC for 24hrs 
before addition of Dex, vehicle was 0.01% ethanol. Viability was assessed using the trypan 
blue exclusion method after 96h of Dex treatment and data was analysed using a 4 
parameter dose response curve and the error bars show standard deviation.  
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Figure 84: The percentage cell survival, assessed by the trypan blue exclusion method in L707 
Presentation, L707 Relapse and L707 presentation CRISPR-NR3C1 and L707 presentation 
CRISPR-NTC (non targeting control) cells. Cells were grown on MSC for 24hrs before addition 
of Dex, vehicle was 0.01% ethanol. Viability was assessed after 96h of Dex treatment and 
Significance was tested using one-way ANOVA and Holm Sidak’s multiple comparison test. 
 
Figure 85: NR3C1 mRNA levels in the L707 presentation and L707 presentation cells 
transduced with a lentiCRISPR pool targeting NR3C1 cells (L707 Pres NR3C1), the two 
samples are not significantly different, as measured using the Wilcoxon signed rank test, 
p=0.125. Analysis was done using the ΔΔCt method and GAPDH as the housekeeping gene.  
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6.3.3.2 PLXND1 and other genes 
 
As well as NR3C1, several other genes were also selected from the screen for validation. 
These choices were based off the data from the ranked gene analysis done in MAGeCK. As 
well as the genes from list of top enriched and depleted genes, SEMA3E was chosen as it is 
the ligand for PLXND1, which was initially thought to be of importance.  
No sgRNA tested, other than NR3C1 showed any effect on dexamethasone resistance (Figure 
86) or cell proliferation (Figure 87). Interestingly, despite no significant decrease in NR3C1 
mRNA in cells transduced with NR3C1 targeting sgRNA, there was a significant reduction in 
PLXND1 mRNA (Figure 88). The reasons for this are unknown, but it does implicate NR3C1 in 
the control of PLXND1, and indeed when looking at the transcriptional start site of PLXND1 
there are two consensus GRE (Glucocorticoid response element) upstream of the 
transcriptional start site. Indeed, when looking further into this using publically available 
ChIP-seq data (ENCODE project Consortium 2013) (GEO:GSM803371), there are 2 peaks 
around the start site of PLXND1 that have NR3C1 binding peaks in the same position as the 
consensus GRE (peaks 7082 and 7083). This gives further proof that NR3C1 is involved in the 
control of PLXND1 expression, and considering loss of NR3C1 signalling results in loss of 
PLXND1 mRNA this would indicate a positive relationship between the two genes.  
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Figure 86: Percentage cell survival of L707 presentation cells with gRNA targeting PLXND1, 
SEMA3E, PAQR7 B4GALNT4 and NTC with 25nM Dex treatment. Only the survival of the L707 
Relapse is significantly different to L707 Presentation (p<0.05). None of the transduced cells 
show a significantly different percentage of surviving cells compared to L707 Presentation 
cells, and all of the transduced cells were significantly different to L707 Relapse cells (p<0.05), 
apart from L707 Pres-SEMA3E. Significance was tested using one-way ANOVA and Holm 
Sidak’s multiple comparison test. Analysis was done using the ΔΔCt method and GAPDH as 
the housekeeping gene. 
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Figure 87: Proliferation of L707 Presentation cells and L707 Presentation cells transduced 
with several different pools of sgRNA over a 25-30 day period in SFEM-II media with an hMSC 
feeder layer for support. Cells were split when deemed necessary from the apparent 
confluency and seeded at 1x106/cm2. No significant change in proliferation is seen with any 
of the constructs when analysed using ANOVA.  
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Figure 88: The decrease in NR3C1 mRNA in cells transduced with NR3C1 sgRNA is not 
significant. There is a significant reduction in PLXND1 mRNA in L707 Presentation cells 
transduced with sgRNA targeting NR3C1 but not in cells transduced with PLXND1, 
significance was determined using 2-way ANOVA with multiple testing, p <0.05.  
 
6.4 Summary 
 
Despite the PCR contamination and the subsequent removal of NR3C1 targeting sgRNA from 
the pool, the CRISPR screen has still been successful. Firstly, a high transduction of the L707 
presentation cells was achieved, and enough cells survived the puromycin selection to be 
injected into NSG mice. This shows that in vivo CRISPR screens are feasible which was not 
known when then screen was first proposed. 
The validation of target genes has shown that loss of NR3C1 results in Dex resistance, and 
considering the deletion of this gene in the L707 relapse confirms NR3C1 deletion as likely 
the major driver for relapse in this case. Loss of the other genes did not have an effect on 
growth or Dex response in vitro. This implies that these genes are not involved in Dex 
response, and this combined with the lack of changes in proliferation rate could suggest that 
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loss of these genes only has impact in vivo. As growth in vivo and in vitro can result in 
different phenotypes of ALL cells, the loss of these genes in vitro may not result in a 
noticeable phenotypic change.  
The top protein coding gene with significantly enriched sgRNA, MSRB2, is an interesting 
screen hit. With a GRE approximately 10,000 bp upstream of the transcription start site this 
gene may be modulated by Dex treatment. The probable mechanistic cause for loss of 
expression of this gene is through its actions protecting the cell against oxidative stress. 
Oxidative stress has been postulated to play a role in oncogenesis as well as leukaemic 
progression, as increased mutagenesis resulting from oxidative stress would result in 
increased clonal diversity (Udensi and Tchounwou 2014); and in ALL patients the expression 
of antioxidant genes has been found to be reduced (Battisti et al. 2008). This information 
potentially connects the loss of MSRB2 in this screen to leukaemia and gives a possible 
mechanistic reason why sgRNA targeting this gene are enriched. 
The genes for which the sgRNA are depleted represent another potentially important list of 
genes, although the data is not as robust and would need further validation. The loss of 
sgRNA targeting PLXND1 could play a role in leukaemic growth and possibly response to Dex 
as PLXND1 signalling is implicated in metastatic growth and invasiveness in several types of 
cancer (Luchino et al. 2013; Casazza et al. 2010; Biankin et al. 2012). The expression of the 
PLXND1 ligand SEMA3E is correlated with metastatic disease in several solid tumours, and 
associated with reductions in patient survival. Loss of SEMA3E/PLXND1 signalling has been 
shown to reduce tumour cell growth and increase apoptosis. This loss is thought to be 
through ligand independent signalling of PLXND1, which can induce apoptosis through its 
interaction with NR4A1, an orphan receptor with both pro survival and pro apoptotic 
functions (Lee et al. 2011; Mohan et al. 2012). Another of the top hits for depleted sgRNA is 
PLXNA1 and although there is less of a role for this protein in cancers, the presence of 2 
Plexins in the top ten hits is indicative of a role for Plexin signalling in engraftment of ALL in 
vivo or Dex response.  Indeed, it is known that the Plexins have a role in the development of 
the immune system (Kumanogoh and Kikutani 2013). PLXNB1 (Plexin B1) is expressed by 
stromal cells in the BM and this interaction between B cells expressing SEMA4D, the ligand 
for PLXNB1, increases proliferation and life span of these cells. Chronic lymphocytic 
leukaemia cells have also been found to express this ligand, indicating that PLXNB1 may have 
a role in increasing the survival of malignant cells (Granziero et al. 2003). There is a lack of 
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data available for the role of PLXND1 and PLXNA1 in leukaemia and Dex response.  How the 
roles of PLXND1 in apoptosis and PLXNA1 are linked to the loss of the sgRNA targeting these 
genes is not known, but it would appear that loss of expression is not tolerated in the L707 
presentation cells.  
This screen is currently being re done by Alex Elder, with both a Dex and Control arm. The 
DNA extraction and PCR steps will be done in a clean area where sgRNA have not been 
opened before, and so will not have the same issues with PCR contamination as this screen 
had. It should hopefully show the same genes with enriched or depleted sgRNA. Further 
work would then be needed to validate these genes and determine their role in leukaemia, 
Dex response and growth of cell in vivo.  
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 Chapter 7: Dexamethasone resistance in Acute Lymphoblastic Leukaemia 
cell lines 
 
7.1 Introduction  
 
Cell lines have been used to study cancer for over 60 years, the first being the HeLa cells in 
1951.  These cells were used widely for all types of research and were considered a good 
model for many studies. The first evidence that cell lines may not be a good model for the 
disease of origin came from a cell line that had been in culture for an extended period of 
time, and as a result had both morphological and karyotypic changes compared to the 
original cells (Nelson-Rees et al. 1976). Investigation of the differences between primary 
samples and cell lines has been greatly improved since this first report, with the advent of 
next generation sequencing hugely expanding the field. A large study that used microarray 
analysis of over 5000 cell lines, primary cancer samples and normal samples found that each 
group clustered together, not with samples from the same tissue of origin. Analysis of the 
genetic signature in cell lines compared to primary cancer samples found that genes 
involved in cell cycle, mitosis and metabolism were upregulated in cell lines (Gillet, Varma, 
and Gottesman 2013; Lukk et al. 2010). Despite this evidence the picture is muddied by 
studies that suggest cell lines are an accurate representation of the disease state they are 
modelling. For example 51 breast cancer cell lines were found to mirror the genomic and 
transcriptional signatures of primary samples with only a few significant differences (Neve et 
al. 2006). These differences have been suggested as artefacts of growing in a different 
microenvironment in vitro and the different signature could simply be subtracted to get 
useful information (Gillet, Varma, and Gottesman 2013).  
Despite misgivings about the faithful representation of disease states, cell lines are still 
incredibly useful. Cell lines often grow well in culture and have shorter doubling times than 
primary cells (Czekanska et al. 2014).  This makes them a very attractive option for drug 
screening, which may require very large numbers of cells. The investigation of drug 
resistance in cell lines may be problematic, due to the altered expression of cell cycle and 
apoptosis genes as a result of growing cells in vitro, as these genes may also have an effect 
on drug resistance. Cell lines have been shown to have different expression profiles of multi 
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drug resistance related genes which would undoubtedly alter the drug response profile of 
cells (Gillet et al. 2011; Gillet, Varma, and Gottesman 2013). 
As already described, resistance to dexamethasone is a problem in ALL, and especially in 
relapsed ALL. For these reasons having the right model to study the emergence of drug 
resistance is important. Cells need to be sensitive to Dex, which considering the relapse 
origin of many cell lines is not often the case.  
The 697 cells are a cell line derived from the BM of a 12 year old male at relapse, and were 
one of the first ALL cell lines to be derived from a paediatric patient (Findley et al. 1982). The 
patient had null cell ALL (non B, non T) ALL at presentation but cells cultured at relapse were 
found to have a pre-B phenotype. The 697 cells contain the translocation t(1;19) which 
generates the leukaemic fusion gene E2A/PBX1. Importantly the 697 cells are sensitive to 
Dex, with a reported IC-50 of 23.3±5.7nM (Inoue et al. 2002).  
 
7.2 The 697 cells show dexamethasone resistance in vivo: An incidental finding 
 
The 697 cells were initially chosen as a Dex sensitive cell line in which to carry out a small 
screen of pTRIPZ plasmids, containing shRNA thought to be important in the emergence of 
Dex resistance at relapse in pre B ALL. A pilot study was carried out with 7 NSG mice, 
engrafted with 104 697 cells each in order to determine the rate of engraftment in NSG mice 
and the concentration of Dex that could be well tolerated. Mice were either given saline 
control, 5 mg/kg or 10 mg/kg Dex I.P on weekdays starting 14 days after intrafemoral 
injection and continued until mice reached license endpoints.  The 697 cells engrafted very 
quickly, and both Dex doses were well tolerated by the mice. Survival was not further 
investigated at the time, although analysis later on reveals that none of the groups had a 
significant difference in survival (Figure 89).  The main pTRIPZ plasmid pool study was carried 
out in a larger group of 17 mice, split into 4 groups with combinations of Dex and 
doxycycline treatment, but essentially 8 control mice and 9 Dex (10 mg/kg) treated mice. 
Dex treatment was started 2 weeks after intra-femoral injection of 697 cells transduced with 
the luciferase expressing plasmid pSLIEW , 697pSLIEW cells. The mice in this study also had 
no significant differences in survival between the control and treated group (Figure 90). It 
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was at this point that the survival from the pilot study was investigated further and the 
differences in survival, or lack thereof were questioned.  
 
Figure 89: Survival of mice from first test of 697 engraftment in NSG mice. Dex treatment 
was started 14 days from intrafemoral injection and continued every weekday until mice 
were killed due to license defined endpoints. Survival is not significantly different between 
the 3 groups as determined using Log Rank (Mantel Cox) testing. 
 
Figure 90: Survival of mice engrafted with 697 transduced with pTRIPZ shRNA pool treated 
with either saline or Dex (10 mg/kg). Treatment was started 2 weeks after intra-femoral 
injection of 697 cells and was give on weekdays after that until mice were killed as per license 
endpoints. Survival is not significantly different between the groups as determined using Log 
Rank (Mantel Cox) testing.  
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From this initial study it was determined that Dex treatment did not have any effect on the 
survival of mice engrafted with the 697 cells.  This was surprising considering the IC-50 of the 
697 cells in vitro was found to be around 25 nM in both the literature (Inoue et al. 2002) and 
with cytotoxicity experiments carried out over a 96hr time course in vitro (Figure 91). We 
therefore decided to further investigate the reasons for this in vivo resistance.  
 
Figure 91: In vitro Dex sensitivity of the 697 cells. Determined using the WST-1 assay. Cells 
were seeded at 0.5x106 cells/ml and treated with Dex for 96 hours before readings were 
taken. The plotting method  used was a 4 parameter dose response curve, error bars show 
standard deviation. n=3.  
 
7.2.1 697 cell dexamethasone resistance is not mediated by adhesion in vitro 
 
The initial hypothesis for this acquired resistance in vivo is that it was due to adhesion-
mediated drug resistance. Increased resistance to chemotherapeutic agents caused by cell 
adhesion has been demonstrated in both multiple myeloma and chronic myelogenous 
leukaemia (Damiano, Hazlehurst, and Dalton 2001; Landowski et al. 2003). It is mediated 
through the cell surface integrins and NF-kappa β signalling. 
In order to test this hypothesis, several lines of feeder cells were used to support 697 cells to 
mimic the in vivo niche, with adherence of the leukaemic cells to the stromal cells. These 
were the murine BM lines M210B5 and MS5 and primary human MSC. To increase the 
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likelihood of feeder dependency in these cells 2% FBS was used as well as 10%. The rationale 
behind this is that without high levels of FBS as is usual with culture of the 697 cell line, the 
cells would become dependent on the factors produced by the feeder cell layers. Before use, 
697 cells previously transduced with the pSLIEW plasmid were sorted to enrich for GFP 
positivity (Figure 92). The pSLIEW plasmid contains GFP and luciferase so that cells can be 
quantified either using FACS or a luciferase assay, whereby the luciferase in the cells 
converts the substrate luciferin to oxyluciferin and light. Although for in vivo studies 
transduction efficiency does not need to be high to determine engraftment, when 
investigating the cells in vitro the entire population needs to have luciferase activity in order 
to get accurate readings.   
 
Figure 92: GFP expression in 697 pSLIEW cells after sorting (green) compared to 697 control 
cells without transduction (red). As can be seen from the plot there is GFP expression in 
approximately 98%. 
Three types of supporting cells were used, 2 murine BM stromal cell lines, MS5 and M210B4 
as well as human MSC. In order to test all possibilities in regards to feeder dependence, as 
this might alter the phenotype of the leukaemic cells, the 697pSLIEW cells were tested with 
4 different conditions (Table 32). Feeder cells were seeded 24 hrs before addition of 
697pSLIEW cells and dex at a range of 1-5,000nM. Co-cultures of cells were incubated with 
dex for 96hrs before cytotoxicity readings were taken. This was done using the luciferase 
assay as cytotoxicity assay that used metabolism as a readout for cell numbers such as the 
WST-1 assay would have been contaminated by contributing readings from the feeder cells. 
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Briefly, 10 µl of 7.5% luciferin was added to each well and bioluminescence readings taken at 
3 minutes. Readings were used to calculate the number of cells in each well compared to the 
vehicle (0.05% ethanol). The luciferase assay is a measure of the level of luciferase enzyme 
activity in the sample, to determine the number of cells.   
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Cell concentration/ml FBS concentration (%) 
0.5x106 10 
0.5x106 2 
0.5x104 10 
0.5x104 2 
Table 32: The cell and FBS concentrations used for the four different conditions for testing 
697pSLIEW cells on different supporting stromal cells.  
None of the conditions used resulted in a significant increase in dex resistance when grown 
on any of the feeder cells (Figure 93-95). In fact, the opposite was seen all conditions for the 
M210B4 and MSC feeder cells, and one condition with the MS5 cells. The reasons for this are 
not known, but it would appear that growth on a BM stromal feeder layer does not induce 
dex resistance in the 697pSLIEW cells and is likely not the cause of the resistance seen in 
vivo.   
 
Figure 93: Dex cytotoxicity of 697 pSLIEW cells on a feeder layer of MS5 cells. 697 cells tested 
at 4 different conditions, (Table 32), error bars show standard deviation, n=1. No conditions 
other than 0.5x104 cells/ml & 10% FBS show any significant difference (p<0.05) to 697pSLIEW 
cells, this difference is an increase in Dex sensitivity.  Data shown is log2 transformed and 
normalised. The plotting and statistics used were a 4 parameter dose response curve and two 
way ANOVA. Error bars show standard deviation. 
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Figure 94: Dex cytotoxicity of 697 pSLIEW cells on a feeder layer of M210B4 cells. 697 cells 
tested at 4 different conditions, (Table 32), error bars show standard deviation, n=3. All 
samples on M210B4 cells are significantly less Dex resistant than the 697pSLIEW cells in 
normal culture conditions (p<0.05).  Data shown is log2 transformed and normalised. The 
plotting and statistics used were a 4 parameter dose response curve and two way ANOVA. 
Error bars show standard deviation. 
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Figure 95: Dex cytotoxicity of 697 pSLIEW cells on a feeder layer of MSC cells. 697 cells were 
tested at 4 different conditions (Table 32), error bars show standard deviation, n=4. All 
conditions show significantly increased Dex sensitivity compared to the 697pSLIEW cells 
under normal culture conditions. (p<0.05). Data shown is log2 transformed and normalised. 
The plotting and statistics used were a 4 parameter dose response curve and two way 
ANOVA. Error bars show standard deviation. 
7.2.2 Growth of 697 in vivo does not result in resistance when cells are tested in vitro 
 
The finding that the Dex resistance in the 697 pSLIEW cells did not appear to be mediated by 
cell adhesion to stromal cells, at least not in an in vitro setting, resulted in another study in 
vivo to determine the mechanisms of this resistance. The hypothesis was that 697 cells that 
had been injected into mice, and then collected once mice were killed may retain Dex 
resistance when tested in vitro. Mice were injected with 104 sorted 697pSLIEW cells and spilt 
into 3 treatment groups: control (saline), Dex the day after intrafemoral (7.5 mg/kg), and 
Dex after engraftment (7.5 mg/kg). A lower concentration of Dex was used for this study 
than the initial one because of concerns over potential toxicity and issues with weight loss 
seen in other studies using Dex with other ALL cells. 
Engraftment was monitored using the IVIS to determine levels of bioluminescence produced 
by the luciferase in the 697pSLIEW cells engrafted in the mouse when the animal is dosed 
with luciferin, at day 14. Engraftment was determined sufficiently high and treatment was 
started for the later Dex treatment group. At this time point there was no difference in the 
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total bioluminescent flux (p/s2) of the control mice compared to those that had already been 
treated with Dex for 2 weeks (Figure 96).  
Overall survival was not affected by which group mice were in, and Dex treatment did not 
prolong survival (Figure 97), unlike the Dex sensitive L707 presentation ALL cells also used in 
this thesis. Mice were killed when they reached endpoints as defined on the license and 
samples collected from the BM of the femurs, the spleen and the liver. Spleen and liver 
samples were purified by ficoll separation before use in vitro.  
 
Figure 96: Total flux (photons/s2) emitted from the mice in the two of the treatment groups 
after dosing with luciferin and imaging using the IVIS. No significant difference is seen after 
13 days of treatment in the Dex treated group compared to the controls using multiple t 
tests.  
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Figure 97: The survival of mice engrafted with 104 697 pSLIEW cells, dosed with Dex (10 
mg/kg), every weekday; starting after intrafemoral injection, 2 weeks later, or controls. None 
of the groups are significantly different from each other using a Log Rank (Mantel ox) test.  
 
To determine if the Dex resistance was retained after cells were grown in vivo, the 
697pSLIEW cells from mouse organs were tested for Dex sensitivity in vitro after collection. 
Cells were seeded the day of collection in 96 well plates and Dex added, cytotoxicity was 
measured 96hrs later by luciferase assay.  
Samples collected from the mice that were tested in vitro did not show any differences in 
Dex sensitivity between the three treatment groups (Figure 98-100). There was a significant 
increase in Dex sensitivity in the BM and spleen samples, similar to what was seen with the 
697 pSLIEW cells with feeder support. The cause for this is not known, but it could possibly 
be a result of reduced viability in these samples. If there was an alteration to the phenotype 
of the cells induced by in vivo growth, it would be expected to be present in the cells 
collected from the liver as well. It would also, considering the Dex resistance of these cells in 
the mouse be expected to be shift towards resistance not away from it.  
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Figure 98: Dex sensitivity of 697pSLIEW cells collected from the BM of engrafted mice 
compared to 697pSLIEW that were not grown in vivo. BM 697pSLIEW cells are significantly 
more sensitive to Dex compared to 697pSLIEW in vitro samples (p<0.001) but are not 
significantly different to each other.  Reduced viability of cells from BM samples could 
account for the increased sensitivity of BM 697pSLIEW cells compared to 697pSLIEW in vitro 
samples. Measured by luciferase assay after 96hrs incubation with Dex. The plotting and 
statistics used were a 4 parameter dose response curve and two way ANOVA. Error bars 
show standard deviation, 5 or 6 mice per group. 
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Figure 99: Dex sensitivity of 697pSLIEW cells collected from the spleens of engrafted mice 
compared to 697pSLIEW cells that were not grown in vivo. Spleen 697pSLIEW samples are 
significantly more sensitive to Dex compared to 697pSLIEW cells grown in vitro (p<0.05) but 
not significantly different to each other. Measured by luciferase assay after 96hrs incubation 
with Dex. The plotting and statistics used were a 4 parameter dose response curve and two 
way ANOVA. Error bars show standard deviation, 5 or 6 mice per group. 
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Figure 100: Dex sensitivity of the 697pSLIEW cells collected from the livers of engrafted mice 
compared to 697pSLIEW cells not grown in vivo. Liver 697pSLIEW cells are not significantly 
different from each other or the 697pSLIEW cells not grown in vivo. Measured by luciferase 
assay after 96hrs incubation with Dex. The plotting and statistics used were a 4 parameter 
dose response curve and two way ANOVA. Error bars show standard deviation, 5 or 6 mice 
per group.  
 
7.2.3 No changes in histology are seen in mice from different treatment groups 
 
Samples from the mice engrafted with 697 pSLIEW cells were sent for histology to discern if 
there were any differences in engraftment between the three groups.  H/E staining was used 
to determine the tissue structure and CD45 and CD19 were used to mark human 697 cells. 
However, the CD45 staining was not very strong and so CD19 was used for all further 
investigations (Figure 101).  
The engraftment in all three groups was similar, with the same picture in the organs of mice 
from all groups. The spleen has a relatively uniform engraftment with CD19+ 697 pSLIEW 
cells whereas the liver has more focal growth, indicating clonal growth may have more of a 
role in the liver (Figure 102-101). The 697 cells engraft very quickly in NSG mice. They also 
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have a slightly different phenotype to the other ALL cells used in this PhD, the L707, in as 
much that they engraft the liver heavily, not just the spleen. Analysis of peripheral blood of 
mice engrafted with 697 pSLIEW cells did not show engraftment, implying that the cells do 
not appear to circulate in the peripheral blood in any significant number.  
 
Figure 101: H&E, CD45 and CD19 staining of liver from an NSG mouse injected intra-
femorally with 104 697 pSLIEW cells. 697pSLIEW cells are strongly positive for CD19, but 
CD45 staining is weak and so for further experiments only H&E and CD19 were used. 
Sectioning and staining was carried out by the histopathology department at the RVI 
hospital. 
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Figure 102: Liver (top) and spleen (bottom) samples from a control mouse that received 
saline injections after injection with 104 697 pSLIEW cells intra-femorally. H&E (pink and 
purple) and CD19 (brown and blue) staining are both shown. The liver shows less engratment 
than the spleen,a and the engraftment is also less uniform. Sectioning and staining was 
carried out by the histopathology department at the RVI hospital. 
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Figure 103: Liver (top) and spleen (bottom) samples from a mouse that received Dex straight 
after injection with 104 697 pSLIEW cells intra-femorally. H&E (pink and purple) and CD19 
(brown and blue) staining are both shown. As can be seen from the images the liver shows a 
less uniform engraftment that the spleen, similar to the images for the control mice and the 
mice treated with Dex starting later. Sectioning and staining was carried out by the 
histopathology department at the RVI hospital. 
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Figure 104: Liver (top) and spleen (bottom) samples from a mouse that received Dex 14 days 
after injection with 104 697 pSLIEW cells intra-femorally. H&E (pink and purple) and CD19 
(brown and blue) staining are both shown. As can be seen from the images the liver shows a 
less uniform engraftment that the spleen. The reasons for this are not fully understood but it 
is seen with the majority of ALL engraftment in NSG mice where there is liver involvement. 
Sectioning and staining was carried out by the histopathology department at the RVI 
hospital. 
 
7.3 Dexamethasone pharmacokinetics  
 
To determine the levels of Dex in vivo, pharmacokinetic (PK) studies were carried out to 
check that the lack of Dex response in vivo was not due to insufficient concentrations 
reaching the cells.  
Two PK studies were carried out; dosing by oral gavage, or dosing by I.P. injection, both with 
7.5 mg/kg. Both routes of administration were tested as both methods were used 
throughout the PhD for Dex dosing.  
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For the oral gavage study 12 male CD1 mice were used and 6 time points were taken. For the 
I.P. PK study 9 male RAG2 mice were used and the last time point, at 72hrs, was removed as 
levels of Dex in the blood were reduced to zero by 48hr after dosing so it was considered 
unnecessary. Peripheral blood was collected by tail vein venepuncture or cardiac puncture, 
samples were centrifuged to separate the red cells and the serum collected and stored at -
20°C. Dex concentrations in the peripheral blood were determined by mass spectroscopy by 
Rosie Jackson. Although there was a trend for higher concentrations with oral dosing this 
was not found to be significant (Figure 105). By 24hrs after dosing by either route Dex was 
cleared from the peripheral blood. Despite the fast clearance, for all time points taken 
before 24hrs the concentration of Dex in the peripheral blood was well above the IC-50 for 
697 cells in vitro (~25nM). Although there is no significant difference between the two 
routes as determined using a one tailed T test (p=0.68), there is a slight trend that would 
imply oral dosing has a slower clearance. As most of the Dex is cleared relatively quickly this 
would have been a better experiment if more time points had been taken, especially 
between 6 and 24 hrs. However, due to limitations in the number of mice available this was 
not possible.  
 
Figure 105: Concentration of Dex (ng/ml) in the peripheral blood of mice (oral – CD1 mice, 
I.P. – RAG2 mice) as measured by mass spectroscopy (done by Rosie Jackson). Blood was 
collected via tail venepuncture for the 2,4 and 6hr measurements and by cardiac puncture 
under terminal anaesthesia for the later time points. Boh I.P. and Oral dosing of 7.5 mg/kg 
Dex are shown. Dosing routes are not significantly different to each other, determined by a T 
test, p=0.68.  
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The high levels of Dex in the peripheral blood imply that the cells are receiving a sufficient 
dose to induce apoptosis if they showed the same sensitivity as cells in vitro. This leads to 
the theory that although the cells are receiving the drug, they are not having the same 
reaction that would normally result in apoptosis. The fast clearance from the blood indicates 
that mice only have therapeutic levels of Dex for somewhere after 6 but before 24 hrs after 
dosing, which considering mice were not dosed over the weekend would leave long 
treatment free periods. Mice were only treated at the weekends due to the effect of Dex 
dosing on weight loss, it was found that if mice were given a break then the weight increased 
again. This was important due to restrictions on the license around the amount of weight 
mice are permitted to lose before they have to be killed. A slow release pump for Dex might 
be a good option to consider in future experiments.  
 
7.4 RNA sequencing  
 
With the failure to determine a mechanism for 697 cell in vivo Dex resistance using in vitro 
testing, another strategy had to be used. Without knowing how to test for this change in the 
cells, RNA sequencing was chosen as the best possible way to investigate the cells, as the 
expression profiles of the cells and the differences between in vitro and in vivo should 
provide evidence for the changes occurring that could account for the Dex resistance.  
Mice were injected intrafemorally with 104 697 pSLIEW cells (98% GFP+). Mice were 
monitored for engraftment using IVIS and once they were engrafted, 5 days of Dex (7.5 
mg/kg, I.P.) treatment was given, controls were dosed with saline. Six hours after dosing 
mice were humanely killed and the organs collected. Liver samples were purified using ficoll 
separation and RNA extracted using the RNeasy kit (Qiagen). RNA quality was determined 
using a Bioanalyser (Figure 106) and samples were sent for sequencing to AROS (Table 33). In 
vitro samples were grown at 0.5x106 cells/ml and treated with 20 nM Dex for 96hrs before 
samples were taken, washed with PBS and RNA extracted in the same way. Large numbers of 
cells were treated with Dex in vitro in order to have enough viable cells to use for RNA 
sequencing. A lower centrifugation speed (300g) was used when washing to increase 
removal of dead cells.  
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Figure 106: Bioanalyser traces for 4 of the representative mouse samples sent for RNA 
sequencing. The RNA Integrity Number (RIN) is determined by electrophoresis of the RNA 
sample, showing fluorescence (FU) over time. All of the samples show high RIN values 
indicating that the RNA was not degraded.  
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Sample Group 
697pSLIEW control (1) in vitro control 
697pSLIEW control (2) in vitro control 
697pSLIEW Dex 20 nM – 96 hrs (1) in vitro DEX 
697pSLIEW Dex 20 nM – 96 hrs (2) in vitro DEX 
KD111 Control Male 
KD119 Control Male 
KD121 DEX Male 
KD124 DEX Male 
KD127 DEX female 
KD128 DEX female 
Table 33: Samples used for the 697 Dex resistance RNA sequencing. Both male and female 
mice were used to eliminate sex specific differences. However, the sequencing for KD124 
failed to produce reads and so is not included in any of the analysis.  Male mice were 
originally used for the entire experiment but not enough samples were collected due to two 
mice dying early. As a result more mice were injected and treated with Dex, the only mice 
available at the time were female mice. 
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Figure 107: Quality score across the bases in the RNA sequencing reads for a representative 
FASTQ file. All bases are in the highest quality range (the green area). The plot was 
generated using the programme FASTQC which is used to run quality control on FASTQ files 
before they are used for downstream applications. The type of sequencing used was 100bp, 
paired end RNA sequencing.  
Raw RNA sequencing data, from a 100bp paired end sequencing run was returned from 
AROS in the form of FASTQ files and quality control showed that the sequencing quality was 
very high (Figure 107).  The Cufflinks suite was used to analyse data and produce plots.  
In order to determine the differences between in vitro and in vivo samples as well as 
treatment vs control, several permutations of analysis were run (Figure 108). It should be 
noted that cuffdiff has a minimum p value of 5.00E-05, so if genes scored as significant they 
were then ranked by the log2(fold change) FPKM. In RNA sequencing analysis expression is 
referred to in units of FPKM which is the fragments per kb of transcript per million mapped 
reads. As well as changes is FPKM and the subsequent fold change differences, with Cuffdiff 
the other possible option to use is the test statistic value which is used to determine 
significance of the change in FPKM between samples and thus relates to the effect size. 
However, it more complicated to comprehend than the log2 fold change and so is not often 
used, but may still be useful. 
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Figure 108: The 5 comparisons that were run using the 697 RNA sequencing data in order to 
determine which genes might be important for the differences between in vitro and in vivo 
Dex response. Blue boxes indicate control samples and green boxes indicate Dex treated 
samples, the darker of the two for each represents the in vivo sample.  
Initial evaluation showed that the dispersion, and the squared coefficient of variation (CV2) 
which are both measures of the biological variation between the samples is very similar for 
all of the samples tested. If these plots show the same pattern it means the data is not 
substantially different between groups, indicating lower variance and so a higher likelihood 
that genes with differential expression will be significant. The comparisons for all of the 
permutations of comparison are very similar (Figure 109-110). 
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Figure 109: Dispersion plot for the RNA sequencing data of the 697 control TC samples and 
Control mouse samples. The dispersion is very similar between the two indicating low 
variance between samples. This indicates the raw data is high quality so can be used to 
generate robust results. Plots produced in CummRBund with CuffDiff analysed data. 
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Figure 110: Density of the log10 (FPKM) values for the 697 cell TC and mouse control sample 
data from the RNA sequencing analysis. Each replicate is shown separately but there is not a 
lot of variance between them. Plots produced in CummRBund with CuffDiff analysed data.  
 
7.4.1 in vitro control vs in vivo control 
 
Comparison of the in vivo and in vitro samples should allow for the elucidation of which 
genes are important for engraftment in vivo, and may provide insight for how the cell 
phenotype changes in response to the murine microenvironment.  
TC samples cluster separately from the mouse samples (Figure 111), and 3225 genes were 
significantly (P<0.05) up or down regulated in the control TC vs control mouse samples 
(Figure 112). To narrow down this list, we only looked at genes which had a log2 fold change 
of greater than two. This resulted in 139 genes with decreased in vivo expression and 253 
genes with increased expression.  
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Figure 111: Dendrogram showing the 2 697 cell TC and 2 697 cell mouse control samples 
cluster separately from each other, but together with the treatment replicates indicating that 
even for control samples there is a lot of variance between mouse and TC samples. Ideally 
there would have been more biological repeats to make this fata more robust.  
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Figure 112: Volcano plot showing the spread of log2(fold change) of FPKM values for genes 
between control mouse samples compared to control TC samples. Data points in red indicate 
which genes are significant (p<0.01). Points to the left of centre are down regulated and 
points to the right of centre are upregulated. Points at the edge of plot are those for which 
the fold change is inferred due to one of the conditions having an FPKM value of 0. 
Significance was calculated and the plot generated using the R package CummRBund, which 
is designed for the analysis and visualisation of CuffDiff RNA sequencing data. 
 
7.4.1.1 Up regulated genes 
 
FOS, FOSB (FosB proto oncogene) and JUN, were all highly upregulated in the mouse 
compared to TC. These genes are all components of the transcription factor AP-1, which is 
associated with proliferation. These genes have been demonstrated as oncogenes due to 
their ability to cause oncogenic transformation when overexpressed (Kappelmann, 
Bosserhoff, and Kuphal 2014; Castellazzi et al. 1993; Miller, Curran, and Verma 1984), which 
makes the upregulation in mice an interesting finding. These are not the only interconnected 
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genes in the upregulated gene list, as 7/10 of the top 10 hits are connected using the online 
functional protein association network, STRING (Figure 113). Gene ontology indicates an 
upregulation in the response to cAMP and Ca2+ as significantly enriched in the gene set 
(FDR<0.005), and the upregulation of the three most differentially regulated genes was seen 
in both replicates (Figure 114).  
Despite the gene ontology for these upregulated genes indicating cAMP and Ca2 response, 
both FOS and JUN are both part of the AP-1 transcription factor and are associated with 
MAPK signalling which was not indicated in the gene ontology (Kappelmann, Bosserhoff, and 
Kuphal 2014; Jones et al. 2015; Bakiri et al. 2000).  
Analysis of separate isoforms rather than genes shows that there is a mixed picture, with 
only some isoforms being upregulated (Figure 115). It is important to look at RNA 
sequencing both on a gene level and at isoforms due to different isoforms of a gene often 
having alternate functions and effects within different cells. The difference in isoform 
expression may represent isoforms with different functions, or isoforms that are not 
expressed at high levels in lymphocytes.  
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Figure 113: Interactions between the top 10 protein coding genes upregulated in mouse 
control samples compared to TC control samples.  Interactions were determined using the 
online protein interaction database, STRING (version 10.0), and the types of interaction are 
shown in the legend below. 
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Figure 114: Differences in FPKM between control TC samples and control mouse samples for 
the 3 most differentially regulated genes in the control mouse samples. The 3 most 
differentially regulated genes, measured by fold change (p<0.01), FOS, FOSB and EGR1. Both 
replicates are shown in plots.  
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Figure 115: Differences in FPKM in the 697 cells between TC control samples and Mouse 
control samples for FOSB in the RNA sequencing data, both replicates are shown in plots. 
Changes for 8 isoforms are shown.  
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7.4.1.2 Downregulated genes 
 
Amongst the genes downregulated in mice are several interesting candidates. ASS1 
(Argininosuccinate synthase 1) and ASNS (Asparagine Synthetase (Glutamine-Hydrolyzing)) 
have both been identified in drug resistance to L-Aspaginase in T cell ALL (Estes et al. 2007) 
and have a log2 fold decrease in mouse compared to TC of -4.5 and -2.9 respectively. 
Although the reduction in expression is the opposite to the literature, the differential 
expression of these genes may suggest a change in the drug sensitivity profile of the cells 
overall. Several other highly reduced genes are implicated in metabolism, such as SCD 
(Stearoyl-CoA Desaturase(Delta-9-Desaturase)) (log2 fold(-7.2)) and LDLR (Low density 
lipoprotein receptor) (log2 fold(-5)), which might indicate that there is an altered metabolic 
profile of the cells in the mouse compared to in tissue culture, which considering the 
different microenvironment and proliferation conditions is highly feasible. Protein 
association reveals a highly complex picture with many of the down-regulated genes 
interconnected. Ontology analysis of the genes with decreased expression in mice reveals 
down regulation of small molecules biosynthesis (Figure 116) (FDR=1.84e-11) and amino acid 
biosynthesis (FDR=1.31e-6), which support the theory of an altered metabolic processes.  
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Figure 116: Snapshot from genes down regulated >2 log2(fold change) in control mouse vs 
control TC, genes in red are those involved in the biosynthesis of small molecules. Interactions 
were determined using the online protein interaction database, STRING (version 10.0), and 
the types of interaction are shown in the legend below. 
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7.4.2 Dexamethasone in vitro vs dexamethasone in vivo 
 
The comparison of Dex TC and Dex mouse should allow for the identification of genes that 
are differentially expressed in response to Dex between the two. Any genes found in this set 
of comparisons could be effectors of resistance in vivo. Dispersion and CV2 was the same as 
for the control vs control permutation, indicative of good quality data. Mouse and TC 
samples cluster separately (Figure 117) and 2035 genes were scored as significantly 
differently expressed between mouse and tissue culture . 
 
Figure 117: Dendrogram showing clustering of 697 cell TC and mouse samples with Dex 
treatment. TC samples cluster separately from mouse indicating a different expression profile 
in response to Dex between the two conditions.  
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7.4.2.1 Upregulated genes 
 
The genes that are upregulated in the Dex mouse samples compared to Dex TC represent 
the genes required for engraftment in the mouse that are unaffected by Dex treatment, as 
well as genes responsible for the different actions of Dex in vivo, and possibly the resistance 
to Dex. Of the 2035 genes that were significantly different between Dex treated cells in TC 
and mouse, 74 have a greater than 2(log2) fold increase in FPKM in the mouse. The highest 
ranked of the upregulated genes in the mouse Dex group is the same as for the mouse 
control group, FOS (Figure 118). Four of the top eight upregulated genes for both control 
and Dex TC vs mouse are shared between both groups indicating a role for these genes in 
growth of ALL cells in the murine environment. Many of the genes are also interconnected 
when looking at protein interactions, including FOS, FOSB and JUN, further highlighting the 
likelihood that these genes are important in the growth of the 697pSLIEW cells in vivo 
(Figure 119).  
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Figure 118: The top 3 upregulated genes in the 697 cells for TC Dex vs mouse Dex samples; 
FOS, EGR1 and MS4A1. Genes are ranked by log fold change and all replicates are shown on 
plots as separate data points. As can be seen the increase in FOS expression is around 10 fold 
higer than that of either EG1 or MS4A1.   
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Figure 119:The protein interactions of all 74 genes with more than 2 log2 (fold upregulation) 
in the 697 cells in the mouse vs tissue culture for Dex treated samples. Interactions were 
determined using the online protein interaction database, STRING (version 10.0), and the 
types of interaction are shown in the legend below. 
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7.4.2.2 Down regulated genes 
 
Genes that show reduced expression in the Dex mouse samples compared to the Dex TC 
samples represent genes that are not induced in response to Dex in the mouse, thus any 
genes that are not induced by Dex in the mouse but are in TC may be Dex inducible genes 
important for the induction of apoptosis. There are 39 genes that have reduced expression 
in both control mouse and Dex mouse, and within this list of genes biosynthesis of amino 
acids and steroids is enriched in the list (FDR<0.05). This would imply that the metabolism of 
the 697 cells is altered in vivo.  
 
Figure 120: The overlap between the downregulated genes (with gene IDs only) in the 697 
cells when control samples were compared to Dex treated samples for both the in vitro and in 
vivo conditions.  
Perhaps the more interesting genes to investigate are those that have differential expression 
only in TC or mouse samples, as these might indicate a differential Dex response in the 
mouse compared TC. There are 114 genes downregulated in Dex TC vs Dex mouse treatment 
groups that are not downregulated in the control TC vs control mouse (Figure 120). Included 
in this list is RASD1 (Ras related Dex induced 1), a member of the RAS family of genes that is 
Dex induced. Further investigation shows this gene, which is downregulated in Dex TC vs Dex 
mouse, is actually upregulated in TC samples when Dex treatment is given. The mouse 
samples do have a higher basal level of expression than the TC samples, but this is less than 
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the levels seen with Dex induction of expression (Figure 121). This lack of RASD1 
upregulation in response to Dex could be the cause for Dex resistance in the mouse.  
Figure 121: Changes in RASD1 FPKM in four of the analyses. Increased expression in response 
to Dex treatment is seen in the control samples (A), as well as an increased basal level in 
mouse control samples compared to TC control samples (C). There is no significant increase in 
RASD1 expression in mouse samples when they are treated with Dex (D) and the levels of 
RASD1 expression are much higher in the TC Dex treated samples (B) 
 
7.4.3 Control vs Dexamethasone 
7.4.3.1 Control vs dexamethasone in vitro 
 
The comparison of the gene expression differences between the control TC samples and the 
Dex TC samples will show the expression changes that occur normally in Dex sensitive cells in 
vitro in response to Dex treatment. Analysis of control TC samples vs Dex TC samples shows 
the two treatment groups cluster separately (Figure 122). 1407 genes are significantly 
(p<0.05) up or down regulated between the two groups (Figure 123).  
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Figure 122: Dendrogram produced using the normalised read counts from the 697 RNA 
sequencing data with the CummeRbund programme in R. The dendrogram shows the 
treatment groups cluster separately from each other when the 697 TC samples are analysed.   
 
 
251 
 
 
Figure 123: Log2 fold change in FPKM in the 697 cells between control and Dex treated 
samples in vitro. Red points indicate significant genes (p<0.01), data points to the left of 
centre indicate down regulated genes and points to the right indicate upregulated genes. 
Data points on the edge of the plot are those for which the log2(fold change) is inferred due 
to one of the conditions having an FPKM value of 0. Significance was calculated and the plot 
generated using the R package CummRBund, which is designed for the analysis and 
visualisation of CuffDiff RNA sequencing data. 
 
7.4.3.2 Up regulated genes 
 
The genes that show upregulation of expression in Dex TC compared to control TC will 
include the genes which are induced by Dex under normal conditions in the 697 cells. These 
genes will show the picture of which genes should be differentially expressed between 
control and Dex treatment. Of the 1407 genes significantly up or down regulated, 36 have 
more than 2 fold decrease in expression and 197 have more than 2 fold increased expression 
with Dex treatment. Of the genes upregulated in the Dex treated group there are several 
genes that are direct targets of NR3C1, such as UBA7 (Ubiquitin Like Modifier Activating 
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Enzyme 7) and FKBP5, which have several GRE within the area of the genes (Figure 124). 
Another gene, PLS3 (Plastin 3) (Figure 125) has a log2 fold increase in FPKM of 3.3 in the Dex 
treatment group compared to control, this gene has been implicated in osteoporosis (van 
Dijk et al. 2013; Fahiminiya et al. 2014) and binds calcium. Given that osteonecrosis is a 
known side effect of treatment with synthetic glucocorticoids, upregulation of this gene is 
potentially interesting.  
 
Figure 124: GRE consensus sequences indicated by the green lines in the genomic sequence of 
UBA7 (top) and FKBP5 (bottom). Data was obtained from the Qiagen website online function 
to search for Transcription factor binding sites.  
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Figure 125: Increase in the FPKM of PLS3 seen in the 697 Dex TC samples compared to control 
TC samples. All replicates are shown in the plot.  
7.4.3.3 Downregulated genes 
 
The genes down regulated in the Dex TC samples will again represent the normal 
transcriptional changes occurring in the 697 cells upon Dex treatment.  The most 
downregulated gene in Dex treatment compared to control in the tissue culture samples is 
INHBE (Inhibin Beta E), an activin, some of which have been shown to have reduced 
expression upon Dex treatment in adipose cells (Sethi 2010). Only one of the INHBE isoforms 
has a large reduction, but this is significant enough to make the gene the top hit. The third 
most down regulated gene, ITGB7 (Integrin subunit Beta 7), an integrin, which are proteins 
involved in extracellular signalling, has a reduction in more isoforms (3/5) than seen with 
INHBE (Figure 126), but still not all of the isoforms. 
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Figure 126: Plots showing the reduction in FPKM for 2 of the most significant genes down 
regulated in the 697 Dex TC samples compared to the 697 control TC samples. Plots show 
separate repeats to indicate the range seen between samples in the same condition.  
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The treatment of 697 cells in vitro with Dex results in the upregulation of several Dex 
inducible genes, such as FKBP5. This shows that there is not an issue with substrate binding 
to the receptor, or the subsequent homodimerisation, nuclear translocation and 
transcriptional regulation by NR3C1.  Although not directly linked to Dex, INHBE is related to 
genes that are, and could well be another gene inhibited by Dex treatment.  
 
7.4.4 Control vs dexamethasone in vivo 
 
The comparison of control mouse samples and Dex treated mouse samples will allow for the 
changes induced by Dex treatment in an in vivo setting to be determined. Any overlapping 
genes with the in vitro expression changes would allow for the determination of whether the 
cells are still being affected by Dex in vivo. The differentially expressed genes would give 
clues to why this resistance is occurring and possible mechanisms.  
As with all the other data, the dispersion and grouping of the control samples vs the Dex 
samples shows the same picture. The samples cluster dependent on treatment (Figure 127-
129), and there are 2881 genes significantly (p<0.05) up or down regulated in the Dex 
treatment group (Figure 129). 
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Figure 127: Dendrogram showing the clustering of mouse control and mouse Dex treated 697 
samples. Dex treated 697 samples cluster together whilst the control treated 697 samples 
cluster separately. 
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Figure 128: PCA plot for the in vivo samples, the control samples are separated from the Dex 
samples based on principle component M1, and from each other on M2. Two of the Dex 
samples cluster tightly whilst the other has more differences based on component M2. The 
Dex treated outlier is one of the female Dex treated mice, indicating the difference in 
expression was not due to sex differences.  
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Figure 129: Log2 fold change in FPKM in the 697 cells between control and Dex treated 
samples in vivo. Red points indicate significant genes (p<0.01), data points to the left of 
centre indicate down regulated genes and points to the right indicate upregulated genes. 
Data points on the edge of the plot are those for which the log2(fold change) is inferred due 
to one of the conditions having an FPKM value of 0. Significance was calculated and the plot 
generated using the R package CummRBund, which is designed for the analysis and 
visualisation of CuffDiff RNA sequencing data. 
 
 
7.4.4.1 Upregulated genes 
 
The upregulation of genes in the Dex mouse group compared to control mouse give an idea 
of how Dex is affecting the cells. Of the significantly altered genes in the control mouse vs 
Dex mouse, 108 are more than 2 log2 fold increased following Dex treatment. 22 of the 
genes with > 2 log2 fold increase with Dex treatment are common between the two analyses 
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(Figure 130). These genes include the known NR3C1 targets FKBP5 and IL6ST (Interleukin 6 
signal transducer).  
The induction of these genes indicates that that despite the Dex being cleared from the 
peripheral blood completely within 24hrs in vivo the downstream effects of NR3C1 induced 
transcriptional modulation is still present. This indicates that NR3C1 does indeed bind to Dex 
before homodimerizing and translocating to the nucleus where it interacts with GRE to 
induce gene modulation.  The exact timescale of this is unknown in the 697 cells but NR3C1 
is known to bind to GRE only transiently, this interaction is known as the ‘hit and run’ 
hypothesis. First described in 2000 by McNally et al the mechanism was based on the finding 
that the receptor moves from the chromatin to the nucleoplasm very rapidly (McNally et al. 
2000). This finding that there was a dynamic exchange of transcription factors at chromatin 
binding sites changed the way that receptor binding was viewed. This mechanism was 
further supplemented by the finding that this rapid interaction the response element results 
in the ability of many transcription factors being able to bind in quick succession to induce 
transcriptional alteration, which results in a lack of competition between transcription 
factors binding to response elements in promoter regions (McNally et al. 2000; Ratman et al. 
2013). The PK data shows that Dex is cleared from the peripheral blood completely by 24hrs 
of dosing, this combined with the induction of NR3C1 transcriptional modulation supports 
the hit and run hypothesis in this instance. 
The mechanism of resistance therefore must be downstream of this process. Genes that are 
specific only to control mouse vs Dex mouse represent the genes that are affecting the 
differential response to Dex in the mouse compared to TC. Included in these genes is SCD, 
this gene is downregulated by Dex treatment (Daniel et al. 2004), and although this evidence 
is from adipose tissue rather than B cells, the reversal of this relationship, with an increase in 
SCD shows that the cells are not responding to Dex as expected in vivo.  
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Figure 130: Venn diagram showing the crossover between genes upregulated in the 697 cells 
control vs Dex for both the in vivo and in vitro conditions. There is only 10.5% of overlap 
between the two treatment conditions.  
 
7.4.4.2 Downregulated genes 
 
The downregulation of genes in Dex mouse compared to Dex TC can be used to elucidate the 
difference in transcriptional regulation in vivo compared to in vitro. Between control and Dex 
treatment in vivo, 182 genes were reduced more than 2 log2 fold. The top three of these are 
shown in Figure 131. In this list of down regulated genes are several JUN-EGR pathway genes 
such as JUNB (JunB proto-oncogene), and JUND (JunD proto-oncogene) as well as EGR1,2 
and 3 (Early growth response 1-3). This indicates suppression of AP-1 driven transcription in 
response to Dex, and this same pathway was also found upregulated in the mouse in control 
samples, and mouse Dex samples. This pathway appears to be important for both 
engraftment and Dex response in vivo.   
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Figure 131: Plots showing the reduction in FPKM for the top three down regulated genes in 
the 697 cells when the control samples are compared to the Dex treated samples in vivo. 
SH3D19 is the most down regulated, followed by HTR7 and EGR3. For each plot both of the 
data points representing each mouse is shown.  
The genes that might be most significant for the Dex response will be those that are down 
regulated in the Dex treated mouse samples but not the Dex treated TC samples. One of 
these such genes in SLAMF6 (Slam family member 6). This gene is reduced in the Dex treated 
mouse samples, but actually has increased expression in the Dex treated TC samples 
indicating opposing control between in vivo and in vitro. Although little evidence links this 
gene and Dex, it is involved in regulation of the immune system, in particular natural killer 
cells (N. Wu et al. 2016).  
7.4.4.3 Control vs dexamethasone, combined samples 
 
The combination of all control samples and all Dex samples will show which genes are 
important in the Dex response that is still shared between in vitro and in vivo, this could be 
important to determine how far downstream the loss of Dex responsiveness occurs in vivo.  
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When the samples are grouped into control vs Dex for TC and mouse samples combined, the 
data has the same dispersion and CV2 profile as the other data sets. Despite this there are no 
significantly up or downregulated genes. Looking at the clustering of the samples shows why 
this might be the case, as the TC samples cluster separately from the mouse (Figure 132).  
However, looking on an isoform level there are some isoforms that are significantly altered. 
Thirty-five of these isoforms have greater than 2 fold increase in expression Within these 35 
genes is FKBP5, a known NR3C1 target gene that is upregulated in both the TC and mouse 
Dex treatment samples compared to control. One isoform of FKBP5 is highly upregulated in 
all Dex samples compared to controls but the others have little or no change (Figure 133). 
Another high ranking isoform is TP53INP1 (Tumour protein P53 inducible nuclear protein 1), 
a pro-apoptotic gene that is involved in the stress response of the cell (Figure 134). 
TP53INP1 is also upregulated in Dex vs control for TC and mouse alone.  
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Figure 132: Dendrogram showing clustering of all 697 samples. They do not cluster into 
control and Dex but rather the samples from tissue culture (red line) cluster together, 
separate from the samples taken from the mice (blue line).  
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Figure 133: The change in expression of the isoforms of FKBP5 in the 697 cells control vs Dex 
treatment. All samples are included in the analysis. Just one isoform is significantly (p<0.05) 
upregulated in Dex treated samples as determined by CuffDiff and CummRBund, the RNA 
sequencing analysis software programmes.  
265 
 
 
Figure 134: Transcripts of TP53INP1, a gene with one significantly upregulated isoform in Dex 
vs control in the 697 cells when both in vitro and in vivo samples are analysed together. 4 
different isoforms are shown, and all repeats are shown as data point.    
 
7.5 Summary 
 
Despite several approaches being used to determine the cause for the apparent Dex 
resistance of the 697 cells to Dex in vivo, no definite mechanism has been found, although 
there are several possibilities.  
All of the work on Dex treatment of the 697 cells in vitro, including treatment of cells 
collected from mice, did not show any increase in Dex resistance of the 697pSLIEW cells as 
was seen in vivo.  
The lack of increased Dex resistance in the 697 cells when grown on the BM stromal feeder 
cells would indicate that these are not sufficient to provide the in vivo microenvironment 
that is required for the alteration in cell phenotype. The increase in Dex sensitivity seen in 
some of the conditions cannot be explained other than when the 697 cells are grown at low 
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density they do not have high viability, suggesting cell-cell interactions are important for this 
cell line.  
The increase in Dex sensitivity observed in the 697pSLIEW cells collected from the spleen 
and BM of the mice is likely to be a result of reduced cell viability and it was most 
pronounced in the BM samples followed by spleen and not present in the liver. The number 
of leukaemic cells collected from the BM was the lowest, followed by the spleen whereas 
there was an abundance of cells collected from the liver, so this might have an effect. One 
reason why no resistance was seen in the samples collected from the mouse could be that 
testing was done 96 h after extraction from the mouse. This could be too long and any 
change in Dex sensitivity could already be lost. It could also have been a microenvironment-
mediated effect that is lost once cells are cultured in vitro. One experiment that would have 
been useful would have been testing cells from the mouse with the support of a feeder layer 
such as the MSC or MS5. By supporting the cells with a feeder layer as soon as they are 
collected from the mouse the phenotype of the cells from growing in vivo might be retained.   
The RNA sequencing of the cells that were collected from the mice compared to cells grown 
in vitro is the only experiment that has revealed anything that could account for the 
resistance. However, this data is convoluted with differences between each permutation of 
analysis. Further validation of the genes would be needed before a definite answer could be 
stated. 
The upregulation of JUN and FOS mRNA in the mouse samples compared to tissue culture in 
both control and Dex treated samples is interesting. Similar genes are also downregulated in 
both the mouse and TC Dex samples compared to control, indicating a role in both 
engraftment in the mouse and Dex response. JUN and FOS are subunits of the AP-1 
transcription factor, which is involved in proliferation, survival, oncogenic transformation 
and cell migration (Kappelmann, Bosserhoff, and Kuphal 2014). Furthermore, AP-1 has 
several possible subunits, and the dimer composition of the transcription factor affects 
transcription and which genes are targeted. The composition of subunits affects whether the 
transcription factor has oncogenic properties, whereby c-Jun homodimers have been shown 
to result in oncogenic transformation when artificially stabilised (Castellazzi et al. 1993). 
Over expression of c-FOS is also sufficient for oncogenic transformation (Miller, Curran, and 
Verma 1984). Upregulation of the specific subunits JUN and FOS may result in more dimers 
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with oncogenic potential, altering the phenotype of the cell. It is unlikely that the increases 
in FOS and JUN mRNA are directly responsible for the apparent Dex resistance in the 697 
cells. A previous study of patient samples found no correlation between levels of AP-1 
binding or expression of FOS and JUN with prednisolone response in vitro (Bailey et al. 1999).  
Another group of genes that are upregulated in the same pattern as FOS and JUN are the 
EGR genes EGR1, 2 and 3 (Figure 135). EGR1 is upregulated in both mouse control and Dex, 
and down regulated Dex treatment (Mouse and control). These genes encode zinc finger 
proteins, and EGR1 is known to be down regulated by Dex treatment (Kharbanda et al. 1991) 
This has even been found in the 697 cells after 24hrs treatment with 100nM Dex (Yamada et 
al. 2003). The EGR genes are highly interconnected with the FOS and JUN related genes 
(Figure 136), and this network of genes is associated with response to cAMP (FDR=2.8e-15) 
and transcriptional activation (FDR=1.59e-7). The upregulation of these genes in mouse 
samples compared to TC would imply a role in engraftment and proliferation in vivo. 
Combined with the negative effect of Dex on EGR transcription, this indicates that the cells 
in the mouse are getting sufficient Dex, but components downstream may induce resistance 
to Dex induced apoptosis. One gene that is downstream of NR3C1 that could be a cause for 
loss of apoptosis is RCAN1 (regulator of calcineurin 1), which is upregulated upon Dex 
treatment in TC samples but not in the mouse. This gene is upregulated in response to Dex in 
ALL cells, and in the CEM cell line has been correlated with apoptosis. In Dex resistant CEM 
cells RCAN1 is not upregulated as it is in the Dex sensitive cells which indicates a role in Dex 
resistance (Hirakawa, Nary, and Medh 2009; Bindreither et al. 2014) . 
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Figure 135: Schematic detailing the deregulation of FOS, JUN and EGR genes in the 697 cells 
in vitro and in vivo. The four different permutations of comparison are shown, and the 
differentially regulated genes including the direction of change for each.  Although the 
picture is complicated, the same genes are repeatedly differentially expressed in the different 
conditions indicating a major role for these genes in why the 697 cells are not responsive to 
Dex in vivo,  
 
 
Figure 136: The known protein interactions between the JUN, FOS and EGR genes found 
differentially expressed in the analysis of Dex and control 697 samples both in vivo and in 
vitro. Interactions were determined using the online protein interaction database, STRING 
(version 10.0), and the types of interaction are shown in the legend below.  
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The differences between primary cells and cell lines include alterations in cell cycle and 
metabolism (Carette et al. 2010; Gillet et al. 2011). As well as the already outlined roles of 
AP-1,  c-Jun has also been shown to increase transcription of Cyclin D, an important cell cycle 
regulator (Bakiri et al. 2000). Several metabolic genes were also differentially regulated in 
mouse samples compared to tissue culture.  It could be that growth in vivo promotes a more 
primary cell like phenotype in the 697 cells, and this altered transcription is enough to 
render the cells resistant to Dex. The mechanisms of this are unknown.  
Both mouse and tissue culture cells had a similar response to Dex with the induction of some 
NR3C1 target genes, including FKBP5, supporting the PK data that the bioavailability of Dex is 
sufficient. Only around 30% of genes with >2 log2 fold change in mouse or tissue culture 
were shared between the two conditions indicating a different response in tissue culture 
compared to the mouse.  
One gene that is differentially regulated in response to Dex in TC and the mouse is RASD1, a 
Dex inducible gene that is associated with control of aberrant growth, and control of 
proliferation of B cells  (Vaidyanathan et al. 2004; Lindsey 2007).  
Expression of RASD1 is increased in response to Dex treatment in TC samples, but in mouse 
samples there is no increase, demonstrating a lack of Dex induced transcriptional activation 
of the gene. However, there is already higher basal expression of RASD1 in mouse samples 
compared to TC. RASD1 is found at low levels in freshly collected B cells from lymph nodes, 
but as cells are cultured in vitro the expression increases rapidly (Lindsey 2007). Although 
this is the opposite to what is seen in the samples run, this differential expression dependent 
on culture could account for why the mouse and tissue culture control samples have 
significantly different RASD1 levels.  
A role for RASD1 in Dex resistance in the mouse could result from the lack of induction of 
RASD1 expression in the mouse. RASD1 has been proposed as an effector of apoptosis in 
response to chemotherapeutic agents in breast cancer (Tian et al. 2013), and expression of 
RASD1 results in an inhibition of growth and increased apoptosis (Vaidyanathan et al. 2004).  
The lack of increase in response to Dex in the mouse samples could be the mechanism by 
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which these cells are resistant. However, what that does not explain is how the loss of 
RASD1 induction by Dex is mediated.   
RASD1 signalling, or lack thereof provides a probable cause for the Dex resistance of the 
697pSLIEW cells in vivo. The lack of effect once cells are removed from the mouse implies 
that there is signalling within the murine microenvironment that is needed to support this 
change in transcription, and when the microenvironment is lost, so too are the 
transcriptional changes and the cells revert to a sensitive phenotype. The changes in the 
697pSLIEW cell line between in vitro and in vivo culture also appears to involve AP-1 
transcription factor mediated changes. This change in transcription could be the cause for 
de-regulation of RASD1 signalling. RASD1 has been shown to be increased in EGR1 over 
expressing non-small cell lung carcinoma cell lines (Zhang et al. 2014) but there is little other 
data to support this hypothesis.  
The 697 cells, although Dex sensitive in vitro should not be used as a model for Dex 
sensitivity due to the change in sensitivity that is seen when cells are grown in vivo. This 
altered drug sensitivity profile may not just be for Dex, as genes implicated in asparginase 
resistance were also found differentially regulated in mouse samples compared to tissue 
culture samples (Estes et al. 2007). Although these genes are downregulated, which is 
counterintuitive to their role in resistance it might indicate an underlying alteration in drug 
sensitivity when these cells are cultured in vivo compared to in vitro. Unfortunately, 
asparginase was not tested in the 697pSLIEW cells during these experiments, as this would 
be an interesting experiment to do in the future.  
The differences between engraftment and drug sensitivity to chemotherapeutic agents of 
ALL cell lines in vitro and in vivo culture are part of the larger issue of finding the right model 
to examine drug resistance in ALL. An interesting experiment, if it could ever be done would 
be the culture of a cell line and the parental primary cell sample in vitro and in vivo to 
investigate the changes and the clustering of the samples, to determine if growth of a cell 
line in vivo results in a phenotype closer to the primary cell sample.  
Other future experiments would be to validate some of the targets found through this RNA 
sequencing through knock out and pharmacological inhibition. Genes that would be 
interesting to investigate further include RCAN1, RASD1 and several of the AP-1 transcription 
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factor subunits. How the loss of these genes affect engraftment of the 697 cells in vivo as 
well as response to Dex could prove important for the study of Dex resistance in ALL.  
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 Chapter 8: Discussion 
 
The issue of Dex resistance in ALL has important prognostic implications, as patients that do 
not respond well to Dex at presentation, or become resistant, have a significantly worse 
outcome (Moricke et al. 2008; Bachmann et al. 2005). The high frequency of Dex resistance 
in relapsed ALL is not normally mirrored by mutations or deletions in NR3C1, the target for 
Dex (Klumper et al. 1995; Mullighan et al. 2007). This discrepancy and the resulting 
hypothesis that NR3C1 is important for the fitness of ALL resulted in the investigations into 
the role of NR3C1 in the evolution of Dex resistance that was carried out as part of this PhD.  
 
8.1 Paired primary presentation and relapse cells 
 
Comparison of the L707 presentation and relapse using gene expression microarrays 
confirmed what was known about the 5q deletion from work previously done by Dr. Elda 
Latif. The loss of NR3C1 and HMHB1 expression in the relapse pointed to one of these two 
genes as drivers for relapse, and the other 4 genes as passengers due to lack of expression in 
the presentation determined by the microarray analysis. The enrichment of pathways 
involved in chromatin silencing in the relapse is perhaps more interesting and might indicate 
a role for altered epigenetic and transcriptional programmes in the L707 cells. More work 
would need to be done to determine exactly what this is, and comparison to online data sets 
for presentation and relapse cases may have proven useful.  
Without a germline sample, the WGS data for the L707 presentation and relapse could not 
identify cancer specific mutations in these samples. Despite this, several interesting SNPs 
and indels were found in the relapse specific variants.  These SNPs and indels could be 
involved in the genesis of relapse and several of these warrant further investigation, 
especially those that are already associated with cancers such as the variants in CLEC1A, 
TRRAP and NDUFB11. Despite the lack of a germline sample, the SNPs and Indels that are 
shared between the L707 presentation and relapse provide perhaps the most interest. The 
presence of variants in known tumour suppressors (BRCA2), cell cycle proteins (ATR, CHEK1) 
and TP53 associated genes (TP53BP1, TP53RK, MDM2) all point to possible oncogenic 
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mechanisms. However, to determine whether these variants are significant, a large pool of 
reference genomes would be needed in place of a germline sample. This data is available 
through the 1000 genomes project but the analysis was determined to not be feasible after 
talking with Dr Matt Bashton due to the time constraints of this PhD and my own limited 
bioinformatics experience.  
The possibility of a cell with a pre-existing heterozygous deletion in the L707 presentation, 
which then emerges when treated with Dex has not been robustly proven with this work, as 
all but one sample were below the cut-off for positivity. Despite there being no robust proof 
of this clone being present, with more rounds of engraftment and treatment it is likely to be 
identified.  
 
8.2 Role of NR3C1 in ALL 
 
The original hypothesis for this work was that loss of NR3C1 would result in reduced fitness 
of the ALL cells. This was tested in several ways using the 697 cell line and the L707 
presentation cells. In the 697 cells this was tested using a pool of pTRIPZ shRNA constructs 
targeting the genes in the L707 relapse 5q deletion. This showed that NR3C1 knockdown 
results in Dex resistance, and further supported the idea that the other genes are likely 
passenger deletions as they appear to have no effect on proliferation or Dex sensitivity. 
There is no evidence that there is a deleterious effect of loss of NR3C1 as it would be 
expected that if loss of signalling through RNAi was harmful to the cells then these 
constructs would be lost when cells are induced by Dox but without Dex treatment.  
The same screen when the cells were engrafted in vivo did not produce the expected results, 
and there are several possible reasons why. Firstly, the silencing of constructs in vivo, which 
has been seen in these samples and in other work in our groups (unpublished data) could be 
responsible, as if shRNA is not expressed then the construct will have no effect on the 
expression of genes. It does highlight the need to use plasmids with promoters that are less 
susceptible to silencing when the cells will be used in vivo. The second possibility is that, as 
well as the silencing, the lack of Dex sensitivity of the 697 cells in vivo could be a reason that 
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there is no correlation in construct enrichment or depletion. If the cells are not responding 
to Dex, then the NR3C1 targeting constructs will have little effect.  
In order to test if the loss of NR3C1 signalling had an effect on the L707 cells, which could 
not be transduced with pTRIPZ, pharmacological inhibition was used. Mifepristone was 
chosen for this as the only commercially available NR3C1 antagonist. There has also been 
evidence for the use of mifepristone in murine models of leukaemia (Check et al. 2009). 
However, the treatment of the L707 presentation cells with mifepristone had no effect on 
survival and very little effect on the expression profile of the L707 cells when tested by gene 
expression microarray. This could be because mifepristone was found to work as a partial 
agonist in the 697 cells in vitro.  
Lastly, the treatment of the L707 presentation with Dex did result in prolonged survival of 
mice, as had been seen previously. When the gene expression changes were analysed by 
microarray there was a change in the expression profile consistent with Dex treatment. This 
included the upregulation heat shock proteins, which are known to mediate the action of 
NR3C1 (Prota et al. 2012) and the upregulation of S1100A8 and S100A9, which have been 
implicated in Dex resistance (Spijkers-Hagelstein et al. 2012).  
 
8.3 lentiCRISPR screen 
 
The aims of the lentiCRISPR screen was to prove the feasibility of a genome-wide lentiCRISPR 
screen in primograft ALL cells using the in vivo NSG mouse model and to use this screen to 
investigate the mechanisms of Dex resistance in matched presentation and relapse ALL cells. 
This is the first time to our knowledge that a genome wide lentiCRISPR screen has been 
carried out in primary derived material in vivo and despite encountering many issues with 
the sequencing and PCR contamination, this work represents a major technical advance.  
Both of the aims were completed, with the successful transduction of the L707 presentation 
cells with the lentiCRISPR GeCKO library, puromycin selection and injection of cells into mice. 
The investigation of genes responsible for Dex resistance was partly hampered by the finding 
that the library was contaminated with NR3C1 targeting sgRNA during the production of the 
amplicon library by PCR and the subsequent removal of these sequences from the analysis. 
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Several genes that could have implications in Dex resistance were highlighted and when the 
expression of the L707 presentation is taken into account with the enrichment and depletion 
of sgRNA, several genes warrant further investigation.  
Amongst the genes identified by the CRISPR screen was MSRB2 which is expressed in both 
the L707 presentation and relapse, with a modest reduction at relapse (0.45 fold). This gene 
also has GRE binding sites upstream of the transcriptional start site, and there is binding of 
NR3C1 to these in A549 cells when treated with 100nM Dex (ENCODE project Consortium 
2013). This combination of evidence presents this gene as an interesting possible driver gene 
in leukaemia. Its roles in oxidative stress, and the finding that oxidative stress genes are 
reduced in leukaemia (Battisti et al. 2008), points to a probable mechanistic reason for the 
loss of expression of this gene.  Other sgRNA that are enriched in the L707 presentation cells 
when treated with Dex, MSL1 and RRBP1 also have NR3C1 binding peaks when ChIP-seq data 
from A549 cells treated with Dex is analysed (ENCODE project Consortium 2013). These 
genes have an enrichment of sgRNA targeting them when the L707 cells are treated with Dex 
but in the microarray data there is no difference in expression between the presentation and 
relapse and neither of the genes are expressed at very high levels, they might still represent 
interesting genes to investigate further. 
Although no effect was seen when L707 presentation cells were transduced with PLXND1 
targeting sgRNA, this gene warrants further investigation due to the significant reduction in 
PLXND1 mRNA when NR3C1 signalling is disrupted by sgRNA in the L707 cells. As well as this, 
there are consensus GRE sites upstream of the transcriptional start site, and when ChIP-seq 
data is analysed, there are binding peaks from NR3C1 binding to this region in the presence 
of 100nM Dex (ENCODE project Consortium 2013).  
 
8.4 Dex resistance in an ALL cell line 
 
The last, and in my opinion most fascinating part of this PhD was the incidental finding that 
the 697 cells were Dex sensitive in vitro with an IC-50 of just 20 nM but appear completely 
Dex resistant in vivo. This Dex resistance is not a result of the cellular interactions with 
murine BM stromal cells, or if they do play a role which is likely, this is not evident in vitro. 
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The effect also appears to be transient, as once cells are removed from the mice they are no 
longer Dex resistant. The RNA sequencing data for these cells revealed the most about 
possible mechanisms for this Dex resistance.  
There are two areas that could provide the mechanistic cause for this resistance. Firstly, the 
upregulation of FOS, FOSB and JUN in the mouse samples compared to TC indicate a role for 
these genes in the engraftment of cells in vivo and growth in the murine microenvironment. 
These genes have been found to be oncogenic, and overexpression results in oncogenic 
transformation (Kappelmann, Bosserhoff, and Kuphal 2014; Castellazzi et al. 1993; A. D. 
Miller, Curran, and Verma 1984). Not only are the individual proteins oncogenic but they are 
all components of the AP-1 transcription factor. Signalling though AP-1 has been found to be 
involved in several cellular processes that could be important in leukaemia cells including, 
proliferation, survival and cell migration (Kappelmann, Bosserhoff, and Kuphal 2014). No 
correlation between AP-1 expression and Dex resistance in ALL cells has been found (Bailey 
et al. 1999). c-JUN also increases transcription of Cyclin D (Bakiri et al. 2000) indicating a role 
for altered cell cycle in the possible mechanisms.  
Another possible cause for the in vivo Dex resistance is the de-regulation of RASD1 (Ras 
related Dex induced 1). RASD1 is a Dex induced gene that is upregulated in response to Dex 
in vitro but not in vivo. Lack of RASD1 induction in vivo indicates that although the leukaemic 
cells are receiving adequate Dex treatment, as shown by PK studies, the response to the Dex 
in vivo.  
To fully understand how this is occurring the genes which appear to have an effect would 
have to be investigated separately through other methods. The best option for this would be 
to use lentiCRISPR, as this should not be affected by the in vivo silencing of RNAi transcripts 
that was seen in the 697 cells in the pTRIPZ plasmid transduction experiments.  
To summarise, loss of NR3C1 in ALL cells results in Dex resistance, but does not appear to 
affect fitness of these cells. There is another mechanism that is the cause of this in the L707 
relapse, and although several possible genes have been highlighted through microarray 
analyses and WGS this is still unknown.  
Despite this, the L707 cells are a good model to use for whole genome lentiCRISPR 
screening. We were able to retain 12X screen coverage but with changed parameters higher 
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yield and coverage would be attainable.  The issue with PCR contamination in the screen 
carried out for this PhD did not render the data useless but does highlight the need for care 
when carrying out such sensitive PCR reactions. PCR contamination is a known problem but 
it was not considered in this screen which was a mistake. In future to avoid this issue, 
separate areas should be used for PCR set up and use of products. Single constructs should 
also not be taken from the library sequences, so that if contamination does occur it can 
easily be removed from analysis. 
Lastly, the emergence of Dex resistance in cell lines is unpredictable, and the 697 cells are 
testament to this as they are sensitive to Dex in vitro but resistant in vivo. The causes for this 
were explored but no firm mechanism was found, although several possibilities were found. 
This data is both interesting and highlights the need for careful consideration of models 
when investigating drug resistance.  
The work carried out in this PhD has both given insight into the genesis of relapse and Dex 
resistance in ALL and provided excellent training in research science.  
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